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We did it! 
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ABSTRACT 
Cachexia is common in patients with incurable cancer, particularly of 
the lung and upper-gastrointestinal tract, and impacts adversely on 
treatment options, morbidity, quality of life and survival. Current 
management of cancer cachexia is inadequate and progress is 
required. This thesis explores the use of exercise as a proactive 
supportive therapy with a focus on maintaining physical function. 
 
The first piece of work was a systematic review of the use of 
therapeutic exercise in patients with or cured of cancer. Across 65 
exercise studies, the median [IQR] rates of uptake, adherence and 
completion were 63 [33±80]%, 84 [72±93]% and 87 [80±96]% 
respectively, with no characteristic influencing the proportion of patients 
taking up or completing a programme. The main reasons reported for 
refusal were lack of interest or the impracticality of the programme and 
for withdrawal were medical complication or deterioration. Overall, only 
about half of patients offered an exercise programme completed one. 
This review highlighted a need to modify existing programmes or 
explore novel alternatives if exercise is to be acceptable to the majority 
of patients. 
 
The second study explored exercise preferences in patients with 
incurable cancer. $TXHVWLRQQDLUHZDVXVHGWRGHWHUPLQHSDWLHQWV¶
perceived capability and preparedness to undertake six different 
4 
 
exercise programmes, each illustrated by video clips and 
accompanying text, and preferences for the delivery of the most 
preferred programme. All 200 patients considered themselves 
physically capable of undertaking an exercise programme and two-
thirds were prepared to undertake one at that moment in time. The 
most preferred type of exercise was neuromuscular electrical 
stimulation (NMES) 36 [35í44]%, IROORZHGE\ZDONLQJ>í@% and 
UHVLVWDQFHWUDLQLQJ>í@DQGWhe majority preferred to undertake 
exercise at home, alone and unsupervised. This survey suggested that 
it is realistic to offer therapeutic exercise programmes to patients with 
incurable cancer and provided rationale to explore NMES in this group. 
 
The third study was a randomised controlled pilot study of NMES 
in patients with non-small cell lung cancer. Sixteen patients were 
randomised to a control group, which received usual care, or NMES 
group, which received daily stimulation to the quadriceps for up to 
30min (frequency 50Hz, on phase 11í25%) for four weeks. All patients 
found the NMES device acceptable and median (range) adherence to 
the recommended programme was 80% (69 100). In the NMES group, 
quadriceps muscle strength and free-living physical activity improved by 
a mean of 7.4 Newton metres (22%) and 136 steps (11%) respectively, 
whilst exercise endurance deteriorated by a mean of 20 metres (4%). 
This compared favourably with the control group however none of the 
differences were statistically significant. These findings suggested 
5 
 
NMES was an acceptable type of exercise and that further study is 
warranted in patients with lung cancer. 
 
The final piece of work was a feasibility study into the use of a 
lightweight ActivPAL monitor to measure physical activity level. The 
aims were to determine if this form of assessment is acceptable to 
patients, the optimal period of monitoring and to explore the added 
value of the monitor's energy expenditure (EE) estimate over a simple 
step count. Sixty patients with lung or upper-gastrointestinal cancer 
wore a monitor for one week. All but one found the monitor acceptable 
and mean [&,@DGKHUHQFHZDV>í100] %. Mean daily step 
count and EE values measured over 2 and 4 days were significantly 
higher than those from 6 days (p<0.01). Step count was strongly related 
to stepping EE and non-stepping EE. The ActivPAL monitor was 
shown to be an acceptable method of assessing physical activity level. 
A mean daily step count obtained over 6 days was recommended for 
use in future cachexia studies. 
 
Collectively, this work supports the use of therapeutic exercise 
and highlights a particular role for novel approaches, e.g. NMES, which 
may be more acceptable to patients. Findings can be used to guide 
future research which ultimately will determine if therapeutic exercise 
can help patients with cancer to maintain their level of physical activity 
and independence for as long as possible. 
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1.1 General introduction 
Cachexia is common in patients with incurable cancer, particularly of 
the lung and upper-gastrointestinal tract, in whom it becomes universal 
as the cancer progresses (Laviano et al, 2005; Stewart et al, 2006). It 
impacts adversely on treatment options, morbidity, quality of life and 
survival (Macdonald, 2005). Current management of cancer cachexia is 
inadequate and progress is required (Muscaritoli et al, 2006). Experts 
have suggested that a multimodal approach to include nutrition, 
immunomodulation and exercise, offered proactively to those most at 
risk of cachexia is likely to provide benefit (Fearon, 2008). However, 
this is a newly emerging field of enquiry and limited data exist. 
 
1.2 Aims and objectives 
The overall aim of this thesis is to examine the role of therapeutic 
exercise in patients with or at risk of cancer cachexia to help maintain 
physical function and independence for as long as possible. 
More specific objectives are to: 
 review the use of exercise in patients with cancer to determine if it 
is an acceptable and practical therapy 
 identify and pilot the most acceptable type(s) of exercise in patients 
with incurable cancer most risk of cachexia 
 identify and examine outcome measures suitable for use in studies 
aimed at maintaining physical function in this group. 
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1.3 Thesis outline 
Objectives are met through a review of relevant literature leading to four 
original research studies. The background is divided into three chapters 
which consider the cachexia syndrome, the role of therapeutic exercise 
and the assessment of physical function respectively. 
 
 The second chapter introduces the cancer cachexia syndrome 
and considers the mechanisms by which it impacts adversely on 
physical function. This is used to identify the patient groups at whom 
this thesis is concerned, i.e. those with cancers in which cachexia is 
most common, and to highlight physical consequences of cachexia 
which may be addressed with interventions such as therapeutic 
exercise. 
 
 Chapter three examines the evidence base regarding to the use 
of exercise in patients during or following treatment for curable cancer 
and with incurable cancer. This chapter provides further support to 
examine the use of exercise in those with incurable cancer and 
highlights the lack of research in this group. It also raises issues with 
the acceptability of therapeutic exercise and provides a rationale to 
consider the broader utility of exercise before undertaking intervention 
studies. This led to the development of the original studies described in 
chapters five and six. 
 
26 
 
 Chapter four completes the literature review by appraising 
various measures of physical function that may be used in studies 
aimed at patients with or at risk of cancer cachexia and comparing their 
respective psychometric properties and utility. The purpose of this 
chapter is to inform the selection of outcome measures used in the 
intervention studies presented in chapters seven and eight. 
 
Chapter five describes a systematic review of the use of 
therapeutic exercise, which demonstrated that overall only about half of 
patients with or cured of cancer offered an exercise programme 
completed one. This highlighted a need to modify existing programmes 
if exercise is to be acceptable to the majority of patients. It also 
provided rationale to consider more novel approaches to exercise, e.g. 
neuromuscular electrical stimulation (NMES), which may be more 
practical and thus acceptable to a greater proportion of patients. 
 
Chapter six describes a study exploring exercise preferences in 
200 patients with incurable cancer. When presented with six different 
exercise programmes, all patients considered themselves physically 
capable of undertaking an exercise programme and two-thirds were 
prepared to undertake one at that moment in time. The most preferred 
type of exercise was NMES, which provided rationale to explore this 
approach and led to a pilot study in patients with lung cancer. 
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Chapter seven describes a randomised controlled pilot study of 
NMES in sixteen patients with lung cancer. The intervention was 
supported by the popularity of NMES and outcome measures were 
selected on the basis of the background review presented in chapter 
four. This chapter suggests that NMES was acceptable to participants 
and that further study is warranted in patients with lung cancer. 
 
Chapter eight describes the final piece of original work relating to 
the use of a lightweight monitor. This can be used to assess physical 
activity level, which was identified in chapter three as an outcome well-
suited to studies in those with or at risk of cancer cachexia aimed at 
maintaining physical function. The monitor was shown to be an 
acceptable method of assessing physical activity level and a mean daily 
step count obtained over 6 days was recommended for future use. 
 
Finally, chapter nine reflects on the thesis by revisiting the 
original aims and objectives and drawing general conclusions in light of 
the main strengths and limitations of this work. These form the basis of 
suggestions for further work and are used to highlight the clinical 
implications of the overall findings. 
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CHAPTER 2: 
THE CACHEXIA SYNDROME 
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2.1 Introduction 
This chapter will explore the syndrome of cachexia, a major contributor 
to the loss of independence and quality of life in patients with cancer 
(Macdonald, 2005). The definition, pathophysiology and clinical impact 
of cancer cachexia are outlined to highlight the complexity and scale of 
the problem this syndrome represents.  There is a more detailed 
overview of the mechanisms by which cancer cachexia impacts on 
physical function and how this relates to quality of life. Finally, current 
and emerging treatment options for cancer cachexia are outlined to 
highlight the potential role that therapeutic exercise may have in its 
management. 
 
2.2 What is cachexia? 
2.2.1 Definition 
&DFKH[LDLVGHULYHGIURPWKH*UHHNµNDNRVKH[LV¶ meaning µEDG
FRQGLWLRQ¶ and describes a multi-factorial syndrome associated with 
wasting and malnutrition. The majority of the literature has used weight 
loss alone to define cachexia, for example the loss of RURI
the pre-morbid stable weight (e.g. Inui, 2002; Dewys et al, 1980). 
However, this is increasingly considered too simplistic (Fearon et al, 
2006) and a much broader definition has recently been proposed by 
experts in the field: 
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³DFRPSOH[PHtabolic syndrome associated with underlying 
illness and characterized by loss of muscle with or without loss of fat 
mass. The prominent clinical feature of cachexia is weight loss in adults 
(corrected for fluid retention) or growth failure in children (excluding 
endocrine disorders). Anorexia, inflammation, insulin resistance and 
increased muscle protein breakdown are frequently associated with 
wasting disease. Wasting disease is distinct from starvation, age-
related loss of muscle mass, primary depression, malabsorption and 
K\SHUWK\URLGLVPDQGLVDVVRFLDWHGZLWKLQFUHDVHGPRUELGLW\´ (Evans et 
al, 2008). 
 
This definition is accompanied by diagnostic criteria of at least 5% 
weight loss in the previous year in the presence of underlying illness, 
plus three of (Evans et al, 2008): 
 decreased muscle strength 
 fatigue 
 anorexia 
 low fat-free mass  
 abnormal biochemistry, i.e. raised c-reactive protein, low albumin 
and anaemia. 
 
As most of the literature in this field pre-date the consensus definition, 
the terms cachexia and weight loss will be used interchangeably in this 
thesis and the term cachectic will occasionally be used to describe 
patients who have lost 5% of their pre-morbid stable weight. 
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2.2.2 Prevalence 
Weight loss is common in patients with solid cancers, even around the 
time of diagnosis with the highest levels seen in patients with upper-
gastrointestinal or lung cancer (Laviano et al, 2005) (Table 1.1). One 
survey suggests half of all patients with cancer will lose some body 
weight and one third more than 5% of their pre-morbid weight (Inui, 
2002). However, in many cancers weight loss will be inevitable as the 
disease progresses (Stewart et al, 2006). 
 
Table 2.1 Incidence of weight loss around the time of diagnosis in various 
types of cancer (Laviano et al, 2005). 
 
Cancer type Incidence (%) 
Pancreatic 
Gastric 
Oesophagus 
Lung 
Colorectal 
Prostate 
Breast 
83 
83 
79 
í 
í 
56 
í 
 
 
 
2.3 Pathophysiology 
Multiple factors contribute to the cachexia syndrome in cancer (Figure 
2.1). These factors are produced by the cancer or by the patient in 
response to the cancer (Gordon et al, 2005; MacDonald, 2005). One 
outcome of this is a persistent pro-inflammatory state incorporating 
increased levels of circulatory cytokines, e.g. Tumour Necrosis Factor-Į
71)Į,QWHrleukins 1 and 6 (IL-1, I-6) and Interferon-Ȗ,1)ȖZKLFK
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contribute to a number of features of cachexia (Argilés et al, 2005; 
MacDonald, 2005; Muscaritoli et al, 2006). Additional cancer-derived 
catabolic factors have been identified in some cancers including 
proteolysis inducing factor (PIF) and lipid mobilising factor (LMF), which 
exacerbate the metabolic disturbance and further promote the 
degradation of muscle and fat tissue respectively (Gordon, 2005; 
Tisdale, 1997). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Pathogenesis of the cancer cachexia syndrome. 
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Both pro-inflammatory cytokines and PIF upregulate proteolytic 
pathways through a number of mediating ligases (Gordon et al, 2005; 
Tisdale, 2009). This leads to muscle tissue breakdown, the major cause 
of net loss of muscle tissue loss (Laviano et al, 2005; Melstrom et al, 
2007). Rates of protein synthesis are also reduced, in part due to the 
reciprocal relationship which exists with muscle breakdown (Glass, 
2005) and also to a lack of available amino acids, which are diverted to 
produce acute-phase proteins (Dworzak et al, 1998; Melstrom et al, 
2007). In addition, there is a net loss of fat tissue, as LMF stimulates 
adipose tissue breakdown and the raised levels of cytokines inhibit 
lipase and prevent the storage of fatty acids (Gordon et al, 2005; 
Tisdale, 2009). 
 
This catabolic state is often compounded by an increased and/or 
inefficient metabolism and a reduced food intake. An increase in resting 
energy expenditure has been observed in various cancers such as 
those of the lung and upper-gastrointestinal tract (Falconer et al, 1994; 
Jatoi et al, 2001). Pro-inflammatory cytokines can lead to an increase in 
mitochondrial uncoupling proteins, resulting in the production of heat 
instead of adenosine-triphosphate (Gordon et al, 2005; Muscaritoli et al, 
2006). Cytokines also impact on the hypothalamus and gastrointestinal 
tract causing anorexia, early satiety, changes in taste and food 
aversions which reduce food intake (Laviano et al, 2003; Wilcock, 2005; 
Yavuzsen et al, 2009). 
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2.4 Clinical impact of cachexia 
Cancer cachexia impacts adversely on patient survival, treatment 
options and response, morbidity and quality of life (Muscaritoli et al, 
2006; Fearon et al, 2006). 
 
2.4.1 Survival 
Both the presence and the degree of weight loss around the time of 
diagnosis are independent predictors of survival. In a study of over 
1,500 patients with locally advanced upper- or lower-gastrointestinal 
FDQFHUVXUYLYDOZDVVLJQLILFDQWO\VKRUWHULQWKRVHZLWK weight loss 
at diagnosis compared to weight-stable patients (median 7.6 months vs. 
11.9 months, p<0.01) (Andreyev et al, 1998). A multivariate analysis 
revealed that this degree of weight loss was associated with a 63% 
increased risk of death (hazard ratio 1.63, 95% C,í
(Andreyev et al, 1998). In a study of over three thousand patients with 
variety of cancers receiving anti-cancer treatment, survival was 
VLJQLILFDQWO\DQGSURJUHVVLYHO\VKRUWHULQSDWLHQWVZKRKDGZHLJKW
loss, or >10% weight loss compared to those who had no weight loss 
(Dewys et al, 1980). When examined by cancer type, mean survival in 
SDWLHQWVZKRKDGORVWZHLJKWZDVíZHHNVVKRUWHUWKDQLQ
those who had not (Dewys et al, 1980). Thus, the presence of cachexia 
at diagnosis or during anti-cancer treatment has negative implications 
on the overall survival of patients. 
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2.4.2 Treatment options and response 
Patients with cachexia, because of a poorer performance status, are 
less likely to be candidates for intensive chemotherapy or radiotherapy 
regimens and surgical procedures, which offer survival potential 
(Laviano et al, 2005; Antonelli et al, 2006). Weight loss prior to 
chemotherapy is associated with suboptimal dosing, more numerous 
and severe toxicities, more breaks from treatment and premature 
discontinuation of treatment (Andreyev et al, 1998; Ross et al, 2004). 
These events all contribute to a poorer objective response and shorter 
time to disease progression (Davidson et al, 2004; Ross et al, 2004). 
 
2.4.3 Morbidity and poorer quality of life 
Cancer cachexia increases morbidity as a result of the associated 
symptoms such as anorexia, fatigue, muscle weakness, mood 
disturbance and insomnia (Seruga et al, 2008), which together impact 
adversely on performance status and quality of life (Teunissen et al, 
2007). Studies in patients with advanced upper-gastrointestinal cancer 
(n=119) and non-small cell lung cancer (n=106) have shown that 
performance status and quality of life are significantly lower in patients 
ZLWKcompared to those with minimal or no weight loss (Scott et al, 
2¶*RUPDQHWDO6LPLODUO\DJURXSRIfifty-three 
patients with various cancers and ZHLJKWORVVUDWHGDOODVSHFWVRI
quality of life FRYHUHGE\WKH6)íTXHVWLRQQDLUHsignificantly lower 
than a reference group of age-matched healthy controls (Fouladiun et 
al, 2007). 
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2.5 Impact of cancer cachexia on physical function 
Cancer cachexia has a profound effect on physical function, which 
HQFRPSDVVHVWKHSDWLHQW¶VOHYHORISK\VLFDOFDSDELOLW\LQdependence 
and activity. This is important not least because performance status, a 
global indicator of physical function, is used to assess eligibility for 
various anti-cancer treatments and is a strong independent predictor of 
survival (low performance status, HR 1.15 95% CI 1.í, Scott et 
al, 2003; hazard ratio 1.46 95% &,í1.88, Maione et al, 2005). 
 
2.5.1 Primary consequences 
Three primary consequences of cancer cachexia on physical function 
have been identified; impaired muscle function, an overall energy deficit 
and an increased symptom burden. These as shown in Figure 2.2, 
which is the authors own representation, and will be described 
separately in the proceeding sections of this chapter. 
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Figure 2.2. Mechanisms by which cancer cachexia impairs physical function. 
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2.5.1.1 Impaired muscle function 
The in-depth examination of muscle function in patients with cancer is 
limited to a small number of studies involving patients with small cell 
lung cancer following potentially curative treatment (n=11) (Baracos et 
al, 1994), advanced non-small cell lung cancer (n=26) (Wilcock et al 
2008a; Reinglas et al, 2007), or advanced upper-gastrointestinal cancer 
(n=64) (Reinglas et al, 2007; Weber et al, 2008). Methodology varies 
between the studies making direct comparison difficult, but generally 
the quadriceps have been studied with isokinetic testing and function 
compared to healthy controls or reference data sets matched for age 
and gender. Patients consistently produce values of peak torque 
(Newton metres, Nm) and total work values (Joules, J) 20í40% lower 
than expected. This impairment in muscular strength and endurance 
was greatest in patients with substantial weight loss (>10% over 6 
months) (Weber et al, 2009) and least in those with a recent diagnosis 
(Reinglas et al, 2007) or good performance status (Wilcock et al, 
2008a). 
 
The Weber et al study also explored the mechanism of muscle 
function impairment and found despite a global reduction in function, 
parameters of microcirculation, e.g. capillary density and blood flow, 
and muscle metabolism, e.g. high-energy phosphates, resting pH, were 
comparable between patients and healthy controls. Differences in 
quadriceps strength disappeared when normalised for muscle cross-
sectional area (mean difference [95% CI], isometric 0.03 [-0.3, 0.4] Nm 
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and isokinetic -0.3 [-0.7,0.2] Nm) suggesting that muscle function  
appears to be impaired by the quantity, i.e. mass, and not the quality, 
i.e. aerobic capacity, of remaining tissue (Weber et al, 2009). 
 
2.5.1.2 Overall energy deficit 
Energy expenditure is comprised of three main components: resting 
energy expenditure, thermogenesis related to food consumption and 
physical activity (Gibney, 2000). If energy expenditure exceeds energy 
intake, an energy deficit occurs. 
 
Compared to age-predicted values or age-matched controls, 
UHVWLQJHQHUJ\H[SHQGLWXUHKDVEHHQIRXQGWREHLQFUHDVHGE\í
in studies with various sample sizes involving patients with advanced 
pancreatic cancer (Falconer et al, 1994 (n=21); Moses et al, 2004 
(n=24)) and both local or advanced lung cancer (Gibney et al, 1997 
(n=8); Jatoi et al, 2001 (n=18); Fredrix et al, 1991 (n=18); Jebb et al, 
1994; Stall-van den Brekel et al, 1995 (n=87); 1997 (n=66). In 
health, increases in energy expenditure are generally compensated for 
by an increase in energy intake. However, in patients with advanced 
cancer, energy intake is often already reduced or cannot be increased 
because of anorexia; food portions generally become smaller, and 
meals and snacks are missed (Hutton et al, 2006). Some patients with 
cancer adopt a µKHDOWK\¶ diet, e.g. skimmed milk, cereals, soups, etc. 
which also lowers energy intake (Hutton et al, 2006). 
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The alternative means of addressing an energy deficit is to 
reduce expenditure related to physical activity, which may 
occur voluntarily or in response to symptoms relating to the deficit, e.g. 
fatigue, exhaustion (Kulstad and Schoeller, 2007). There is evidence 
that this occurs in patients with cancer and raised resting energy 
expenditure. Gibney et al (1997) compared energy expenditure in 8 
patients with advanced SCLC to age-predicted control values (DoH, 
1991) and found patients had a significantly reduced total energy 
expenditure due to a lower level of physical activity (Figure 2.3). These 
findings were later replicated in 24 patients with advanced pancreatic 
FDQFHUDQGZHLJKWORVW in whom total energy expenditure was 
lower than age-match controls (1732 vs.1903 kcal/day, P=0.02) 
secondary to a reduced level of physical activity (Moses et al, 2004). 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 2.3 Energy expenditure in patients with advanced SCLC and healthy 
reference values (Gibney et al, 1997). 
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2.5.1.3 Increased symptom burden 
The symptom burden for patients with incurable cancer is substantial. In 
the largest database to date, Teunissen et al (2007) examined overall 
symptom prevalence across 44 studies involving over twenty-five 
thousand patients. This sample size allowed precise 95% confidence 
intervals to be calculated so findings could be generalised to a 
population level. More than half of patients experienced symptoms 
related to cachexia with mean [95% CI] rates of fatigue, lack of energy, 
ZHDNQHVVDQGDQRUH[LD>í@>í@>í@DQG
>í@UHVSHFWLYHO\ (Teunissen et al, 2007). The pro-inflammatory 
state associated with cancer cachexia may contribute to these symptom 
as elevated levels of cytokines increase fatigue, depression, cognitive 
impairment and disrupted sleep (Seruga et al, 2008). The muscle 
wasting and weakness associated with cancer cachexia also lead to an 
early onset and increased levels of leg muscle fatigue and 
breathlessness (Coats, 2002; Hamilton et al, 1996). 
 
2.5.2 Secondary consequences of cachexia on physical function 
The impaired muscle function, energy deficit and increased symptom 
burden reduce physical function through their effect RQSDWLHQWV¶
exercise capacity, level of physical activity and ability to undertake 
activities of daily living (Figure 2.2). 
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2.5.2.1 Reduced exercise capacity 
Exercise capacity is dependent on the ability of the ventilatory and 
circulatory systems to deliver oxygen to the muscle together with 
factors affecting muscular performance, e.g. capillarisation, oxidative 
capacity (Bassett et al, 2000). During exercise, the perceived effort of 
breathing and sensation of leg muscle fatigue gradually increase until 
either one or the other or both together reach a level which causes the 
patient to stop (Killian et al, 1992; Hamilton et al, 1996; Jones and 
Kiilian, 2000). In cancer cachexia, when muscle function is impaired 
due to wasting, a smaller amount of muscle mass is available to 
undertake any given workload (Stendardi et al, 2005). Thus, the sense 
of effort is increased and patients are prevented from exercising at 
levels they were previously able to manage (Killian et al, 1992; 
Hamilton et al, 1995). 
 
 Only two studies have formally examined exercise capacity using 
recommended assessment methods in patients with advanced cancer. 
In the first, patients with non-small cell lung cancer (n=42) undertook a 
maximal cycle ergometry test and peak VO2 values were compared to 
those predicted for age and gender using healthy control data. Despite 
patients having a reasonable performance status (KPS $SSHQGL[
1.2), values were 33% lower than predicted (Jones et al, 2008). In the 
second, patients with pancreatic cancer (n=50) and age-matched 
healthy controls (n=40) undertook a symptom-limited incremental 
treadmill exercise test. Compared to controls, patients had less muscle 
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mass (9%), reached their anaerobic threshold at lower workloads (13%) 
and had increased levels of fatigue leading to a much reduced exercise 
capacity (peak VO2, 30%) (Heinz et al, 2007). In both groups, exercise 
capacity was shown to be moderately related to leg muscle mass 
(patients r=0.42; controls r=0.81, p<0.01), LQNHHSLQJZLWK:HEHUHWDO¶V
findings that loss in muscle quantity is responsible for impaired muscle 
function (Weber et al, 2009). 
 
2.5.2.2 Reduced physical activity 
The energy deficit caused by cancer cachexia leads to a reduction in 
levels of physical activity (Gibney et al, 1997; Moses et al, 2004). The 
development of lightweight monitors worn on the wrist or thigh has 
allowed these to be examined more easily. Studies have examined 
physical activity levels of cachectic patients, predominantly with upper-
gastrointestinal cancer, either around the time of diagnosis (n=53) or 
during first-line palliative chemotherapy (n=20). Compared to  age-
matcKHGKHDOWK\FRQWUROVSDWLHQWVKDGVLJQLILFDQWO\OHVVDFWLYLW\µcounts¶ 
per minute $FWL*UDSK)RXODGLXQHWDORUVpent a median of 2h 
less upright and took 43% IHZHUVWHSVHDFKGD\$FWLY3$/ Dahele et 
al, 2007). In the latter study, despite spending less time upright, 
patients got into standing a similar number of times suggesting activity 
was limited by the ability to undertake prolonged periods of work. 
Physical activity levels have also been shown to decline over time with 
worsening disease (Fouladiun et al, 2007) and with increasing morbidity 
(Dahele et al, 2007). 
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Physical inactivity is both a contributor to and a consequence of 
impaired physical function. As patients reduce their level of physical 
activity, muscle disuse atrophy and cardiovascular deconditioning 
occur, which exacerbate existing symptoms and lead to a greater level 
of limitation (Biolo et al, 2005). Thus, patients are at high risk of 
entering a spiral of deconditioning where physical function and physical 
activity level decline as consequences of each another. 
 
2.5.2.3 Reduced ability to undertake activities of daily living 
%RWKWKHQXPEHURIV\PSWRPVDQGWKHLUVHYHULW\DUHUHODWHGWRSDWLHQWV¶
ability to undertake various functional activities (Sarna, 1993; Ferreira et 
al, 2008). When asked which symptoms interfere with daily activities, 
patients with advanced lung cancer and a good performance status 
(ECOG 0-1) reported that global fatigue and breathlessness were 
particularly troublesome (Sarna et al, 1993; Tanaka et al, 2002; 
Okuyama et al, 2001). Most commonly, these were reported to interfere 
ZLWKSDWLHQWV¶DELOLW\WRZDONwork and complete more strenuous 
household chores (Sarna et al, 1993b; Tanaka et al, 2002; Okuyama et 
al, 2001). In patients with a variety of cancers on a specialist palliative 
care unit (median survival 8 weeks), symptoms of breathlessness and 
muscle fatigue either alone or together prevented many patients from 
completing many daily activities, e.g. washing and dressing. For most 
activities, greater proportions of patients reported being limited by 
muscle fatigue alone or in combination with breathlessness than by 
breathlessness alone (Wilcock et al, 2008b). 
45 
 
2.6 Relationship between physical function and quality of life 
A reduction in physical function may prevent patients from completing 
activities they enjoy or those necessary for independent living. Figure 
2.4, adapted from its original presentation (Walker et al, 1999), depicts 
this interaction and assumes patients will do what they wish or need to, 
provided they are able. In an unimpaired state (a), patients can meet all 
their activity related needs and, although some wishes are unattainable, 
e.g. running fast for a bus, most can be met. When physical function is 
impaired (b), initially more demanding wishes, e.g. a tiring work 
schedule, more active hobbies, become unattainable. As physical 
function deteriorates further (c), even less demanding wishes cannot be 
met and some needs IDOOEH\RQGSDWLHQWV¶ability, representing a loss of 
independence (Figure 2.4). 
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Figure 2.4 Impact of physical function on ability to meet activity-related wishes 
and needs. 
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The progressive loss of ability and independence are likely 
impact adversely on quality of life. This is in keeping with Stewart and 
KLQJ¶V (1999a) conceptualisation of quality of life being comprised of 
two main categories: function (physical abilities, dexterity, cognition, 
activities of daily living) and well-being (symptoms, bodily state, 
emotional well-being, self-concept, global perceptions). The relationship 
between physical function and quality of life is complex and moderated 
E\PXOWLSOHIDFWRUVHJKRZPXFKSDWLHQWV¶YDOXHIXQFWLRQDQGZHOO-
being or adjust to iOOQHVVDQGµUHIUDPH¶WKHLUZLVKHVbut generally a 
reduction in physical function appears synonymous with a poorer 
quality of life. This is important as if patients with or at risk of cancer 
cachexia can be better managed. Maintaining or reducing the decline in 
their physical function may also impact on their overall quality of life. 
 
Data supporting the notion that physical function is related to 
quality of life and psychological well-being exist. In older adults, 
accumulating evidence supports a close relationship between physical 
activity and these domains. Netz and Wu (2005) conducted a meta-
analysis to examine the effects of increased participation in physical 
activity and found a causal enhancement effect on several components 
of well-being including emotion, self-perception and life satisfaction. 
Rejeski and Mihalko (2001) provided further support with a narrative 
review which concluded that physical activity positively influenced 
multiple outcomes associated with quality of life regardless of age, 
activity level and health status (Rejeski and Mihalko, 2001). 
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In cancer survivors, several large cross-sectional studies 
Q íKDYHcategorised patients according to whether or not 
they meet physical activity guidelines, usually of 150 minutes of 
moderate activity each week (Haskell et al, 2007; Nelson et al, 2007). 
Those meeting guidelines during or following anti-cancer treatment 
consistently report significantly higher quality of life as assessed by a 
variety of measurement tools (Vallance et al, 2005, Milne et al; 2007; 
Stevinson et al, 2007; Blanchard et al, 2004; Lynch et al, 2008). In 
patients with cancer, there are limited data on physical activity but 
performance status appears to be moderately associated with quality of 
life. For example, in two studies of groups about to commence 
chemotherapy (Pinquart et al, 2006 (n=170); Wedding et al, 2007 
(n=347)), the Karnofsky Performance Score was associated with global 
quality of life (r=0.41, p<0.01) and could be used to predict quality of life 
when used in regression modelling (Pinquart et al, 2006; Wedding et al, 
2007). Furthermore, the change in Karnofsky Performance Score 
between 6 and 3 months prior to death in 67 advanced cancer patients 
was significantly correlated with change in the well-being domain 
(r=0.43, p<0.01) and global quality of life as measured by the FACT-G 
questionnaire  (r=0.36, p<0.05) (Hwang et al, 2003). 
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2.7 Management of cancer cachexia 
Despite the magnitude of problem cancer cachexia represents, 
progress in developing effective treatments is slow (Steer, 2004; 
Baracos, 2006). Studies have generally focused on either reducing the 
anorexia or altered metabolism and interventions have ranged from 
nutritional counselling (Isenring et al, 2004) and simple dietary 
intervention, e.g. offering small but energy-dense meals (Laviano et al, 
2005), through to pharmacological therapies including progestagens 
(Berenstein et al, 2005), corticosteroids (Willox et al, 1984) and omega-
3 fatty acid enriched oral nutritional supplements (Fearon et al, 2003; 
Moses et al, 2004). 
 
Attempts to identify a sole therapy for cachexia have produced 
mostly disappointing results. Dietary interventions have generally failed 
to prevent further weight loss (Ng and Lowry, 1991; Laviano et al, 
2005). Although corticosterioids and progestragens have temporarily 
improved appetite and/or body weight, weight gain often reflects 
unhelpful fluid retention and these drugs may exacerbate muscle 
weakness (Pascual Lopez et al, 2004; Fearon, 2008). More success 
has been found combining two or more treatments. For example, the 
combination of Ibuprofen with megestrol acetate was more effective 
than either alone in terms of weight gain in patients with gastrointestinal 
cancer (McMillan et al, 1999). Nutritional support, indomethacin (anti-
inflammatory) and erythropoietin (anti-anaemia) combined has 
improved energy expenditure and physical function in patients with 
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>10% weight loss (Lundholm et al, 2004). Furthermore, interim findings 
of a large phase III study show more benefit from a combination of anti-
oxidants, nutritional support, progestagen and an anti-inflmammatory 
agent compared to other study arms in which only two or three 
therapies are given (Mantovani et al, 2008). 
 
These data are encouraging, but the muscle wasting associated 
with cancer cachexia remains irreversible with currently available 
treatments (Muscaritoli et al, 2006). In addition to nutritional support, 
immunomodulation and anabolic stimulants, exercise is likely to be an 
important component of any future multimodal approach to the 
management of cancer cachexia (Fearon, 2008; Tisdale, 2009). 
Exercise has the potential to help attenuate many of the the primary 
and secondary consequences of cachexia outlined in this chapter and 
depicted in Figure 2.2. The goals of exercise in other settings include 
reducing symptoms as well as improving muscle function, exercise 
capacity and the ability to undertake activities of daily living. Thus, the 
use of exercise in this setting may help address some of the 
consequences of cancer cachexia and slow down the decline in 
physical function and quality of life (Mascaritoli et al, 2004; 2006). 
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2.8 Summary 
Cancer cachexia limits treatment options, increases morbidity, impairs 
quality of life and reduces survival. With no satisfactory treatment, it 
represents a major unmet need in supportive and palliative care. 
Despite the multitude of consequences cancer cachexia has on 
physical function, attempts to manage patients with or at risk of 
cachexia with physical therapies have only recently begun to be 
explored. The use of therapeutic exercise in patients with cancer and 
the challenges of its application are topics of the next chapter.
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CHAPTER 3: 
THE ROLE OF EXERCISE IN  
PATIENTS WITH CANCER 
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3.1 Introduction 
In the last chapter, the cachexia syndrome was outlined as a major 
contributor to the loss of physical function and independence in patients 
with incurable cancer, particularly of the lung and upper-gastrointestinal 
tract. The potential role of therapeutic exercise for those with or at risk 
of cancer cachexia was outlined as a means to improve the 
management of these patients. This chapter examines the use of 
exercise in patients during or following treatment for curable cancer and 
in patients with incurable cancer. After appraising the evidence base in 
these groups, the challenges of using exercise as a therapy are 
considered leading to an exploration of more practical novel types of 
exercise. This chapter provides part of the background for the first three 
pieces of original work presented in chapters five, six and seven, 
examining the acceptability of therapeutic exerciseSDWLHQWV¶
preferences around exercise and the use of neuromuscular electrical 
stimulation as a novel exercise therapy. 
 
3.2 Current use of exercise in cancer 
A search was conducted to identify published reviews and studies 
examining the use of exercise in adults with or cured of cancer.  
Medline, Embase, Cochrane Central Register of Controlled Trials and 
Cinahl electronic databases were searched from their respective 
inceptions to July 2009 using search terms based on exercise (physical 
activity, exercise therapy, physical training, aerobic, strength, walking) 
and clinical studies (study, programme, intervention, scheme, trial). In 
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addition, reference lists of relevant reviews and studies already located 
were searched and experts in the field were contacted to identify grey 
literature. The evidence bases relating to patients during or following 
treatment for curable cancer and those with incurable cancer were 
appraised separately as detailed below. 
 
3.2.1 Patients during or following treatment for curable cancer 
The majority of studies into the use of exercise in the field of cancer 
have involved patients during or following curative treatment. In the 
earliest studies, resistance training led to increased excretion of 
creatinine, a marker of muscle mass, in patients following bone marrow 
transplantation (Cunningham et al, 1986) and endurance training 
improved physical function in patients with resectable breast cancer 
receiving adjuvant chemotherapy (MacVicar and Winningham, 1988). 
The amount of work examining exercise has grown exponentially and 
there are currently >70 primary studies of varying quality. The safety of 
therapeutic exercise in this setting has not been formally examined, 
although no serious adverse events relating to exercise have been 
reported suggesting that it is a safe therapy if used appropriately (Jones 
et al, 2009). Potential adverse events may include an injury when 
exercising or post-exercise muscle soreness and general fatigue, 
however, the risks of these can be effectively managed with adequate 
instruction, training and supervision (McNeely et al, 2006a). 
Numerous reviews of the efficacy of exercise in this setting have been 
undertaken. Most have adopted more inclusive inclusion criteria to 
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involve a greater number of studies (Courneya, 2003; Oldervoll et al, 
2004; Stevinson et al, 2004; Holtzman et al, 2004; Galvao and Newton, 
2005; Shmitz et al, 2005; Knols et al, 2005; Conn et al, 2006). A smaller 
number have focused on a particular effect of exercise, e.g. fatigue 
(Jacobsen et al, 2007; Cramp and Daniel, 2008) or quality of life 
(Courneya and Friedenreich; 1999). Others have focused on a 
particular group of patients, e.g. with breast cancer (McNeely et al, 
2006b) or those receiving anti-cancer treatment (Young-McCaughan 
and Arzola, 2007). 
 
Conn et al (2006) provide the most current and comprehensive 
synthesis of these data with a systematic review and meta-analysis of 
30 studies that provided sufficient data to calculate an effect size. This 
was more studies than other reviews had located using similar criteria 
underscoring a comprehensive search strategy. Most studies in this 
review concerned groups consisting entirely (n=13) or predominantly 
(n=5) of patients with curable breast cancer during or following 
treatment. The exercise programmes offered to patients varied, 
however the majority were based at a centre and supervised (n=21) 
and included either aerobic (n=18), resistance (n=11) or flexibility (n=9) 
training components undertaken at moderate intensity (n=21). Sessions 
lasted for DPHGLDQ>,45@RI>í@PLQutes and were completed 3 
>í@WLPHVHDFKZHHNIRU>í@ZHHNV (Conn et al, 2006). 
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To compare outcome across studies, Conn et al (2006) used 
standardised mean differences to construct overall effect sizes with 
95% confidence intervals. One strength of the methodology used was 
that the analysis plan weighted studies such that larger samples had 
proportionally more impact on the effect sizes. An effect size provides a 
generic numerical measure of the effectiveness of an intervention, 
which can be interpreted as small (>0.1), moderate (>0.3) or large 
(>0.5) (Cohen, 1988). It can also be converted into statements which 
use percentage values to describe the overlap between two groups to 
infer a degree of change or difference. For example, an effect size of 
0.1, 0.3 or 0.5 indicates that the score or performance of the average 
patient following an intervention, in this case exercise, would exceed 
that of 54%, 62% and 69% of patients in the respective control groups 
(Cohen, 1988).  
 
From uncontrolled studies, a large effect size from exercise was 
found for physical function, which included aspects such as muscular 
strength or physical fitness, and moderate effect sizes were found for 
fatigue, mood, other physical symptoms and quality of life, all of which 
were statistically significant (Table 3.1). When data from controlled 
studies were pooled, effect sizes reduced and 95% confidence intervals 
became wider such that only the effect of exercise on physical function 
remained significant (Table 3.1). 
 
 
57 
 
 
 Uncontrolled /  
pre- vs. post-exercise 
 Controlled / 
exercise vs. control 
Outcome 
Effect size 
[95% CI] p 
 
Effect size 
[95% CI] p 
Fatigue 
Mood 
Exercise behaviour 
Physical function 
Quality of life 
Physical symptoms 
0.40 
0.34 
0.21 
0.72 
0.43 
0.44 
[ 0.12, 0.67] 
[ 0.19, 0.49] 
[-0.35, 0.96] 
[ 0.43, 1.00] 
[ 0.29, 0.58] 
[ 0.09, 0.81] 
<0.01 
<0. 01 
ns 
<0.01 
<0.01 
<0.05 
 í 
0.19 
0.04 
0.52 
í 
0.35 
í 
[-0.12, 0.50] 
[-0.52, 0.60] 
[ 0.25, 0.78] 
í 
[-0.30, 0.99] 
í 
ns 
ns 
<0.001 
í 
ns 
CI = confidence intervals, ns = not significant (P>0.05) 
 
Table 3.1 Effect sizes for exercise programmes in patients during or following 
treatment for curable cancer (Conn et al, 2006). 
 
The review also examined if cancer type (breast/non-breast), 
presence of exercise prescription, supervision, inclusion of a fitness test 
and timing relative to treatment (during/following) were moderating 
variables for an effect from exercise (Conn et al, 2006). This analysis 
was largely limited by the small number of studies with adequate data 
from which to calculate effect sizes, however, there were indications 
that higher effect sizes were found in groups of patients with a 
diagnosis of breast cancer and when exercise was delivered following 
anti-cancer treatment. However, perhaps owing to the wide 
heterogeneity in samples and study design, none of the moderator 
effects were found to be significant (Conn et al, 2006). 
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This well-conducted review provides support for the use of 
exercise in patients during or following treatment for curable cancer 
(Conn et al, 2006). The main finding of an improvement in physical 
function following exercise is in keeping those of others (Courneya and 
Friedenreich, 1999; Oldervoll et al, 2004; Mock 2004) and the small-to-
moderate effect size estimates encompass reported in previous meta-
analyses of these data (Holtzman et al, 2004; Stevinson et al, 2004; 
Cramp and Daniel, 2008). It is difficult to draw more focused 
conclusions due to the quantity and quality of studies to date. Conn et 
al (2006) did not use a formal instrument to assess the methodological 
quality of included studies, e.g. CONSORT checklist, but reported 
whether studies had features associated with a robust design. Many 
studies had pitfalls which may introduce bias, for example, around half 
were not randomised and few described allocation and/or concealment 
protocols, blinded assessors to treatment allocation or described the 
handling of data from patients who withdrew from a study. Outcomes 
were also assessed by a variety of tools, some of which had not 
undergone appropriate psychometric testing which the authors 
acknowledged but did not take into account in their analysis (Conn et 
al, 2006) As larger, higher quality studies emerge it should become 
possible to estimate effect sizes with more precision, examine 
additional effects from exercise, e.g. on sleep (Burnham and Wilcox, 
2002) and potentially determine the most beneficial type of exercise 
programme, e.g. session duration or frequency, or the minimum amount 
of exercise required to produce a beneficial effect. 
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3.2.2 Patients with incurable cancer 
Only a limited number of studies have examined exercise programmes 
offered to patients with incurable cancer (Table 2.2). Five studies, three 
of which were uncontrolled, and three case studies have reported on a 
total of 119 patients. The cancer diagnosis has varied between and 
within studies but in general patients offered exercise have been 
UHDVRQDEO\ILWDQGLQGHSHQGHQW(&2*SHUIRUPDQFHVFRUHíRU.36
UHIOHFWLQJWKHXVHRIH[HUFLVHDVDSURDFWLYHWKHUDS\WRPDLQWDLQRU
slow down the loss of physical function. The content and structure of 
programmes has been inconsistent. Programmes have used either 
aerobic (n=3) or resistance (n=3) training or a combination of the two 
(n=2). Discounting the case studies, three of the five studies have 
offered exercise at hospital in a group setting and two have offered 
home-based programmes to be undertaken alone. Individual sessions 
of exercise have lasted up to 120 minutes, been completed from twice-
weekly to several times daily and programmes have lasted fRUí
weeks (Table 3.2). 
 
The safety and feasibility of therapeutic exercise in patients with 
incurable cancer is still being explored. As is the case in patients with 
curable cancer, no serious adverse events relating to exercise have 
been reported suggesting it is a safe therapy when used appropriately 
(Jones et al, 2009). Similarly, it appears feasible to use exercise in this 
group as studies have been completed in a range of patients, including 
those receiving concurrent anti-cancer treatment (Headley et al, 2004; 
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Oldervoll et al, 2006; Porock et al 2000). Nonetheless, these aspects 
should be examined formally with adequately powered phase II studies 
before large efficacy studies are attempted. 
 
Overall, data suggest that some patients with incurable cancer 
are able to complete an exercise programme and benefit from 
improvement in physical function and aspects of quality of life. Of three 
studies in which physical function was assessed objectively, muscle 
strength or functional capacity improved in two (Oldervoll et al, 2006; 
Renk et al, 2005) and was maintained in the other (Temel et al, 2009). 
Several case studies which have measured parameters of 
cardiorespiratory fitness have also found improvements, e.g. increased 
peak workload, peak VO2, or resting heart rate (Crevenna et al 2003a 
and 2003b; Kelm et al, 2003). In addition, several studies found 
improvements in one or more domains of quality of life following 
exercise, e.g. dyspnoea, function, emotion and social domains 
(Crevenna et al, 2003a; Temel et al, 2009; Oldervoll et al, 2006), or a 
higher overall quality of life score (Porock et al, 2000; Kelm et al, 2003; 
Headley et al, 2004)  
 
These preliminary findings suggest a potentially beneficial effect 
from exercise but should be considered in light of the heterogeneity in 
study design, setting and patient group and the methodological 
limitations inherent in collecting pilot data (Lowe et al, 2009). Most 
studies have not been statistically powered to examine efficacy and 
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lack a control group therefore improvements may be accounted for by 
motivational or learning effects alone. For example, Renk et al (2005) 
FRQFOXGHGWKDWH[HUFLVHZDVDµYHU\HIIHFWLYHPHWKRGWRSUHYHQWPXVFOH
ZDVWLQJ¶ despite reporting on a limited group of 10 patients. In addition, 
benefit appears to be limited to a select group of patients who were 
able and willing to complete the exercise programme being offered. 
When patient flow data was reported, only about a half of those 
approached about an exercise study started the programme (Porock et 
al, 2000, Oldervoll et al, 2006), thus reducing the ability to generalise 
findings to a larger group of patients. Adherence to the recommended 
programme of exercise was also an issue in some studies, particularly 
involving patients with non-small cell lung cancer (Temel et al, 2009). 
This suggests those most at risk of cancer cachexia and potentially able 
to gain the most from exercise, may also find it least acceptable as a 
therapy. Temel et al (2009) suggested that offering community based 
programmes may improve adherence but it is clearly necessary to 
further explore the utility of exercise in this setting before embarking on 
larger efficacy studies.
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Table 3.2 Summary of exercise studies in patients with incurable cancer. 
 
Study Programme Main findings  
(mean group % change,  
patients first) Author Design Patients Content Outcomes 
Headley et al 
(2004) 
 
RCT  
(n=38) 
Breast cancer 
receiving 
chemotherapy 
Mean age: 51 
 
Home-based seated 
exercises. 30 minutes, 
three times each week 
for 12 weeks 
Fatigue and overall quality of 
life: FACT fatigue scale 
Perceived exercise intensity: 
Borg rating scale 
Sig. slower decline in fatigue 
and overall quality of life in 
exercise group 
Renk et al 
(2005) 
Patients (n=10) 
and age/gender-
matched healthy 
controls (n=10) 
Gastrointestinal 
FDQFHUDQG
weight loss 
Hospital-based 
isokinetic resistance 
training.75% 1RM twice 
weekly for 8 weeks 
Muscle strength: isokinetic 
dynamometry 
Body cell mass: 
bioimpedance 
Thigh CSA: magnetic 
resonance imaging 
BRWKJURXSVVLJĹLVRPHWULF
(20% and 22%) and isokinetic 
(14 and 10%) quadriceps 
strength, body cell mass and 
thigh CSA 
 
Oldervoll et al 
(2006) 
Uncontrolled 
(n=34) 
Variety of cancers 
Mean age: 65 
.36 
 
Hospital-based aerobic 
and resistance circuit 
training. 50 minutes, 
twice a week for 6 
weeks 
Functional capacity: timed sit-
to-stand and 6MWT 
Quality of life: EORTC-C30 
6LJĹIXQFWLRQDOFDSDFLW\VLW-to-
VWDQG0:7Ĺ
dyspnoea, functional, emotional 
and social domains of quality of 
life (subscales í 
Temel et al 
(2009) 
Uncontrolled 
(n=25) 
Newly diagnosed 
non-small cell 
lung cancer 
Median age: 68 
(&2*í 
Hospital based aerobic 
and resistance training. 
120 minutes, twice 
weekly for 8 weeks 
Functional capacity: 6MWT 
Muscle strength: isokinetic 
dynamometry 
Quality of life: FACT lung 
cancers symptom and fatigue 
scales 
Only eleven patients attended 
DOOVHVVLRQVVLJĻV\PSWRPV
and no change in functional 
capacity or muscle strength 
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Porock et al 
(2000) 
Uncontrolled 
(n=9) 
Variety of cancers  
Mean age: 60 
(&2*í 
 
Home-based short 
sessions of walking, 
seated exercises and 
dancing (individualized) 
several times daily for 4 
weeks 
Multidimensional Fatigue 
Index, Hospital Anxiety and 
Depression Scale, Symptom 
Distress Scale, Quality of Life 
Scale 
Non-sigWUHQGVWRZDUGVĻ
fatigue (activity, motivation and 
mental subscales), anxiety and 
ĹTXDOLW\RIOLIHRYHUSURJUDPPH 
Crevenna et al 
(2003a) 
Case study 
(n=1) 
Male (age 55) 
with metastatic 
hepato-cellular 
cancer (lung and 
brain 2°) 
Home-based stationary 
cycling (60% HRmax), 60 
minute sessions, twice 
weekly for 6 weeks 
Peak work: cycle ergometry 
Sub-maximal exercise 
capacity: 6MWT 
Quality of life: SF-36 
ĹSHDNZRUNFDSDFLW\DQG
sub-maximal exercise capacity 
(20%) 
6)íĹSK\VLFDOIXQFWLRQLQJ
(31%), vitDOLW\IDWLJXHĻ
general health (-5%) and pain (-
86%) 
 
Crevenna et al 
(2003b) 
Case study 
(n=1) 
Female (age 48) 
with metastatic 
breast cancer 
(lung, liver and 
bone 2°) 
Home-based stationary 
cycling (60% HRmax), 60 
minute sessions, three 
times weekly for 52 
weeks 
 
Peak VO2 and work capacity: 
cycle ergometry 
Lung function: spirometry 
4XDOLW\RIOLIH6)í 
 
Ĺ peak VO2, (53%) and peak 
work capacity (36%) 
 
Kelm et al 
(2003) 
 
Case study 
(n=1) 
Male (age 58) 
with metastatic 
rectal cancer 
(liver 2°) 
Hospital-based 
resistance (20 reps of 
í50DQG
aerobic training (30 
minutes) 1-2 sessions 
weekly for 13 weeks. 
Exercise endurance: 
reduction in resting heart rate 
Lung function: spirometry 
Quality of life: GIQLI 
ĻUHVWLQJKHDUWUDWH-10%) 
Ĺ)(91 Ĺ)9& 
ĹRYHUDOOTXDOLW\RIOLIH 
ECOG = Eastern Cooperative Oncology Group, EORTC-C30 = European Organisation for Research and Treatment of Cancer core questionnaire, FACT-G = 
functional assessment of cancer therapy, FEV1 = forced expiratory volume in one second, FVC = forced vital capacity, GIQLI = Gastrointestinal Quality of Life 
Instrument, HR = heart rate, 6)í 6KRUW-Form 36, Sig = significant, 6MWT=six minute walk test.
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3.3 Challenges of using exercise as a therapy 
3.4.1 Issues with acceptability and practicality 
Exercise takes time and effort to perform and participation in an 
exercise programme requires a high level of commitment and 
motivation (Oldervoll et al, 2005; Chao et al, 2000). Even in healthy 
older adults, only a minority of the population undertake sufficient 
exercise and physical activity to maintain their current level of health 
and it is difficult to increase levels of exercise over a sustained period of 
time (Thurston and Green, 2004; Nelson et al, 2007). For example, the 
majority of older adults (>65 years) prescribed home-based exercise 
admit to partial or complete non-adherence (Yardley and Donovan-Hall, 
2007) and more than half of healthy older adults who start an exercise 
programme drop out during the first six months (Dishman, 1990). 
 
Cancer and its treatment may make it even more challenging to 
undertake therapeutic exercise. In patients during or following anti-
cancer treatment for curable cancer, rates of uptake, adherence and 
completion across twelve exercise studies have been examined 
(Oldervoll et al, 2004). Of 1697 eligible patients invited to take part in an 
exercise programme, more than half declined (53%). Of those who 
started a programme, a mean (range) of 14% (íof did not 
complete (Oldervoll et al, 2004). Among those patients who were able 
to completed a programme, DGKHUHQFHZDVJHQHUDOO\KLJKí, 
suggesting a high level of motivation. However, overall, less than half 
 65 
 
were able and willing to complete an exercise programme (Oldervoll et 
al, 2004). 
 
In patients with incurable cancer, the successful undertaking of 
studies into exercise represents even more of a challenge and patient 
flow data reflect this. In Oldervoll et al¶V study (2006), of 101 patients 
approached about participation in the exercise programme, 38 
immediately refused and a further sixteen withdrew consent before 
starting. The most common reasons for refusal related to travel to the 
programme (n=9) or patients already exercising (n=3) or lacking energy 
(n=4) and in most patients who withdrew consent this was due to a 
medical reason (n=12). During the course of the programme a further 
thirteen patients dropped out (medical problems n=10, social reasons 
n=2, or death n=1) such that, overall, only one third of those 
approached and about half of those interested managed to complete 
the programme (Oldervoll et al, 2005). The study by Temel et al (2009) 
in patients with incurable non-small cell lung cancer provides another 
example. Data on the number of patients approached were not 
presented but of 25 patients (who took three years to recruit), six did 
not start the programme, two only completed one exercise session, and 
only eleven patients completed the 8 week programme. The reasons for 
withdrawing from the exercise programme included hospitalization 
(n=3), toxicities relating to either chemotherapy (n=2) and deterioration 
in overall health (n=2) (Temel et al, 2009). 
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3.3.2 Barriers to exercise in patients with cancer 
Multiple barriers may prevent patients from taking up and completing an 
exercise programme and/or study (Figure 3.1) (Sherwood and Jeffery, 
2000). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Potential barriers to participation in an exercise study 
 
Personal barriers include a lack of motivation and low self-
efficacy. Patients require motivation in order to be willing to take up 
exercise and need to be convinced that the benefits will offset the 
inconvenience associated with it (Sherwood and Jeffery, 2000; Yardley 
and Donovan-Hall, 2007).  They also need to have sufficient self-
efficacy, i.e. belief in their own capability, which may be compromised 
by current physical symptoms, the perceived demands of an exercise 
Lack of motivation 
 
Low self-efficacy 
 
Fear of discomfort or 
provoking symptoms 
 
Lack of family or 
social support 
Personal Environmental Contextual 
Lack of information  
 
Lack of control over 
treatment selection 
 
 
Perceived change in 
relationship with 
doctor  
Lack of time  
 
Difficulties with 
scheduling  
 
Difficulties with travel 
 
Lack of access to 
equipment 
 67 
 
programme and the opinions of friends, family and other significant 
others (Carron et al, 1996; Leddy, 1997; Courneya and Friedenreich, 
1999). Environmental factors will also impact on the practicality of an 
exercise programme. Lack of time is a common barrier as participation 
in exercise requires the time for travel, preparation as well as the 
prescribed period exercise (Booth et al, 1997; Godin, 1994). Other 
environmental barriers include scheduling difficulties, poor access to 
equipment and, for patients on treatment with compromised immune 
function, the need to avoid crowded public spaces (Doyle et al, 2006). 
Finally, the context of an exercise programme as part of a research 
study may prevent patients from taking it up. Several barriers to the 
study accrual process have been identified. These include a perceived 
lack of information or control when entering a study involving a random 
process and a perceived change in the relationship with the SDWLHQW¶V
physician, who is now bound by a study protocol rather than clinical 
judgement (Mills et al, 2006; Castel et al, 2006). 
 
The review by Oldervoll et al (2004) cited earlier in this section 
provided a useful insight into the acceptability of exercise programmes 
in the cancer setting. However, owing to the recent growth in this 
literature, its findings only represent around a fifth of the available 
studies in patients with curable cancer (12 of >70) and do not 
encompass more recent studies in patients with incurable cancer. 
Furthermore, this piece of work did not consider the most common 
barriers to exercise reported by patients in these groups, which may 
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help to develop exercise as a more acceptable therapy. In view of this, 
an updated version of this work, with a more detailed exploration of the 
factors influencing rates of uptake and reasons for declining or 
withdrawing from an exercise programme, was undertaken and is 
presented in chapter 5. 
 
3.4 Strategies to improve the acceptability of exercise 
Attempts can be made to overcome some of the barriers to exercise to 
help improve acceptability and unlock the potential benefits to more 
patients. These include improving education and awareness around 
exercise participation, eliciting preferences for exercise and exploring 
novel and more practical forms of exercise. 
 
3.4.1 Improving education and awareness 
Education may help address any misconceptions about the demands of 
undertaking exercise and promote the potential benefits among patients 
and clinicians. Clinical guidelines for the use of exercise are limited and, 
due to poor knowledge about specific types or amounts of exercise, 
those that do exist are broad and non-specific. For example, the 
$PHULFDQ&DQFHU6RFLHW\LVOLPLWHGWRUHFRPPHQGLQJWKDW³SK\VLFDO
DFWLYLW\EHHQFRXUDJHG´GXULQJDQGIROORZLQJDQWL-cancer treatment 
(Doyle et al on behalf of the American Cancer Society, 2006). In the 
United Kingdom, there are no specific guidelines on exercise 
prescription but the National Institute of Clinical Excellence recommend 
WKDWµUHKDELOLWDWLRQWUDLQLQJSURJUDPPHVKRXOGEHSURYLGHG¶1,&(
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2004). Recommendations in the public domain are equally sparse, lack 
clarity and are often inconsistent (Humpel and Iverson, 2005). More 
detailed guidance requires greater understanding of the role of exercise 
in patients with curable and incurable cancer. 
 
A more intensive method of education involves individual 
exercise counselling. This provides patients with one-to-one sessions 
with an exercise specialist to explore their self-efficacy and motivations 
around exercise participation (Dishman, 1990). Exercise counsellors 
then employ behavioural strategies, e.g. cognitive behavioural 
approaches, in an attempt to address low levels of motivation, 
unwillingness to change or social barriers and improve levels of 
exercise participation (McNeely et al, 2006). This approach is beginning 
to be explored by some of the large clinics in North America but 
requires extensive resource and expertise, is not suited to all patients 
and a measured effect has yet to have been demonstrated (Courneya 
et al, 2008). 
 
3.4.2 Eliciting patient preferences 
An understanding of exercise preferences can inform the type, location 
and delivery of exercise to help make future programmes more 
congruent with the interests and needs of patients (Booth et al, 1997). 
This could help to facilitate uptake to studies and minimise loss of 
patients due to low levels of motivation (Jones et al, 2007). This 
strategy has been successfully used in healthy older adults where, in 
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response to patient preferences, changes to community-based exercise 
programmes led to higher levels of adherence (Ward, 1998; Dunlop 
and Barry, 1999; Carnall, 2000). These included offering programmes 
on more days of the week, improving flexibility around scheduling and 
PDNLQJFRQWHQWPRUHYDULHGDQGWDLORUHGWRHDFKLQGLYLGXDO¶VFDSDELOLW\
(Dunlop and Barry, 1999; Carnall, 2000). 
 
Preliminary work in cancer has examined preferences in patients 
with various types of curable cancer (Jones and Courneya, 2002), non-
+RGJNLQ¶VO\PSKRPDVallance et al, 2006) and brain cancer (Jones et 
al, 2006). In each study, the majority of patients reported a preference 
to start exercise after anti-cancer treatment had been completed and to 
exercise at home without formal supervision. Walking was preferred by 
more than half of all patients and equal proportions of patients wished 
to complete exercise sessions alone, as part of a group or did not have 
a preference (Jones and Courneya, 2002; Vallence et al, 2006; Jones 
et al, 2007). Although there is general agreement among these studies, 
they do not represent many common types of cancer, i.e. only 
seventeen of nearly 850 patients had upper-gastrointestinal or lung 
cancer. In view of this limitation, further work to examine the 
preferences of patients with common incurable cancers would be of 
value and an original study to address this area of need is presented in 
chapter 6. 
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3.4.3 Novel exercise therapies 
Another strategy is to explore more novel therapies, e.g. neuromuscular 
electrical stimulation or whole-body vibration, which may be more 
practical to some patients. Although passive as they are assisted and 
initiated by an external stimulus, both fulfil the American College of 
6SRUWV0HGLFLQH¶VEURDGHUGHILQLWLRQRIH[HUFLVH, i.e. µplanned, 
structured, and repetitive bodily movement done to improve or maintain 
one or more components of physical fitness¶ (Thompson et al, 2010). 
The former uses a portable device and electrodes to cause a slow, 
controlled contraction and relaxation of the underlying muscles whilst 
seated (Robertson et al, 2006) and can lead to improvements in 
muscular performance and exercise capacity (Bax et al, 2005; Dehail et 
al, 2008). The latter uses a portable platform on which patients stand 
IRUVKRUWSHULRGRIWLPHHJ5 minutes, whilst it vibrates and can lead 
to neural and hormonal changes and, in the longer term, metabolic 
changes within the muscle, e.g. increased blood flow and oxidative 
capacity (Rehn et al, 2007; Cardinale and Wakeling, 2005).  
 
Compared to traditional types of exercise such as walking, 
stationary cycling or resistance training, these novel types of exercise 
are more passive and require less time and/or effort to complete. Both 
whole-body vibration and neuromuscular electrical stimulation are well 
suited to the home environment, generally require low levels of physical 
ability and, as they do not involve vigorous movements or changes in 
posture, are unlikely to provoke symptoms such as breathlessness and 
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fatigue (Sillen et al, 2008). Thus, programmes using these therapies 
may require lower levels of motivation or less of a change in lifestyle to 
complete than programme using traditional types of exercise, e.g. 
walking and stationary cycling (Ambrosino and Srambi, 2004; 
Maddocks et al, 2007). As a result, such approaches may be 
acceptable to a greater number of patients. There is no empirical data 
supporting these as more acceptable types of exercise, however, there 
is growing interest in their use in healthy older adults and patient 
groups such as those with COPD and chronic heart failure. On the 
basis of practicality, neuromuscular electrical stimulation has the most 
potential in patients with or at risk of cancer cachexia and a more 
detailed exploration of this therapy follows. 
 
3.5 Neuromuscular electrical stimulation 
Neuromuscular electrical stimulation (NMES) uses a portable device to 
deliver current to tissue via surface electrodes, causing excitation of 
peripheral nerves and muscular contraction (Robertson et al, 2006). 
When the current of electrons produced from the stimulator unit 
interfaces with the skin it is converted into a flow of ions, which move 
across nerve membranes causing depolarization and an action 
potential. A sufficient number of action potentials will create a muscular 
contraction which, when repeated, can be used for purposes of training 
(Robertson et al, 2006; Dehail et al, 2008). 
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Within a training programme, current is usually delivered in 
phases so a period of muscle contraction is followed by a period of rest 
WRKHOSSUHYHQWPXVFXODUIDWLJXH7KHµGXW\F\FOH¶UHIOHFWVWKHSURSRUWLRQ
of time that the stimulation is active, defined as a percentage of overall 
time. The current itself is characterised by the width of each pulse 
(microseconds, µs), their frequency (hertz, Hz) and their intensity 
(milliamps, mA) which, in combination, create an effect on muscle that 
FDQEHQRUPDOLVHGWRDSDWLHQW¶VPD[LPXPYROXQWDU\FRQWUDFWLRQ
(%MVC). The frequency and pulse width may be important in 
determining the changes brought about by training. For example, use of 
KLJKHUIUHTXHQFLHVHJ+]KDVEHHQUHSRUWHGWRSUHIHUHQWLDOO\
target type II fibres and lead to greater improvements in muscle 
strength compared to endurance (Kit-lan, 1991; Harris et al, 2003; Bax 
et al, 2005; Vivodtzev et al, 2008). Conversely, low frequencies, e.g. 
+]PD\SUHIHUHQWLDOO\WDUJHWW\SH,PXVFOHILEUHVLPSDFWLQJ
predominantly on muscle endurance. No universal agreement exists on 
the optimal training programme and stimulation parameters, which may 
explain in part the wide range used in studies (Table 3.3). 
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Table 3.3 NMES training programmes and stimulation parameters used in 
different patient groups. 
 
Variables Healthy 
subjects COPD 
Chronic 
heart failure Cancer 
Training programme 
  Duration, weeks 
  No. of sessions 
  Session duration, min 
 
í 
í 
í 
 
í 
í 
30 
 
í 
í 
30í 
 
4 
20 
60 
NMES parameters 
  Pulse duration, µs 
  Frequency, Hz 
  Intensity, mA 
  Intensity, %MVC 
  Contraction phase, s 
  Resting phase, s 
  Duty cycle, % 
 
í 
í 
í 
í 
í 
í 
í 
 
í00 
í 
í 
í 
í 
í 
í 
 
í 
í 
í 
í 
í 
í 
í 
 
400 
63 
í 
í 
3.5 
4.5 
44 
 
µs = microsecond, Hz=hertz, mA= milliamp, MVC=maximum voluntary 
contraction, s = second 
 
 
 
 
 
 
 
 
 
 
 
 
 75 
 
3.5.1 Healthy volunteer studies 
Bax et al (2005) examined the efficacy of NMES using data from 
randomised controlled studies comparing NMES of the quadriceps to 
either no treatment, sham treatment or a volitional exercise programme. 
Seventeen reasonably small studies (mean (range) sample size 20 
(í) mostly completed in young adults (mean (SD) age 28(8) 
years) were indentified Training programme and stimulation parameters 
are described in Table 3.3. Pooled data (12 studies, n=235) revealed a 
significant improvement in maximum voluntary contraction following 
NMES compared to no intervention or sham treatment, with a mean 
[95% CI] weighted difference of 8.0Nm [2.8, 13.2]. However, when 
compared to volitional exercise (8 studies, n=155) NMES was less 
effective, with a mean weighted difference was -1.6 Nm [-24.3, 1.13]. 
Only two studies compared NMES as an adjunct superimposed onto a 
volitional exercise programme (n=37) and produced comparable 
findings; NMES alone produced a strengthening effect but did not 
appear to enhance volitional training. Figure 3.2 presents these findings 
with forest plots of NMES versus no exercise (a) and versus volitional 
exercise (b). The squares represent the mean outcome of each study 
with the corresponding horizontal lines depicting 95% confidence 
intervals and the diamonds represent pooled outcomes with the width 
of the diamond corresponding to the 95% confidence interval. For an 
effect to be statistically significant, the pooled 95% confidence intervals 
must not cross the vertical zero line, therefore none of the pooled 
effects were found to be statistically significant (Figure 2.2). 
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 (a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Effect of NMES on mean peak torque [95% CI] compared to (a) no 
exercise or (b) volitional exercise (Bax et al, 2005). 
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Overall, this review supports a strengthening effect of NMES 
applied to the quadriceps but also suggests that volitional exercise 
programmes are generally more effective. Therefore for healthy 
subjects who are able and willing to undertake volitional strength 
training programme, NMES may be an appropriate adjunct therapy but 
cannot be recommended as an alternative therapy to improve 
quadriceps strength. Nonetheless, for weak patients who experience 
difficulties undertaking traditional types of exercise, NMES may be a 
useful alternative therapy. Given that their baseline strength is likely to 
be lower than the young healthy controls examined by Bax et al (2005), 
such patients may also benefit proportionally more from any given 
improvement in muscle strength. 
 
3.5.2 Patients with COPD or chronic heart failure  
A number of studies have examined NMES patients with COPD (5 
studies, n=91) or chronic heart failure (9 studies, n=210), groups who 
are also at risk of cachexia (Tisdale, 2009). In controlled settings, 
NMES has been compared to usual care (no treatment), a sham 
treatment or a stationary cycling programme, or superimposed onto an 
exercise programme (Tables 2.4 and 2.5). Interventions varied but 
typically consisted of 30í60 minute sessions of quadriceps stimulation, 
5±7 WLPHVHDFKZHHNIRUíZHeks. The full range of training 
programmes and stimulation parameters is shown in Table 3.3. 
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Data for studies in patients with COPD have been subject to a 
recent meta-analysis, which concluded moderate improvements in 
muscle function and exercise performance from NMES compared to 
control, sham or intervention groups (Roig and Reid, 2009) (Table 3.4). 
Four out of 5 studies reported significant improvements in outcomes 
relating to muscle function and, overall, NMES groups demonstrated 
significantly greater improvements in peak torque compared to control 
groups (mean difference = 9.7Nm; 95%CI 1.2, 18.1) (Roig and Reid, 
2009). Programmes also led to a beneficial effect on sub-maximal 
exercise capacity such that, compared to control groups, differences in 
improvements in 6MWT distance following NMES (mean difference = 
48m; 95% CI 9,86) were close to the minimal clinically important 
difference of 54m [95% CI 37,71] (Wise and Brown, 2004). Evidence for 
a hypertrophic effect of NMES was more equivocal, as although global 
measures of muscle mass did not change, one study found a small 
increase in thigh circumference (Vivodtez et al, 2006) and another, an 
increase in the cross sectional area of type II muscle fibres (Dal Corso 
et al, 2007). 
 
Studies in patients with chronic heart failure have not been 
pooled but findings appear to be similar and suggest benefits following 
a programme of NMES if a similar nature and magnitude (Table 3.5). All 
but one of the nine studies demonstrate a significant improvement in 
muscle function following NMES with a median [IQR] improvement of 
>í@DQGZKHUHPHDVXUHGPD[LPDODQGVXE-maximal exercise 
 79 
 
capacity improved E\>í@ (Table 3.5). Two studies demonstrated 
changes in thigh cross-sectional area (Maillefert et al, 1998; Quittan et 
al, 2001). Another found histochemical changes following NMES, which 
were not present in a sham±stimulation group, providing robust 
evidence for an effect on muscle tissue (Nuhr et al, 2004). 
 
In summary, NMES appears to be an acceptable therapy in 
patients with COPD and chronic heart failure. Four to ten week 
programmes have been well tolerated by patients (adherence to 
programmes QRWSUHVHQWHGEXWIUHTXHQWO\DQGhave lead to 
potentially meaningful changes in muscle function and whole-body 
exercise capacity. Stronger recommendations supporting the use of 
NMES are limited by the small number of studies with small sample 
sizes and methodological differences between studies, which may in 
part explain differences in findings. Therefore, NMES remains a 
promising experimental therapy in patients with COPD or chronic heart 
failure until further studies, ideally using larger samples and longer 
follow-up periods, are undertaken (Ambrosino and Strambi, 2004). 
These groups have a number of characteristics that are similar to the 
patients this thesis is concerned with. They suffer from chronic illnesses 
and are at risk of developing cachexia and experience the associated 
range of symptoms including severe muscle wasting and weakness. 
Therefore, the beneficial effects from NMES in these groups provide 
strong support for exploring the use of this therapy in patients with 
incurable cancer.
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Table 3.4 Summary of NMES in patients with COPD. 
Study Intervention Significant findings  
(within group changes; NMES first) Author Design n Parameters Programme 
Neder et al 
(2002) 
RCT Crossover  
NMES vs. control 
 
15 
300-ȝV+]-25% 
GXW\F\FOHíP$ 
Quadriceps, 30min sessions, 
5 times/week for 6 weeks 
Between-group differences favouring NMES 
in isokinetic muscle strength (43 vs. 10%) 
and endurance (52 vs. -2%), peak VO2 (20 
vs. 11%), exercise endurance (87 vs. -15%) 
and dyspnoea during daily activities. 
 
Bourjeily-Habr 
et al (2002) 
RCT 
NMES vs. sham 
18 50Hz, 8% duty cycle, 
íP$ 
Sham: NMES not switched 
on. 
Quadriceps and hamstrings, 
20min sessions, 3 
times/week for 6 weeks 
Between-group differences favouring NMES 
in quadriceps (39 vs. 9%) and hamstring (34 
vs. 3%) isokinetic muscle strength, and peak 
VO2 (36 vs. 2%) 
 
Zanotti et al 
(2003) 
RCT 
Active limb 
mobilisation ± 
NMES 
24 ȝV+] Quadriceps and glutei, 30min 
sessions, 5 times/week for 4 
weeks 
Between-group differences favouring NMES 
in isotonic quadriceps muscle strength (131 
vs. 68%), respiratory rate (-10 vs. -2%) and 
time to sit out of bed (11 vs. 14 days). 
 
Vivodtez et al 
(2006) 
RCT 
Treadmill and 
peripheral 
exercise ± NMES  
17 ȝV+]GXW\
F\FOHíP$ 
Quadriceps, 30min sessions 
daily for 4 weeks 
Between-group differences favouring NMES 
in isokinetic muscle strength (35 vs. 14%) 
%RWKJURXSVĹWKLJKFLUFXPIHUHQFHYV
and sub-maximal exercise capacity (11 vs. 
6%) 
 
Dal Corso et 
al (2007) 
RCT Crossover 
NMES vs. sham 
17 ȝV+]í
GXW\F\FOHíP$ 
6KDPȝV+]
íP$ 
4XDGULFHSVíPLQ
sessions, 5 times/week for 6 
weeks 
10(6JURXSĹW\SH,,ILEUH&6$DQGĻ
type I fibre CSA (15%) 
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Table 3.5 Summary of NMES in patients with chronic heart failure. 
Study Intervention Significant findings  
(within group changes; NMES first) Author Design n Parameters Programme 
Quittan et al 
(2001) 
RCT 
NMES vs. control 
42 ȝV+]
GXW\F\FOHí
MVC 
Quadriceps and hamstrings, 
íPLQWLPHVZHHNIRU
weeks 
Between-group differences favouring NMES 
in isometric (23 vs. -7%) and isokinetic (23 vs. 
-8%) quadriceps muscle strength and CSA 
(16 vs. 2%) 
 
10(6JURXSĹKHDOWK-related quality of life 
for all SF-36 subscales 
 
 
Nuhr et al 
(2004) 
RCT  
NMES vs. sham 
32 ȝV+]
GXW\F\FOHí
MVC 
Sham: intensity 
limited 
Quadriceps and calves or 
sham, 4h sessions daily for 
10 weeks 
Between-group differences favouring NMES 
in peak VO2 (32 vs. -10%) and sub-maximal 
exercise capacity (32 vs. 3%) 
 
10(6JURXSĹFLWUDWHV\QWKDVHDFWLYLW\
ĻJO\FHURO-dehydre-phosphate dehydrogenase 
activity (17%), and shift from fast to slow 
myosin heavy chain isoforms 
 
      
Harris et al 
(2003) 
RCT  
NMES vs. 
stationary cycling 
46 25Hz, 50% duty cycle Quadriceps and calves or 
cycling at 70% HRmax, 30min 
sessions, 5 times/week for 6 
weeks 
%RWKJURXSVĹLQTXDGULFHSVPXVFOHVWUHQJWK
(15 and.12%) and endurance (17 and 12%), 
peak VO2 (3 and 5%) and sub-maximal 
exercise capacity (10 and 10%).  
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'REãiNHWDO
(2006a) 
 
Parallel groups 
NMES vs. 
stationary cycling 
 
30 
 
ȝV+]
GXW\F\FOHíP$ 
 
Quadriceps and calves, 1h 
sessions daily 
for 8 weeks or 
Cycling 40min sessions, 3 
times/week for 8 weeks  
 
 
 
Between-group difference favouring 
stationary cycling in peak VO2 (5 vs. 7%)  
 
%RWKJURXSVĹVXE-maximal exercise capacity 
(9 and 14%) 
 
Mífkova et al 
(2004) 
Uncontrolled 10 ȝV+]
GXW\F\FOHí60mA 
Quadriceps, 1h sessions 
daily for 5 weeks 
 
 
ĹLVRPHWULFPXVFOHVWUHQJWK 
 
'REãiNHWDO
(2006a) 
Uncontrolled 15 ȝV+]
GXW\F\FOHíP$ 
Quadriceps and calves, 1h 
sessions daily for 6 weeks 
ĹLVRPHWULFDQGLVRNLQHWLF
muscle strength and resting peripheral blood 
flow (36%) 
 
 
Maillefert et al 
(1998) 
Uncontrolled  14 ȝV+]
GXW\F\FOHíP$ 
Quadriceps and calves, 1h 
sessions, 5 times/week for 5 
weeks 
 
 
ĹPXVFOH&6$ peak VO2 (14%), and 
sub-maximal exercise capacity (ESWT) (10%) 
Quittan et al 
(1999) 
Uncontrolled 7 ȝV+]
GXW\F\FOHí
MVC 
4XDGULFHSVíPLQ
sessions, 5 times/week for 8 
weeks 
ĹLVRPHWULFDQGLVRNLQHWLFPXVFOH
strength and muscle endurance (20%) 
 
CSA = cross sectional area, HRmax = maximum heart rate, Hz=hertz, mA= milliamp, MVC=maximum voluntary contraction, s = second, µs = microsecond, 
VO2 = oxygen uptake
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3.5.3 Patients with cancer 
The use of NMES in patients with cancer is limited to a case report by 
Crevenna et al (2007), who reported beneficial effects in a patient with 
metastatic lung cancer and brain secondaries. The authors used NMES 
due to concerns around the increased risk of seizures due to 
hyperventilation and pathological fractures due to bone disease with more 
active forms of exercise. The programme, offered post- brain irradiation, 
consisted of stimulation of the quadriceps and glutei for one hour sessions, 
five times each week for a month (stimulation parameters Table 2.3). The 
patient found the programme sufficiently practical and tolerable such that 
she was able to integrate sessions into her daily life and adhered to the full 
recommended programme. This led to clinically meaningful improvements 
in sub-maximal exercise capacity (6MWT distance), mobility (timed up and 
go test, 20%) and the physical functioning domain of quality of life (SF-36, 
35%). 
 
Although promising, this case study remains a weak form of 
evidence and the case was not typical of a patient with lung cancer; she 
was relatively young (47 years), had slowly developing disease and a 
reasonable performance status despite a being diagnosed several months 
previously. Other limitations that should be considered when interpreting 
these findings include the failure to include a practice 6MWT and the lack 
of reporting on the use of corticosteroids peri-irradiation. The former could 
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have lead to a learning effect, which may have accounted for the beneficial 
change in sub-maximal exercise capacity (Troosters et al, 2002) and the 
later may have contributed to muscle weakness that would have improved 
on their cessation (Maddocks et al, 2007). Nonetheless, it is reasonable to 
suggest that NMES may benefit patients with incurable cancer by 
improving muscle strength and exercise performance and a pilot study in 
patients with incurable lung cancer is presented in chapter 6. 
 
3.6 Summary 
There is convincing evidence that in patients with curable therapeutic 
cancer exercise can lead to improvements in a broad range of symptoms 
culminating in beneficial changes in physical function and psychological 
well-being. Preliminary work suggests these benefits may also be realised 
in some patients with incurable cancer and further study is warranted. 
However, there are multiple barriers to exercise participation in this group 
and issues relating to poor acceptability and practicality, which must be 
carefully considered. Chapters five and six begin to address some of these 
issues by examining the acceptability of exercise programmes previously 
offered to patients with cancer and preferences for different types of 
exercise in patients with incurable cancer. The next chapter completes the 
background to this thesis by appraising various assessments of physical 
function to inform the selection of outcome measures used in the studies 
presented in chapters seven and eight. 
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CHAPTER 4: 
ASSESSMENT OF PHYSICAL FUNCTION 
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4.1 Introduction 
This chapter provides an overview of measures of physical function that 
may be used in studies aimed at patients with or at risk of cancer cachexia. 
Its purpose is to inform the selection of outcome measures used in 
chapters six and seven. Initially, different aspects of physical function and 
the attributes of an ideal outcome measure are described. Thereafter, a 
range of measurements used to assess various aspects of physical 
capacity and activity are appraised in relation to their psychometric 
properties and utility. 
 
4.2 Aspects of physical function 
The majority of assessments used in cancer cachexia studies to date have 
focused on the nutritional status of the patient reflecting the nutritional 
intervention being examined. Some outcomes, e.g. weight loss, have been 
derived from simple measurements such as body weight whilst others, e.g. 
lean body mass, have required more detailed forms of measurement such 
as bioimpedence analysis or dual-energy X-ray absorptiometry (Dahele 
and Fearon, 2004). 
 
For studies examining therapeutic exercise, outcome measures 
will also need to consider tKHSDWLHQW¶VSK\VLFDOIXnction. Assessments of 
physical function can consider both physical capacity, i.e. what a person 
can do in an exercise test, and physical activity, i.e. what a person actually 
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does in day-to-day life (Figure 4.1). Assessment of physical capacity may 
focus on the performance of one body system, e.g. muscular strength, or 
whole body performance, e.g. maximum workload. Assessments of 
physical activity may directly measure and quantify bodily movement in 
terms of its type, duration or frequency, or seek to deteUPLQHWKHSDWLHQW¶V
energy expenditure, which is the energy cost associated with the physical 
activity they perform (Irwin and Ainsworth, 2004; Valanou et al, 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Aspects of physical function to be assessed. 
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4.3 Attributes of an outcome measure 
The ideal outcome measure would be valid and reliable in the patient 
group being examined, sensitive and responsive to change, whilst being 
useful and practical to apply. 
 
The validity and reliability of an outcome measure determines the 
confidence that can be placed in the inferences drawn from its use. Validity 
LVWKHGHJUHHWRZKLFKDPHDVXUHPHQWUHIOHFWVWKHµWUXH¶YDOXHRIZKDWLV
being measured. Components of validity include: 
 criterion validity: the degree to which outcomes of one instrument 
FRUUHODWHZLWKRXWFRPHVRIDFULWHULRQRUµJROGVWDQGDUG¶PHDVXUH 
 construct validity: the degree to which the construct trying to be 
measured is assessed by a measure 
 content or face validity: the degree to which the appearance or 
content of an outcome portrays it as a reasonable measure  
 convergent validity: the degree to which two instruments are able to 
measure the same construct (Portney and Watkins, 2000; Lang and 
Secic, 2006). 
 
Reliability reflects the ability of an outcome measure to reproduce 
the same results under the same conditions or the degree of consistency 
with which a variable is measured. Components of reliability include: 
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 inter-rater reliability: the degree to which two or more raters can 
obtain the same ratings for a given variable 
 intra-rater reliability: the degree to which one rater can obtain the 
same rating on multiple occasions  
 WHVWíUHWHVWUHOLDELOLW\WKHGHJUHHWRZKLFKDPHDVXUHSURYLGHVWKH
same outcome under the same conditions when repeating the 
measure (Portney and Watkins, 2000; Lang and Secic, 2006). 
 
The sensitivity of an outcome measure is the degree to which it can 
measure an amount or difference. A more sensitive outcome measure will 
be able to detect smaller amounts or differences, irrespective of whether 
they are meaningful to the patient or clinically relevant (Lang and Secic, 
2006). Responsiveness is a similar attribute, but is the degree to which a 
meaningful or clinically important amount or difference can be measured 
(Streiner and Norman, 2003). 
 
In addition to being valid, reliable and sensitive/responsive, the 
optimal outcome measure would also have qualities that make it useful. A 
useful outcome measure would be practical, affordable, simple to 
administer, feasible to use and potentially have some meaning or value to 
the patient. 
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4.4 Assessments of physical capacity 
4.4.1 Physician-rated performance scales 
These provide a global indication of physical capacity based on the 
SDWLHQW¶VOHYHORIindependence, physical ability and activity levels, which 
are estimated from a subjective assessment. Popular scales for assessing 
performance status are the World Health Organisation (WHO, 1979), 
Eastern Cooperative Oncology Group (ECOG) (Oken et al, 1982) and 
Karnofsky Performance Scales (KPS) (Karnofsky and Burchenal, 1949). 
The scores of each scale are broadly comparable with an ECOG 
SHUIRUPDQFHVFRUHRIíHTXDWing to a KPS score of í(&2*WR
.36íDQG(&2*íWR.36íU -0.83 to -0.90, P<0.01) 
(Buccheri et al, 1996) (Table 4.1). 
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Table 4.1 Scores and descriptions from physician-rated performance scales 
(Oken et al, 1982, Karnofsky and Burchenal, 1949) 
 
WHO / ECOG Performance Status Karnofsky Performance Scale 
0 
 
 
 
1 
 
 
 
 
 
 
2 
 
 
 
 
3 
 
 
 
4 
 
 
5 
Fully active, able to carry on pre-
disease performance without 
restriction 
 
Restricted in physically 
strenuously activity but 
ambulatory and able to carry out 
work of a light or sedentary 
nature, e.g. light house work, 
office work 
 
Ambulatory and capable to all 
self-care but unable to carry out 
any work activities. Up and 
about >50% of waking hours 
 
Capable only of limited self care, 
confined to bed or chair >50% of 
waking hours 
 
Completely disabled, cannot 
carry on any self-care. Totally 
confined to bed or chair 
Dead 
100 Normal with no complaints or 
evidence of disease 
90 Able to carry on normal activity 
but with minor signs of illness 
present 
80 Normal activity but requiring 
effort. Signs and symptoms of 
disease more prominent 
70 Able to care for self but unable to 
work or carry on other normal 
activities 
60 Able to care for most needs but 
required occasional assistance 
50 Considerable assistance and 
frequent medical care required; 
some self-care possible 
40 Disabled; requiring special care 
and assistance 
30 Severely disabled; hospitalisation 
required but death not imminent 
20 Extremely ill; supportive treatment 
and/or hospitalisation required 
10 Imminent death 
0 Dead 
 
WHO = World Health Organisation, ECOG= Eastern Cooperative Oncology Group 
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Performance status is the most common form of functional 
assessment in oncology and provides a simple global reference for clinical 
practice. Performance scales are quick to administer, easy to interpret and 
are well-suited to the clinical environment. Scores are also clinically 
PHDQLQJIXODVDSDWLHQW¶Vperformance status is a key determining factor in 
deciding their eligibility for many anti-cancer treatments, e.g. 
chemotherapy or high dose radiotherapy. For hospital in-patients, KPS 
scores have been related to other measures of physical capacity, e.g. 
GUHVVLQJZDONLQJRXWGRRUPRELOLW\VXSSRUWLQJWKHVFDOH¶VFRQVWUXFWYDOLGLW\
(Mor et al, 1984). However, the reliability of performance scales has been 
questioned. In prospective studies using the ECOG performance scale, r 
values for inter-rater reliability between physicians and between physicians 
and patients were r=0.44 (Sorensen et al, 1993) and r=0.45 (Blagden et al, 
2003) respectively. Thus, only around one-fifth (r2) of the variance in 
scores from one rater can be explained by the score of another. Other 
disadvantages to performance status include scales having a limited 
number of categories and thus being insensitive to change and scores 
being third-party rating and suffering from judgement bias (Dahele and 
Fearon, 2004).Thus, for research studies, performance status provides a 
XVHIXOGHVFULSWRUWRKHOSµJURXQG¶DVDPSOHWRDFOLQLFDOSRSXODtion but 
cannot be recommended to evaluate an intervention due to issues with 
reliability and sensitivity. 
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4.4.2 Patient-rated questionnaires 
Patient-rated questionnaires can be used to assess a range of 
components of physical capacity. Only one questionnaire, the Functional 
Assessment of Anorexia/Cachexia Therapy questionnaire, considers 
physical capacity in the context of the cachexia syndrome (Ribaudo et al, 
2000). The assessment of physical capacity in patients with cancer is 
generally otherwise undertaken as part of a holistic assessment of quality 
of life, e.g. EORTC C-30 or FACT-G (Aaronson et al, 1993; Cella et al, 
1993), or in the context of other symptoms, e.g. Brief Fatigue Inventory 
(Mendoza et al, 1999; Jordhøy et al, 2007). 
 
 Advantages of such questionnaires include their ease of use and 
the availability of large comparative datasets (Victorson et al, 2008). 
Common questionnaires are usually developed in large groups of patients 
using systematic criteria which establish good levels of validity and 
reliability.  For example, in the development of the EORTC C-30, 305 
patients with incurable lung cancer were studied and all sub-scales had to 
demonstrate (i) DQDFFHSWDEOHOHYHORILQWHUQDOFRQVLVWHQF\&RQUEDFK¶VĮ
(ii) clinical validity, i.e. discriminate between those with clinically 
distinct features, and (iii) responsiveness in the clinical setting, e.g. change 
following anti-cancer treatment. Conceptually related scales, e.g. physical 
functioning and faWLJXHDOVRKDGWRFRUUHODWHWRHDFKRWKHUU
(Aaronson et al, 1993). Nicklasson and Bergman (2007) examined the 
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EORTC C-30 in 112 patients with advanced thoracic cancer in the 
palliative care setting. Scores from each of the sub-scales were compared 
between patients to examine clinical validity in this group. Those with a 
poorer performance status (ECOG 3-4) were found to have worse physical 
functioning and symptom scores (p<0.05) supporting the criterion validity 
of this sub-scale (Nicklasson and Bergman, 2007). 
 
 When selecting a questionnaire for a study, it should be specific to 
both the patient group being examined and the components of quality of 
life of most concern, i.e. those the intervention is attempting to influence.  
For the purpose of this thesis, the EORTC C-30 fulfils these criteria as it 
has been validated in patients with advanced lung cancer and has a sub-
scale specifically concerned with physical function (Aaronson et al, 1993; 
Nicklasson and Bergman, 2007). This core questionnaire can also be 
supplemented with the LC-13 a lung cancer specific module, which 
assesses frequently occurring physical symptoms that may moderate the 
effect of an intervention on overall quality of life (Bergman et al, 1994). 
 
 The main disadvantage to using questionnaires to assess physical 
capacity is that responses are subjective thus can suffer from recall and 
response bias. Scores may also lack substantive meaning as, for most 
questionnaires, the impact of a high or low score has not been connected 
to external criteria, e.g. ability to perform a task (Mallinson et al, 2006). In 
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addition, some questionnaires can be time consuming to complete and 
frequently require the patient to answer questions of little relevance to 
them, e.g. they will enquire about high level function despite previous 
responses indicting substantial impairment (Helbostad et al, 2009). 
 
4.4.3 Functional performance tests 
Functional performance tests involve asking the patient to perform one or 
more practical tasks and rating their ability. One example used in patients 
with cancer is the Simmonds Functional Assessment (Simmond, 2002). 
This combines a questionnaire regarding physical symptoms and function 
together with a series of nine functional tasks, e.g. tying a belt, putting on a 
sock and walking 50 feet, generally completed under timed conditions 
(Simmonds, 2002). Both inter-rater and test-retest reliability are high with 
intra-class correlation coefficients (ICCs) of >0.98 and >0.69 respectively. 
However, the relationship between performance in the physical tasks and 
questionnaire responses is low (U í, p<0.01) demonstrating poor 
convergent validity (Simmonds, 2002). Responsiveness has not been 
studied to the same extent but studies have found significant differences in 
task performance between reasonably fit patients with lung cancer (ECOG 
0-1) and age-matched healthy controls suggesting some degree of 
sensitivity (Yadav et al, 2003; Montoya et al, 2006). 
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Performance tasks are not reliant on the patient estimating their 
ability as with questionnaire and thus these potentially provide a more valid 
form assessment. However, they are still influenced by a variety of factors 
including the SDWLHQW¶Vcurrent mood, level of motivation and anxiety and 
the environment in which they are completed. Their success also depends 
on selecting appropriate tasks that can discriminate between patients of 
differing ability without suffering from floor and ceiling effects (Streiner and 
Norman, 2003). The utility of performance tests is also limited by the need 
to train assessors for purposes of standardisation, the time taken to 
complete them, and in less able patients, the number of tasks that can be 
performed before fatigue limits performance. 
 
4.4.4 Muscle function assessments 
Isokinetic dynamometers can be used to assess muscle function through 
joint range at a pre-determined speed whilst matching any force that the 
subject exerts in real-time. Common examples of isokinetic dynamometers 
include the Cybex and Kin-Com® systems. These provide the gold 
standard measure of peak torque (Newton metres, Nm), which is the 
maximum force generated by the muscle(s) being tested indicating 
muscular strength (Thompson et al, 2010). In healthy younger adults, 
assessments of peak torque for the quadriceps and hamstrings are highly 
reliable with median (range) test-retest ICCs across studies of 0.93 
íDQGí respectively (Perrin 1986; Montgeomery 
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et al,1989; Li et al, 1996; Maffiuletti et al, 2007; Imprezelli et al, 2008). 
Assessments in patients with advanced upper-gastrointestinal and lung 
cancer are equally reliable, with test-retest ICCs of 0.91í0.99 for 
quadriceps testing (Reinglas et al, 2007; Trutschnigg et al, 2007; Wilcock 
et al, 2008a) and 0.86 for hamstrings testing having been reported 
(Wilcock et al, 2008a). 
 
 Isokinetic dynamometry can also be used to assess muscular 
endurance; the ability of a muscle to maintain a given or expected power 
output (Thompson et al, 2010). Muscular endurance can be assessed 
using absolute parameters, e.g. total work (joules, j) / time to a specified 
reduction in performance, or relative parameters, e.g. work ratios / slope of 
decline in performance (Kannus et al, 1992). Absolute parameters are 
generally more reliable with median (range) ICCs for quadriceps testing of 
0.92 í compared to í for relative parameters 
(Perrin 1986 ; Burdett and van Swearingen, 1987; Montgeomery et 
al,1989; Li et al, 1996; Pincivero et al, 2001; Maffiuletti et al, 2007; Wilcock 
et al, 2008a). On this basis, the use of absolute parameters is 
recommended. Nonetheless, the most common of these, total work, is 
largely dependent RQWKHSDWLHQW¶VVWUHQJWKDVVWURQJHUSDWLHQWVZLOO
undertake more work during the course of a test irrespective of the decline 
in their performance. Therefore, the most reliable outcome measures are 
limited as they do not adequately differentiate between muscular strength 
 98 
 
and endurance. More general disadvantages to isokinetic dynamometry 
include the size and expense of the equipment, assessments being time 
consuming and the expertise required to examine patients and interpret 
findings (Gleeson and Mercer, 1996; Brown and Weir, 2001).Thus, the use 
of isokinetic dynamometry has generally been limited to research settings. 
 
Portable dynamometers are available, which are less expensive 
and more practical than isokinetic dynamometers for the assessment of 
muscle function, however, can only be used to assess isometric or static 
strength. For hand-grip strength testing, the patient is asked to grip and 
squeeze a dynamometer as hard as they can and for other muscle groups, 
an assessor generally holds DG\QDPRPHWHUDJDLQVWDSDWLHQW¶VOLPEDQG
asks them to exert force against their resistance foUíVHFRQGV
(Bohannon, 2002). Test-retest reliability for portable dynamometry has 
been shown to be high for the assessment of hand-grip strength within a 
session (Trutschnigg et al, 2007, r=0.99) and quadriceps strength both 
within a session (Mathur et al, 2004, ICC 0.94) and between sessions up 
to one week apart 2¶6KHDHW al, 2007 ICC 0.79; Mathur et al, 2004 ICC, 
0.88). However, when comparing the measurement of muscle function 
using isokinetic and portable dynamometry, between instrument ICCs have 
been moderate to high for hand-grip strength testing in patients with 
advanced cancer (Trutschnigg et al, 2007, r=0.89) and quadriceps strength 
testing in both older adults (5HHGHWDOU í) and patients 
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with COPD (Martin et al, 2006, r=0.91). Discrepancies tend to arise from 
an underestimation of muscle strength using portable dynamometers, for 
example, Martin and colleagues found a mean error of -15Nm (Martin et al, 
2006). Despite standardised protocols, this is most likely reflects the 
difference in measurement technique, with reliance on the assessor to 
constantO\PDWFKWKHSDWLHQW¶VVWUHQJWKWRPDLQWDLQDVWHDG\WHVWLQJ
position with the portable dynamometer (Bohnannon, 1996; Curb et al, 
2006). Therefore, when there is a choice between assessments using 
portable and isokinetic dynamometers, the later is preferred because of its 
superior validity. 
 
4.4.5 Exercise capacity testing 
Cardiopulmonary exercise testing involves measuring oxygen uptake 
( VO2) whilst the patient performs a progressive exercise test until their 
maximum oxygen uptake ( VO2 max) is reached (Jones et al, 2008). The 
gold standard tests use incremental treadmill or cycle ergometry protocols 
and directly measure VO2 by having the patient continually breathe through 
a mask into a respiratory gas analyser (Jones et al, 2008; Thompson et al, 
2010). Although accurate, these tests require specialised equipment and 
experienced assessors to undertake and use forms of exercise which can 
be unfamiliar to patients (Irwin and Ainsworth, 2004). VO2 max can also be 
estimated from performance in walking tests, which are easier to perform 
and more familiar to patients. The incremental shuttle walk test (ISWT) is 
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one example in which the patient walks around a 10m course, with their 
walking speed dictated by a pre-recorded audio signal, following a 
íOHYHOSURWRFROXVLQJZDONLQJspeeds of 0.5í2.4 m/s (Singh et al, 1992). 
The patient continues until they can no longer maintain the walking speed 
or their symptoms become limiting and VO2 max is predicted from their 
performance. Predicted values relate strongly to those measured directly 
using a mask both during the ISWT (using a portable respiratory gas 
analyser unit) and a treadmill test (r=0.88 and r=0.81 respectively) 
demonstrating high criterion validity (Singh et al, 1994). A single practice 
ISWT provides sufficient familiarisation to account for a learning effect, 
after which test-retest reliability is high with mean differences between 
subsequent tests of 2m in patients with COPD (Singh et al, 1992) and 
1.4m in patients with advanced cancer (Booth and Adams, 2001). 
 
 Submaximum exercise tests can also be used to assess 
cardiopulmonary fitness (Jones et al, 2008). These usually comprise of a 
self-paced test in which the patient walks as far as possible within a set 
time or at a set pace. The 6 minute walking test (6MWT) involves the 
patient walking around two cones, placed 40m apart, and covering the 
furthest distance possible over the duration of the test (American Thoracic 
Society, 2002). Although more practical to administer than a maximal 
exercise test, the 6MWT requires a large clear space, is difficult to 
standardise and suffers from a large learning effect (Guyatt et al, 1984; 
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Gibbons et al, 2001). The learning effect is generally greatest between the 
first two tests, with mean increases of 0±17% reported, which 
encompasses that thought to represent the minimal clinically important 
difference of around 10% (American Thoracic Society, 2002; Redelmeier 
et al, 1997). Thus, even though the American Thoracic Society guidelines 
RQO\VXJJHVWWKDWDSUDFWLFH0:7WHVWµVKRXOGEHFRQVLGHUHG¶DSUDFWLFH
walk and standardised encouragement at set intervals, e.g. after every 
30sec or every minute have been recommended (Toosters et al, 2002, 
Solway et al, 2001). The endurance shuttle walk test (ESWT) is an 
alternative to the 6MWT and minimises the influence of motivation and 
encouragement by pacing the speed of walking externally. In this test the 
patient walks around a shorter PFRXUVHDWDQµHQGXUDQFH¶ZDONLQJ
speed equivalent to 85% of the VO2 max predicted from an ISWT (Revill et 
al, 1999). Although there is no criterion measure to validate the ESWT 
outcomes of time or distance walked against, the test has been shown to 
be highly reliable in patients with COPD with a mean (2SD) difference 
between two tests completed ten days apart of 13 (5)m (<5% of mean 
distance walked, p>0.05) (Revill et al, 1999). 
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4.5 Assessments of physical activity 
In addition to measures of physical capacity, the assessment of physical 
activity can provide additional, perhaps more meaningful, evidence of the 
functional impact of an intervention. 
 
4.5.1 Doubly labelled water 
Doubly labelled water is the gold standard method to assess energy 
expenditure in free-living conditions and is based on the rates of O2 
consumption and CO2 production (Dahele and Fearon, 2004). For this 
method, stable isotopes 2H and 18O are used to label water, which the 
patient consumes. Samples of urine or blood are collected at the beginning 
and end of the assessment period during which isotopes are lost from the 
SDWLHQW¶VERG\ as either water in urine and perspiration (both 2H and 18O) or 
CO2 (18O only). As the 18O is lost from the body as both water and CO2, its 
washout curve is steeper than that of 2H and the difference represents CO2 
production, which is an indirect measure of metabolic rate (Dahele and 
Fearon, 2004). 
 
Mean measurement error using the doubly labelled water method 
is estimated to be <5% (Montoye et al, 1996; Starling, 2002). It is non-
intrusive and performed over a prolonged period of time, usually one to two 
weeks, thus more likely to provide an accurate reflection of DSDWLHQW¶V
habitual energy expenditure. However, the wider use of doubly labelled 
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water is limited by its expense (around £1000 per patient) and technical 
complexity (Valanou et al, 2006). Therefore, its use remains generally 
confined to small scale studies examining metabolism in detail or validation 
studies where it is used as a criterion measure. 
 
4.5.2 Questionnaires and diaries 
Questionnaires may be posted, handed out in person or completed by 
telephone and are frequently used to assess physical activity level. They 
typically ask the patient to provide either a global rating of their physical 
activity level or details about the type, duration and frequency of activities 
performed over a given time period, usually a week or a month 
(Ainsworsth, 2008). Common questionnaires include the Baecke 
questionnaire (Baecke et al, 1982), seven day recall (Blair et al, 1985) and 
International Physical Activity Questionnaire (IPAQ, 2005). Diaries provide 
a more detailed account of physical activity but are typically completed for 
a shorter period of time, usually less than one week (Ainsworth, 2008). 
Diary entry methods range from logging each activity on completion to 
recording activities at specified time intervals, e.g. every minute or every 
four hours (Valanou et al, 2006). Once details about physical activities 
have been captured, questionnaires or diaries either provide a score to 
UHSUHVHQWWKHSDWLHQW¶Voverall physical activity level or estimate energy 
expenditure by considering the time spent in each activity and its intensity. 
To identify the intensity, a compendium can be used which details the 
 104 
 
relative energy cost of various types of physical activity using metabolic 
equivalent of task (MET) values. These reflect the energy cost of physical 
activities expressed as a multiple of the resting metabolic rate. In adults, 
this is equal to 3.5 ml O2 kg-1 min-1, with MET values ranging from 0.9 
(sleeping) to 18 (running at 17.5 km/h) (Ainsworth et al, 2000). 
 
Self-report questionnaires and diaries are practical, low cost and, 
when completed retrospectively, do not alter the paWLHQW¶Vhabitual level of 
physical activity. However, some intrinsic properties make them less valid 
than direct assessment of physical activity (Ainsworth, 2008). A recent 
systematic review synthesised 187 individual questionnaire or diary 
validation studies and revealed low-to-moderate correlations with objective 
assessments of physical activity (mean (SD) r=0.37 (0.25)) (Prince et al, 
2008). A wide range include of positive and negative values were found 
reflecting both over- and under-estimates of physical activity level and 
energy expenditure (r=-0.71 to 0.96) (Prince et al, 2008). This may be 
because subjective assessments suffer from recall and response bias and 
few questionnaires or diaries assess low intensity physical activity or 
capture incidental, intermittent activity characteristic of sedentary 
populations, e.g. household chores and family care (Tudor-Locke and 
Myers, 2001; Shephard, 2003).  
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4.5.3 Pedometers 
Pedometers are small, battery operated motion sensors that are attached 
to the waistband in the midline of the thigh and measure the number of 
steps a person takes during walking. They count steps using a horizontal 
spring-suspended level arm which, during walking, moves up and down 
with vertical accelerations of the pelvis and opens and closes an electrical 
circuit (Berlin et al, 2006). 3HGRPHWHUVUDQJHLQFRVWIURPí0, with 
more expensive models offering additional measures based on the 
SDWLHQW¶VVWULGHOHQJWKHJGLVWDQFHZDONHGPedometers do not have 
internal clocks so are unable to log stepping activity against time, nor do 
they take into account the degree of movement of the lever arm, so are 
unable to distinguish different walking patterns of speeds (Berlin et al, 
2006). 
 
 The validity and reliability of pedometers varies depending on the 
brand and model. The <DPD[ pedometers (Yamax USA Inc. Texas) are 
generally considered the most accurate and produce valid measurements 
at walking speeds typical of younger adults (>1.2m/s) with good intra- and 
inter-instrument agreement (Bohannon, 1999; Shepherd et al, 1999; Le 
Masurier et al, 2004; Schneider et al, 2004). However, even these tend to 
underestimate the number of steps taken at slower walking speeds 
PVDQGin patients with irregular gaits, where measurement error 
can exceed 35% (Bassett et al, 1996; Schmalzried et al, 1998; Swartz et 
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al, 2003; Le Masurier and Tudor-Locke, 2003; Cyarto et al, 2004; Le 
Masurier et al, 2004). This loss of accuracy limits their value in older adults 
and patients with altered gait. 
 
4.5.4 Accelerometers 
Accelerometers use more sensitive technology than pedometers to detect 
change LQWKHERG\¶VFHQWUHRIPDVV. During acceleration, a small mass 
within the accelerometer applies a force to a spring, causing it to stretch or 
compress. The displacement of the spring is measured and used to 
calculate the applied acceleration. Most models use piezoresistive 
materials which respond to gravitational acceleration as well as 
acceleration due to movement, so are also able to detect changes in their 
position (Mathie et al, 2004; De Bruin et al, 2008). Accelerometers vary in 
cost from £50-£1000. Common models include the ActiGraphDQG
7UL7UDFí5' (worn on the wrist or waist), StepWatch (worn on the 
ankle) and ActivPALZRUQRQWKHWKLJK7KH\UHFRUGSK\VLFDODFWLYLW\LQ
µFRXQWV¶ZKLFKUHIOHFW the frequency and intensity of accelerations during 
movement. Counts are displayed over time either in raw form or once 
characterised into different activities, e.g. sitting, walking or running, using 
supporting software. Some models also provide an estimate of energy 
expenditure by applying MET values to the various types of physical 
activity they characterise in the same manner as activity questionnaires 
(Montoye et al, 1996). 
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 Psychometric properties and utility differ depending on the 
accelerometer model, the patient population and the activities performed. 
Accelerometers are more accurate than pedometers at measuring steps 
during slow walking. 7KH$FWL*UDSKVWHSFRXQWIXQFWLRQKDVEHHQ
validated in healthy volunteers against direct observation at various 
ZDONLQJVSHHGVíPVRQD WUHDGPLOOU í:HONHWDO
2000). The AcWLY3$/VWHSFRXQWDQGFDGHQFHIXQFWLRQVKDYHEHHQ
validated during treadmill walking across a range of slower speeds 
íPVDQGGXULQJRXWGRRUZDONLQJDWVHOI-selected slow, normal 
and fast paces in healthy younger subjects (Ryan et al, 2006; Maddocks et 
al, 2008). The $FWLY3$/ PRQLWRU¶V measurement of time spent in different 
postures during everyday activities has also been shown to be valid in both 
healthy and frail older subjects (mean error <1%) (Grant et al, 2006; Stene 
et al, 2008). In direct comparison studies, accelerometers out-perform 
pedometers with consistently low measurement error (<3%) during slow 
walking (PV (Schnieder et al, 2004; Le Masurier and Tudor-Locke, 
2003). On the other hand, many models of accelerometer are 'over 
sensitive' and record more erroneous steps than pedometers during non-
ambulatory activities, e.g. motor vehicle travel (Gotshall et al 2003; Le 
Masurier & Tudor-Locke, 2003) (Table 4.2). 
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Table 4.2 Mean number of erroneous steps [95% CI] recorded with various 
models of pedometer and accelerometer during motor vehicle travel.* 
 
Device type / model 
Erroneous steps per 
10km of travel 
Accelerometers 
     $FWLY3$/ 
     3$/OLWH 
     $FWL*UDSK 
 
Pedometers 
     <DPD['LJL:DONHU 
     Yamax SW- 
     Yamax LS- 
 
>í@ 
>í@ 
>í@ 
 
 
>í@ 
>í@ 
>í@ 
 
*For comparative purposes data have been standardised to a 10km 
distance. 
 
 
Accelerometers tend to underestimate energy expenditure during 
free-living conditions (Leenders et al, 2006). This may be due to the MET 
values supporting software assigns to various types of activity, or the lack 
of consideration for upper limb activities or external factors which may 
increase expenditure, e.g. uneven terrain (Leenders et al, 2006). Many 
studies claiming to validate energy expenditure outcomes use restricted 
physical activity regimens which do not reflect free-living activity and their 
findings should be treated with appropriate caution (Swartz et al, 2000; 
Leenders et al, 2006). Other issues with accelerometers relate to their 
expense in terms of acquisition and data management, methodological 
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inconsistency across studies, e.g. monitoring period, handling of missing 
data, and the tendency for patients to initially increasing their habitual level 
of physical activity in response to being monitored (Ward et al, 2005; 
Clemes et al, 2008). Patient acceptability must also be considered and 
may be a factor in determining the most appropriate model, i.e. some are 
easily placed whilst others require specialist fitting and some use only one 
sensor whilst others use multiple sensors worn at the same time. 
 
Our group compared the relative accuracy of three accelerometers 
during treadmill walking and motor vehicle travel, in order to help inform 
our choice of accelerometer for use in future studies (Maddocks et al, 
2008). We focused on determining the most accurate step count function 
as this is important not only as an outcome per se, but also because it is 
used in the calculation of other outcomes, e.g. distance walked, time spent 
walking (Mathie et al, 2004; De Bruin et al, 2008). Forty healthy volunteers 
(15 male, mean (SD) age 28 (8) years, height 169 (8) cm, BMI 22.9 (2.4) 
Kg/m2) were recruited and undertook either treadmill walking or motor 
vehicle travel wearing an ActivPAL3$/OLWH3$/7HFKQRORJLHV8.) 
and a SW±401 Yamax Digi-:DONHU1HZ/LIHVW\OHV,QFMissouri, USA). 
For the treadmill walking, subjects undertook five treadmill walks, each of 
5min duration, starting at 0.6m/s and increasing to a maximum of 1.4m/s, 
reflecting the range of comfortable walking speeds in the healthy elderly 
(Bohannon, 1997). For motor vehicle travel, subjects occupied the seat of 
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a car, which followed a standardised route incorporating town, housing 
estate and single carriage way driving for as close to 15min as possible 
dependent upon finding a safe place to stop. Step counts recorded by 
each accelerometer were noted after each walk or car journey and actual 
step counts were determined from video recordings, viewed independently 
by two researchers at half-speed and using a zero value respectively. 
Mean percentage error for treadmill walking was calculated using 
individual error values regardless of directionality, i.e. under- or over 
estimates of step count, and for motor vehicle travel, 15min erroneous step 
counts were multiplied by four to calculate 1h estimates. Measurement 
errors and their 95% confidence intervals were compared between devices 
by one-way ANOVA and Students t-test. The sample size of 20 was 
sufficient to detect a 10% difference between actual and measured step 
counts (ȕ8, p=0.05). 
 
During treadmill walking, the mean number of steps for twenty 
subjects ranged from 375 (0.6 m/s) to 578 (1.4 m/s) with estimated stride 
lengths of 0.51cm and 0.73cm respectively. Mean measurement error was 
ORZDQGGLGQRWGLIIHUEHWZHHQWKH$FWLY3$/DQGWKH3$/OLWH
PRQLWRUV&RPSDUHGWRWKH$FWLY3$/DQG3$/OLWHWKH'LJL-:DONHU
tended to underestimate the number of steps taken and was significantly 
OHVVDFFXUDWHDWVSHHGVRIPV(Table 4.3). 
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Table 4.3 Mean percentage error (95% CI) recorded during treadmill 
walking (Maddocks et al, 2008). 
 
Speed (m/s) Steps taken ActivPAL TM PALlite TM Digi-Walker 
0.6 375 
 
1.7 
(0.5±2.9) 
3.4 
(1.8±4.9) 
40.4 
(23.9±60.0)* 
0.8 449 0.7 
(0.3±1.2) 
2.9 
(0.3±5.5) 
16.4 
(9.0±23.9)* 
1.0 450 1.4 
(0.9±1.9) 
1.6 
(0.9±2.2) 
5.8 
(3.3±8.3)* 
1.2 541 1.8 
(0.9±2.7) 
3.9 
(1.5±9.2) 
6.4 
(2.8±10.4) 
1.4 578 0.7 
(0.3±1.1) 
1.1 
(0.3±1.8) 
3.7 
(0.3±7.8) 
*significantly different to other step counts (p<0.01) 
 
 
Ten motor vehicle journeys, each with two subjects, were 
undertaken lasting a mean duration of 15min 3sec (range 14min 59sec to 
15min 11sec) over distances of 9.3±9.8km. The $FWLY3$/GLGQRWUHFRUG
any erroneous steps. Both the PALliteDQG'LJL-:DONHUUHFRUGHG
erroneous steps, the former 10-fold more than the latter (Table 4.4). 
 
Table 4.4 Mean number of erroneous steps (95% CI) recorded during  
motor vehicle travel (Maddocks et al, 2008). 
 
Duration ActivPAL PALlite Digi-Walker 
 
15min 
 
1h (estimate) 
 
0 (0±0) 
 
0 (0±0) 
 
254 (231±278)* 
 
1016 (925±1107)* 
 
25 (7±43)* 
 
101 (26±175)* 
 
*significantly different to actual step count (p<0.01) 
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In this comparison, the ActivPAL accelerometer performed best, 
with the accuracy of the other two accelerometers compromised either 
during slow walking (Digi-Walker) and/or motor vehicle travel (PALlite 
and Digi-Walker) (Maddocks et al, 2008). Differences in accuracy in 
these circumstances may relate to differences in the sensitivity threshold, 
site of attachment, and the algorithms used in the processing of movement 
data (Mathie et al, 2004; Valanou et al, 2006). This study added to 
previous work by examining the accuracy of accelerometers at walking 
speeds which are representative of elderly patient groups, and providing a 
direct comparison of accelerometers of varying cost. In addition, it 
highlighted the importance of accurate measurement during motor vehicle 
travel, an aspect of free-living physical activity which should be routinely 
evaluated in validation studies. On this basis of this and previous studies, 
we decided to further explore WKHXWLOLW\RIWKH$FWLY3$/DFFHOHURPHWHU by 
using it in the study presented in chapter 7 and formally examining its 
acceptability and identifying the optimal period of monitoring in chapter 8. 
 
4.6 Summary 
A variety of assessments can be used to provide outcome measures for 
various aspects of physical capacity and activity. No assessment is perfect 
and the selection of an assessment for use in a study will reflect a balance 
between its validity, reliability and responsiveness and how affordable and 
practical it is. Throughout this chapter assessment methods have been 
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appraised and compared as a means to determine the most suitable 
outcomes for use in the intervention studies within this thesis. Objective 
assessments have generally been shown to be more valid, reliable and 
sensitive than subjective assessments but these can be difficult to 
undertake and more burdensome to patients. These will be adopted for 
use in chapters seven and eight but there remains a need to carefully 
examine how acceptable and feasible they are to patient groups who are 
likely to be the focus of future cancer cachexia studies. 
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CHAPTER 5:  
IS EXERCISE AN ACCEPTABLE AND PRACTICAL THERAPY FOR 
PEOPLE WITH OR CURED OF CANCER? A SYSTEMATIC REVIEW 
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5.1 Introduction 
Physical exercise is reported to be therapeutic in patients with or cured of 
cancer, enhancing physical functioning and psychological well-being (Conn 
et al, 2006; Stevinson et al, 2004). However, rates of uptake, adherence 
and completion of exercise programmes vary widely, suggesting that not 
all patients find exercise an acceptable or practical therapy. This appears 
more so for those undergoing anti-cancer treatment or with advanced and 
incurable disease (Oldervoll, 2006; Stevinson, 2006), reasons for which 
may include the impact of cancer and its treatment on functional status, 
symptoms, and self-efficacy (Lagman, 2005). Therefore, if exercise is to be 
developed as a therapy suitable for the majority of patients with cancer, a 
greater understanding of the factors influencing its utility is required. 
 
Only one review has considered the acceptability of exercise 
programmes offered to patients with or cured of cancer, and this predates 
the majority of work in this field, encompassing only around one-fifth of 
studies to date (Oldervoll et al, 2004). To explore acceptability further, this 
review examines all exercise programmes offered to this group of patients 
in order to identify rates of uptake, adherence and completion together with 
reasons for declining or withdrawing from exercise programme. It also 
explores whether the characteristics of an exercise programme or the 
group of patients it is offered to influence how acceptable it is. 
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5.2 Methods 
5.2.1 Search strategy and selection criteria 
Medline, Embase, Cochrane Controlled Trials Register and CINAHL 
electronic databases were searched from their respective inceptions to 
July 2008 for studies of exercise programmes for people with or cured of 
cancer. Searches used key words based on: cancer (carcinoma, 
neoplasm, tumour, chemotherapy, radiation therapy, surgery), exercise 
(physical activity, exercise therapy, physical training, aerobic, strength, 
walking) and clinical trials (programme, intervention, scheme, trial) 
modified according to the specific vocabulary of each database. In 
addition, hand searches were conducted in European Journal of Cancer 
Care, Psycho-Oncology and Journal of Clinical Oncology, and the 
reference lists of relevant reviews and studies already located were 
checked. 
 
To be eligible, the exercise intervention studies had to contain a 
minimum of five patients, 18 years or older, who had previously or were 
currently receiving treatment for cancer. Studies were excluded if they did 
not report patient flow data for either the number of eligible patients who 
were approached or the number of patients who were lost from the study. 
To determine eligibility, full reports of readily available studies were 
reviewed. Abstracts of remaining articles were assessed and full texts of 
potentially relevant articles obtained. 
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5.2.2 Data extraction and validity assessment 
Studies were identified by first author, year of publication and trial design. 
Where possible, data were extracted on age, gender, cancer type and 
stage, prior and current treatment, characteristics of the exercise 
programme (location, type of exercise, length and frequency of sessions, 
overall duration), the number of eligible patients approached and the 
number declining, starting, withdrawing and completing the exercise 
programme. Reasons given for declining or withdrawing were documented 
along with their frequency. Patient flow data for follow-up periods (time 
points beyond the first post-intervention assessment) were not included. 
The mean level of adherence to the intervention across the sample and 
assessment methodology was recorded. Data were extracted by one 
researcher then verified by one of two assistants, by cross-referencing 
proformas containing the review data with original texts. 
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5.2.3 Statistical analysis 
Data were expressed as mean (SD) or median [IQR] as appropriate. 
Percentage rates were calculated for proportions of eligible patients 
entering an exercise study on being approached and, when allocated to an 
active study arm, completing the programme. Adherence to programmes 
was expressed as percentage adherence to the recommended exercise 
schedule and compared according to the assessment method used (self-
report, objective) with a Mann Whitney U test of difference. 
 
 To determine the influence of patient or programme characteristics 
on uptake and completion of programmes, patient and study 
characteristics were transformed into binary data. For some 
characteristics, e.g. treatment status (on / off treatment) and study design 
(randomised / single arm), a reduction in the level of data was not 
necessary as these naturally fitted within one of two groups.  For data 
regarding cancer diagnoses (breast cancer / other cancer) and exercise 
settings (home / centre), dichotomous divisions were based on the 
evidence base regarding exercise in people with cancer, e.g. 
predominantly patients with breast cancer either in the home or a 
community or hospital setting. For remaining exercise programme 
characteristics; exercise intensity (low / mod±high), session length (less / 
more than 30min), session frequency (less / more than 3 times weekly), 
and programme duration (less / more than 6 weeks), groupings were 
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based on exercise prescription guidelines for healthy elders of at least 
three 30min bouts of moderate exercise each week for 6 weeks (Haskell et 
al, 2007; Nelson et al, 2007). To examine if each characteristic influenced 
the acceptability of exercise, rates of uptake and completion for each 
binary pair were compared using a Student's t-test or Mann Whitney-U test 
as appropriate. 
 
 Reasons provided by patients when declining or withdrawing from 
an exercise programme were listed by category in order of prevalence by 
study and by number of patients. Calculations were performed using 
Statistical Package for the Social Sciences (SPSS) version 15.0. A p value 
of <0.05 was regarded as statistically significant. 
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5.3 Results 
5.3.1 Included studies 
The literature search yielded 1373 separate article titles. Of these, 97 trials 
of exercise interventions were retrieved for potential inclusion and 65 were 
included in the review (Figure 5.1). 
 
 
Figure 5.1. Study selection diagram. 
 
1373 studies yielded from 
search strategy 
 
1278 studies deemed ineligible from abstract 
 
97 full reports retrieved 
for review 
 
32 studies ineligible: 
 no patient flow data reported   (n=14) 
 duplicate report             (n=14) 
 subjects <18 years    (n=3) 
 did not involve exercise  (n=1) 
 
 
65 studies deemed eligible 
for inclusion 
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5.3.2 Study descriptions 
The majority of included studies contained patient groups made up entirely 
(n=29) or predominantly (n=18) of patients with breast cancer. Of the 
remainder, groups consisted of patients with hematological (n=5), prostate 
(n=4), lung (n=4), gastro-intestinal (n=2), head and neck (n=2), or skin 
(n=1) cancer. In studies reporting disease stage (n=29), the study groups 
generally consisted of patients with early stage disease with only one or 
two patients with advanced disease (n=20). The remaining nine studies 
consisted of patients only with early (stage I±II) (n=8) or advanced (stage 
III±IV) (n=1) stage disease. Thirty-one studies involved patients receiving 
concurrent anti-cancer treatment such as adjuvant chemo- or radiation 
therapy (n=14), radical or palliative chemo- or radiation therapy (n=12) or 
biological or hormone treatment (n=5). In the 50 studies reporting prior 
treatment, the majority of patient groups had undergone surgery (n=44) ± 
adjuvant chemo- or radiation therapy (n=23). Others had received bone 
marrow transplantation (n=4) or chemo- or radiation therapy (n=3) (Table 
5.1). 
 
Patients were randomly allocated to either a control group or an 
exercise programme in 42 of the 65 studies. Programmes generally 
consisted of either one aerobic exercise (e.g. walking (n=10), cycling 
(n=8), or patient selected (n=14)), resistance exercises (with (n=4) or 
without (n=4) weights), or a combination of the two (n=25), undertaken at 
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low to moderate intensities. Walking was employed as the main or a 
contributory exercise in over three-quarters of the exercise programmes. 
Less traditional programmes included Tai Chi and trunk stability exercises 
(e.g. Pilates), generally used to promote patient relaxation and well-being.  
 
Programmes were delivered in the home setting (n=24) or at an 
alternative centre (n=41), such as hospital, health centre, private gym, or 
community hall. Generally, patients were recommended to complete or 
attend 3 to 5 sessions each week (n=43) lasting 15 to 30 minutes (n=29). 
The frequency of sessions ranged from 1 to 7 times per week and session 
length ranged from 10 to 120 minutes, with longer sessions usually 
concerning low intensity types of work, e.g. relaxation exercises, Tai Chi. 
Most programmes were of 6 to 12 weeks duration (n=36) with shorter 
SURJUDPPHVLHZHHNVJHQHUDOO\EHLQJRIIHUHGWRLQSDWLHQWVDQG
ORQJHUSURJUDPPHVLHZHHNVWHQGLQJWREHEDVHGRQpromoting an 
active lifestyle (Table 5.2).
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Table 5.1. Study participant characteristics. 
Study (n) Random Gender (m : f) 
Mean  
age Group Stage Previous treatment Current treatment 
Adamsen et al, 2001 17 N 17:0 57 Mixed NR NR NR 
Adamsen et al, 2003 23 N 9:14 40 Mixed NR Chemotherapy / RT Chemotherapy 
Adamsen et al, 2006 82 N 26:56 40 Mixed NR Surgery / RT Chemotherapy 
Berglund et al, 1993 60 Y 2:58 54 Mixed NR Surgery / chemotherapy / RT Post active Rx 
Berglund et al, 2004 199 Y 0:199 53 Mixed NR Surgery / chemotherapy / RT Post active Rx 
Bobbio et al, 2008 12 N 10:2 71 Lung I±II NR Pre-surgery 
Burnham & Wilcox, 2002 21 Y 3:18 53 Mixed NR Surgery / chemotherapy / RT Post active Rx 
Campbell et al, 2005 22 Y 0:22 48 Breast NR Surgery Chemotherapy / RT 
Cesario et al, 2007 25 N NR NR Lung NR Surgery Post-surgery 
Coleman et al, 2003 24 Y 14:10 55 Multiple Myeloma NR NR Chemotherapy, stem cell 
transplant 
Coleman et al, 2008 135 Y 70:65 55 Multiple myeloma NR NR Chemotherapy 
Courneya et al, 2002 108 Y 16:92 52 Mixed I±IV Surgery / chemotherapy / RT Chemotherapy / RT / none 
Courneya et al, 2003a 52 Y 0:52 59 Breast NR Surgery / chemotherapy / RT Post active Rx 
Courneya et al, 2003b 100 Y 59:41 60 Colorectal NR Surgery Chemotherapy / none 
Courneya et al, 2007 242 Y 0:242 49 Breast I±III Surgery Chemotherapy 
Daley et al, 2007 108 Y 0:108 51 Breast NR Surgery / chemotherapy / RT Post active Rx 
Decker et al, 1989 12 N 9:3 43 Leukemia ± BMT Post-BMT 
Denmark-Wahnefried et al, 
2008 
90 Y 0:90 42 Breast I±III Surgery Chemotherapy 
Dimeo et al, 1996 20 N 11:9 36 Hematological NR BMT / chemotherapy Post-BMT 
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Dimeo et al, 1997a 36 N 11:21 42 Mixed NR Chemotherapy / RT Chemotherapy, stem cell 
transplant 
Dimeo et al, 1997b 70 Y 19:51 40 Mixed NR Chemotherapy Post active Rx 
Dimeo et al, 1999 59 N 22:37 40 Mixed ± NR Chemotherapy, stem cell 
transplant 
Galvao et al, 2006 11 N 11:0 70 Prostate NR NR Androgen deprivation therapy 
Headley et al, 2004 38 Y 0:38 51 Breast IV NR Chemotherapy 
Hwang et al, 2008 40 Y 0:40 46 Breast NR Surgery RT 
Heim et al, 2007 63 Y 0:63 NR Breast NR Surgery / chemotherapy / RT Post active Rx 
Irwin et al, 2008 75 Y 0:75 56 Breast I±III Surgery / chemotherapy / RT Post active Rx 
Jones et al, 2007 25 N 6:19 65 Lung I±III NR Pre-surgery 
Kolden et al, 2002 51 N 0:51 55 Breast I±III  Surgery / chemotherapy / RT Post active Rx 
Korstjens et al, 2006 665 N 140:525 51 Mixed NR Surgery / chemotherapy / RT Post active Rx 
Ligibel et al, 2008 101 Y 0:101 52 Breast I±III Surgery / chemotherapy / RT Post active Rx 
MacVicar & Winningham, 1989 62 Y 0:62 45 Breast II Surgery Chemotherapy 
Matthews et al, 2007 36 Y 0:36 51 Breast I±III Surgery / chemotherapy / RT NR 
May et al, 2008 147 Y 24:123 49 Mixed NR Surgery / chemotherapy / RT None 
McNeely et l, 2004 17 Y 14:3 61 Head and neck ± Surgery Post±surgery 
McNeely et al, 2008 52 Y 37:15 52 Head/neck I±IV Surgery Post active Rx 
Mello et al, 2003 18 Y 8:10 29 Hematological ± Bone marrow transplant  Post±BMT 
Midtgaard et al, 2006 61 N 16:45 43 Mixed NR NR Chemotherapy 
Milne et al, 2008 58 Y 0:58 55 Breast I±III Surgery / chemotherapy / RT Post active Rx 
Mock et al, 1994 18 Y 0:18 44 Breast I±II Surgery Chemotherapy 
Mock et al, 1997 50 Y 0:50 49 Breast I±II Surgery  RT 
Mock et al, 2001 52 N 0:52 48 Breast I±III Surgery Chemotherapy / RT 
Monga et al, 2007 21 Y 21:0 68 Prostate NR NR RT 
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Mutrie et al, 2007 203 Y 0:203 NR Breast I±III NR Chemotherapy / RT 
Na et al, 2000  Y NR 58 Stomach ± Surgery Post-surgery 
Ohira et al et al, 2006 86 Y 0:86 53 Breast I±III Surgery / chemotherapy / RT Post active Rx 
Oldervoll et al, 2006 34 N 15:19 65 Mixed NR Surgery / chemotherapy / RT Chemotherapy, HRT, none 
Payne et al, 2008 20 Y 0:20 65 Breast NR Surgery / chemotherapy / RT Hormone therapy 
Pickett et al, 2002 52 Y 0:52 48 Breast I±III Surgery Chemo/radiotherapy 
Pinto et al, 2003 24 Y 0:24 53 Breast I±II Surgery / chemotherapy / RT Hormone therapy 
Pinto et al, 2005  86 Y 0:86 53 Breast I±II Surgery / chemotherapy / RT Post active Rx 
Porock et al, 2000 9 N 3:6 60 Mixed NR Surgery / chemotherapy / RT Post active Rx 
Schulz et al, 1998 39 N 0:39 54 Breast NR Surgery Chemotherapy / none 
Schwartz, 1999 31 N 0:31 47 Breast I±IV  Surgery Chemotherapy 
Schwartz, 2000 31 N 0:31 47 Breast I±IV Surgery Chemotherapy 
Schwartz et al, 2001 72 N 0:72 47 Breast NR Surgery Post-surgery 
Schwartz et al, 2002 12 N NR 44 Melanoma III Surgery Interferon-Į 
Segal et al, 2001 123 Y 0:123 51 Breast I±II NR Chemotherapy / RT / 
hormone therapy 
Segal et al, 2003 155 Y 155:0 68 Prostate I±IV  NR Androgen deprivation therapy 
Segar et al, 1998 30 Y 0:30 49 Breast NR Surgery Post-surgery 
Stevinson & Fox, 2006 12 N 5:7 59 Mixed NR Surgery / chemotherapy / RT Chemotherapy / RT / none 
Thorsen et al, 2005 111 Y 36:75 39 Mixed NR Surgery / chemotherapy / RT Post active Rx 
Van Weert et al, 2005 81 Y 13:68 52 Mixed I±IV Surgery / chemotherapy / RT Post active Rx 
Wall, 2000 104 Y 56:48 65 Lung I±III NR Post surgery 
Windsor et al, 2004 66 Y 66:0 68 Prostate ± NR RT 
 
.H\< \HV1 QR15 QRWUHSRUWHG57 UDGLDWLRQWKHUDS\PL[HGFDQFHUW\SHGHQRWHVFDQFHUW\SHVXVHGLQWKHVWXGy 
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Table 5.2. Exercise programme characteristics and patient flow data. 
Study Location Type of exercise Intensity Session length (min) 
Frequency 
(per week) 
Duration 
(weeks) 
Uptake 
(%) 
Completion 
(%) 
Adamsen et al, 2001 Centre Tai chi, balance Low 60 1 16 NR 59 
Adamsen et al, 2003 Centre Cycling, resistance, relaxation Low / moderate 90 3 6 NR 85 
Adamsen et al, 2006 Centre Aerobic, resistance High 90 3 6 NR 71 
Berglund et al, 1993 Centre Mobility, relaxation Low 120 1.5 7 80 83 
Berglund et al, 2004 Centre Mobility, resistance, aerobic Low 120 1.5 7 68 92 
Bobbio et al, 2008 Centre Cycling Moderate 90 5 4 NR 100 
Burnham & Wilcox, 2002 Centre Aerobic Low / moderate 15±30 3 10 NR 100 
Campbell et al, 2005 Centre Aerobic (chosen) Moderate 10±20 2 6 NR 75 
Cesario et al, 2007 Centre Cycling Moderate / high 30 5 4 12 100 
Coleman et al, 2003 Home Aerobic, resistance Moderate 60 3±5 24 NR 78 
Coleman et al, 2008 Home Walking, resistance Low moderate NR 3±5 15 NR 88 
Courneya et al, 2002 Home Aerobic (chosen) Moderate 20±30 3±5 10 80 85 
Courneya et al, 2003a Centre Cycling Moderate 15±35 3 15 16 96 
Courneya et al, 2003b Home Aerobic (chosen) Moderate 20±30 3±5 16 35 90 
Courneya et al, 2007 Centre Aerobic, resistance Moderate 15±45 3 18 33 94 
Daley et al, 2007 Centre Aerobic Moderate 50 3 8 25 97 
Decker et al, 1989 Home Cycling Moderate 30 3 NR NR 58 
Denmark-Wahnefried et al, 2008 Home Aerobic, resistance Moderate 60 3 24 81 90 
Dimeo et al, 1996 Centre Treadmill walking Moderate 30 5 6 91 70 
Dimeo et al, 1997a Centre Treadmill walking Moderate 15±30 5 6 90 89 
Dimeo et al, 1997b Centre Bed cycling Low 30 7 NR NR 94 
Dimeo et al, 1999 Centre Bed cycling Low 30 7 NR NR 83 
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Galvao et al, 2006 Centre Resistance Low / moderate 60 2 20 41 91 
Headley et al, 2004 Centre Walking, resistance Moderate NR 5 NR 41 NR 
Hwang et al, 2008 Home Arm and leg (seated) Moderate 30 3 16 NR NR 
Heim et al, 2007 Centre Aerobic, resistance Moderate 50 3 5 NR 100 
Irwin et al, 2008 Centre / home Aerobic Moderate 15±30 3±5 24 20 97 
Jones et al, 2007 Centre Cycling Moderate / high 15±30 5 4±6 71 92 
Kolden et al, 2002 Centre Aerobic, resistance Moderate 60 3 16 NR 78 
Korstjens et al, 2006 Centre Aerobic, resistance Low / moderate 120 2 12 NR 100 
Ligibel et al, 2008 Home Aerobic. resistance Low / moderate 30±50 2±5 16 86 78 
MacVicar & Winningham, 1989 Centre Aerobic, cycling Moderate NR 3 10 NR NR 
Matthews et al, 2007 Home Walking Moderate 20±40 3±5 12 13 100 
May et al, 2008 Centre Aerobic, resistance Low / moderate 120 2 12 91 92 
McNeely et l, 2004 Centre Resistance Moderate 45 3 12 80 80 
McNeely et al, 2008 Centre / home Resistance Low / moderate 45 2±3 12 47 88 
Mello et al, 2003 Centre Arm and leg, treadmill walking Low / moderate 40 7 6 NR 100 
Midtgaard et al, 2006 Centre Aerobic, resistance, cycling Low / moderate 540/week NR 6 NR 93 
Milne et al, 2008 Centre Aerobic, resistance Low / moderate 60 3 12 44 100 
Mock et al, 1994 Home Walking Moderate 10±45 4±5 NR NR 50 
Mock et al, 1997 Home Walking Low / moderate 20±30 4±5 6 77 88 
Mock et al, 2001 Home Walking Low / moderate 10±15 5±6 6 NR 92 
Monga et al, 2007 Centre Aerobic Moderate 45 3 8 71 84 
Mutrie et al, 2007 Centre Aerobic, resistance Moderate NR 3 12 27 93 
Na et al, 2000 Centre Cycling, resistance Low / moderate 30 5 2 NR 71 
Ohira et al et al, 2006 Centre Resistance NR 30 2 26 65 91 
Oldervoll et al, 2006 Centre Aerobic, resistance Low / moderate 50 2 6 52 95 
Payne et al, 2008 Home Walking Moderate 20 4 12 35 90 
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Pickett et al, 2002 Home Walking Moderate 10±30 5 6 NR 88 
Pinto et al, 2003 Centre Aerobic (chosen), resistance Moderate 30 3 12 NR 75 
Pinto et al, 2005  Home Aerobic (chosen) Low / moderate 30 2±5 12 70 91 
Porock et al, 2000 Home Walking, arm and leg Low NR 7 4 11 82 
Schulz et al, 1998 Centre Walking, core stability Low / moderate 90 2 10 NR 72 
Schwartz, 1999 Home Aerobic (chosen) Low / moderate 15±30 3±4 8 89 87 
Schwartz, 2000 Home Aerobic (chosen)   Low 15±30 3 8 NR 87 
Schwartz et al, 2001 Home Aerobic Low / moderate 15±30 3±4 8 NR 92 
Schwartz et al, 2002 Home Aerobic (chosen) Low 15±30 4 16 NR 100 
Segal et al, 2001 Home Walking Low / moderate NR 5 26 33 79 
Segal et al, 2003 Centre Resistance Moderate 30±40 3 12 31 90 
Segar et al, 1998 Centre Aerobic (chosen), resistance Low / moderate 30±40 4 10 100 80 
Stevinson & Fox, 2006 Centre Aerobic and resistance Low / moderate 30±60 5 10 39 82 
Thorsen et al, 2005 Home Aerobic (chosen) Moderate 30 2 14 63 86 
Van Weert et al, 2005 Centre Cycling, resistance Low / moderate 90 2 15 NR 78 
Wall, 2000 Home Walking, resistance, breathing Low 30±40 7 1±3 NR 92 
Windsor et al, 2004 Home Walking Moderate 30 3 4 86 97 
 
Key:  "centre" indicates setting other than patient's home, NR = not reported.
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5.3.3 Acceptance and adherence data 
Overall, 7224 eligible patients were approached about participation in an 
exercise programme and 4524 accepted and enrolled. The median [IQR] 
rate of uptake was 63% [33±80]. Allowing for randomisation of some 
patients to a control group, this left 3220 patients commencing an exercise 
programme. Of these, 2824 completed the programme, a median [IQR] 
programme completion rate of 87% [80±96]. 
 
Most studies assessed adherence by either a patient diary (n=19) or 
an attendance register (n=21) for programmes located in the home or a 
centre respectively, although a range of methods were employed 
(telephone or face-to-face interview, accelerometer). Median [IQR] 
adherence to the recommended programme was 84% [72±93]. No 
statistical difference was found between adherence measured by self-
report or independent assessment methods (p=0.42). 
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5.3.4 Factors influencing acceptability 
No characteristic was found to significantly influence the uptake to an 
exercise programme. Non-significant trends suggested patients with or 
cured of breast cancer were less inclined to take up exercise than those 
with other types of cancer and that greater proportions of patients agreed 
to undertake programmes which recommended walking as the main 
exercise, used shorter bouts of low intensity exercise and had a shorter 
overall duration. Once enrolled and allocated to an exercise group, no 
characteristic was found to influence the proportion of patients completing 
the exercise programme (Table 5.3). 
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Table 5.3. Median [IQR] uptake and completion data according to patient or 
exercise programme characteristics. 
Characteristic 
Rate of 
uptake 
 (%) 
p 
value 
Rate of 
completion 
(%) 
p 
value 
Cancer type: 
Breast cancer 
Other cancer 
Treatment status: 
On treatment 
Off treatment 
Study design: 
Randomised 
Single arm 
Exercise type: 
Walking 
Other exercise 
Location: 
Home 
Centre / hospital 
Intensity: 
Low 
Low / Moderate 
Session length: 
PLQ 
> 30min 
Session frequency: 
SHUZHHN 
> 3 per week 
Programme duration: 
ZHHNV 
> 6 weeks 
 
51 [35±80] 
67 [24±80] 
 
56 [33±82] 
63 [35±80] 
 
64 [33±80] 
51 [40±90] 
 
74 [38±88] 
47 [31±80] 
 
63 [35±81] 
58 [32±80] 
 
60 [45±88] 
49 [27±80] 
 
70 [35±86] 
49 [33±80] 
 
57 [33±80] 
70 [34±88] 
 
74 [47±89] 
47 [33±80] 
 
 
0.87 
 
 
0.96 
 
 
0.54 
 
 
0.20 
 
 
0.85 
 
 
0.08 
 
 
0.55 
 
 
0.79 
 
 
0.23 
 
90 [82±93] 
91 [86±94] 
 
90 [86±93] 
90 [82±94] 
 
90 [85±95] 
87 [76±92] 
 
88 [83±91] 
91 [83±94] 
 
88 [85±91] 
91 [82±94] 
 
85 [81±92] 
90 [86±96] 
 
90 [86±92] 
90 [82±95] 
 
91 [86±95] 
88 [81±92] 
 
89 [73±96] 
90 [84±93] 
 
 
0.90 
 
 
0.76 
 
 
0.16 
 
 
0.34 
 
 
0.97 
 
 
0.97 
 
 
0.70 
 
 
0.50 
 
 
0.79 
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5.3.5 Reasons for refusal or withdrawal 
Common reasons for refusal included the impracticality of undertaking the 
exercise programme; time commitment associated with exercise, travel 
requirements and disinterest in exercise. These were reported by over 
three-quarters of patients who did not take up an exercise study. Once 
randomised to an exercise programme, the main reasons for withdrawal 
from a study included development of a medical complication, including 
adverse responses to treatments, e.g. chemotherapy, and acute events 
such as pulmonary emboli, deterioration in medical condition and personal 
or social problems (Table 5.4). In cases of a medical condition or 
deterioration in condition, this was reported to be related to anti-cancer 
treatment rather than participation in the exercise programme studied. 
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Table 5.4. Main reasons for refusing or withdrawing from an exercise programme 
Reason Number of 
studies 
reporting 
% of 
studies 
reporting 
Number of 
patients 
reporting 
% of all 
patients 
reporting 
Refusing 
Too busy / no time  
Too far to travel 
Lack of interest 
Worried about physical ability 
Already managing exercise 
Too much of a strain 
Declined randomisation 
Wanted a break 
Wanted medical approval 
Reminder of illness 
Work commitments 
Personal reason 
Withdrawing 
Medical complication 
Deterioration of condition 
Personal / social reasons 
Time commitment too much 
Problems with travel 
Exercises too strenuous 
Cancer recurrence 
Not strenuous enough 
 
17 / 36 
15 / 36 
15 / 36 
7 / 36 
7 / 36 
4 / 36 
7 / 36 
2 / 36 
2 / 36 
1 / 36 
3 / 36 
1 / 36 
 
18 / 63 
18 / 63 
11 / 63 
7 / 63 
7 / 63 
3 / 63 
4 / 63 
1 / 63 
 
47 
42 
42 
19 
19 
11 
19 
6 
6 
3 
8 
3 
 
29 
29 
17 
11 
11 
5 
6 
2 
 
203 
261 
477 
63 
21 
34 
40 
11 
37 
4 
35 
1 
 
42 
32 
22 
11 
5 
9 
22 
1 
 
17 
22 
40 
5 
2 
3 
3 
1 
3 
<1 
3 
<1 
 
29 
23 
15 
8 
3 
6 
15 
1 
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5.4 Discussion 
The acceptability of therapeutic exercise in this patient group has not 
recently been subject to a systematic review. Although rates of uptake and 
completion of exercise programmes varied, overall, only about half of 
patients approached and allocated to an exercise group undertook and 
completed the exercise intervention. Median [IQR] rates of uptake,  
adherence and completion across 65 studies were 63% [33±80], 84% 
>í] and 87% [80±96] respectively. These are in keeping with previous 
findings of Oldervoll et al (2004) who reported median rates of 63% and 
86% for uptake and completion relating to a smaller group of patients 
(1697 vs. 7224 eligible patients) across twelve studies. 
 
The main reasons reported for declining a programme concerned 
either a lack of interest or the impractical nature of the exercise offered, for 
example the time, travel, strain and commitment a programme demands 
(Table 5.4). This reflects findings from other patient groups offered 
exercise rehabilitation programmes including those with cardiac disease 
(Evanson and Fluery, 2000) and COPD (Taylor et al, 2007) where factors 
known to discourage participation include problems with access, e.g. 
travelling long distances, poor parking facilities, time and scheduling 
conflicts. A greater understanding of these factors and how they contribute 
WRDSDWLHQW¶VGHFLVLRQPDNLQJLVUHTXLUHG if exercise programmes are to 
become more practical in nature. In contrast, the experimental design of 
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many of the studies which can be a barrier to participation (Castel et al, 
2006; Mills et al, 2006), did not appear to have a major influence on uptake 
and was cited as the main reason for refusal by only 3% of all patients. 
 
Once enrolled, the adherence and completion rates were high 
(>80%) and the main reason for withdrawal was the occurrence of a 
medical complication, generally associated with an anticancer treatment, 
suggesting that patients were highly motivated. The rates are similar to 
those reported by studies involving healthy elders (Thurston and Green, 
2004), which may reflect that the majority of patients were receiving 
potentially curative or adjuvant treatment for early stage breast cancer. It 
also suggests that patients who started an exercise programme found 
sufficient benefit from the initial sessions to maintain their interest and 
continue participating regularly. This highlights the importance of the initial 
approach to patients about participation in an exercise study. As the 
evidence base for therapeutic exercise in patients with incurable disease is 
limited, it is inappropriate to suggest that this group will benefit from a 
programme. However, it may help improve uptake if the potential benefits 
are discussed and explored in some detail. 
 
Because studies which did not explicitly report rates of uptake and 
completion were excluded, these data should be accurate and valid. 
However, missing data may influence the validity of other results in this 
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review. Adherence was recorded by about one-third of studies and the 
main reason for declining or withdrawing from a programme was recorded 
in about half and one-thirds of patients respectively. The high proportion of 
reports failing to provide full details of patient flow data and study 
characteristics highlights the importance of thorough documentation. 
Hopefully reporting will improve following consensus documents on 
minimum datasets for scientific reporting such as those from the 
CONSORT group. 
 
Factors such as duration of exercise, setting, programme length and 
disease status have been suggested as possible influences on uptake and 
completion (Thurston and Green, 2004; Chao et al, 2000; Sherwood and 
Jeffery, 2000). We found no significant relationships between the 
characteristics of a patient group or exercise programme we considered 
and rates of uptake and completion. The most likely explanation for this is 
the wide ranges seen in these rates across a relatively small number of 
studies resulting in overlap. Another reason could be the nature of our 
analysis and the arbitrary cut off points we selected for the dichotomous 
divisions. The use of multiple linear regression models would have been 
our preferred means of analysis as these consider the independent 
contribution of each characteristic being examined whilst accounting for 
multi-colinearity (Portney and Watkins, 2000). However, based on Lang 
and Secic¶VUHFRPPHQGDWLRQRIDWOHDVWWHn studies for each 
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independent characteristic being considered in a model, the number of 
studies was deemed insufficient and simple tests of difference were used. 
Another methodological decision regarded the reduction of some 
characteristics from ratio, interval or ordinal level data into nominal level 
data, which may have resulted in a loss of precision (Portney and Watkins, 
2000). However, when transforming data, all decisions regarding cut-off 
points were all determined a priori and were based on epidemiological and 
clinical grounds or current public health and exercise prescription 
guidelines, e.g. 3 times per week, 6 weeks duration (Haskell et al, 2007; 
Nelson et al, 2007). 
 
It remains plausible that in a more homogenous population those 
patients who are willing to participate in an exercise programme may differ 
from those who decline with regard to characteristics such as age, gender 
and treatment status. It is also possible that other characteristics which 
were not considered in this review, e.g. depression, education, social 
status and pre-diagnosis exercise behaviour, may influence rates of uptake 
and completion. These variables have been highlighted as barriers to 
exercise (Rogers et al, 2007; 2008) and have also been associated with a 
reduced level of interest in exercise counselling (Jones and Courneya, 
2002). However, as only a minority of studies reported on such 
demographics, these were not considered. Authors are encouraged to 
provide these details to allow for synthesis in the future. 
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This review can be used to compare the acceptability of future 
exercise studies to median rates of uptake across all studies and similar 
previous programmes. It also helps inform the planning of future research 
studies by providing an approximation of the proportion of patients likely to 
be interested in taking up exercise. Finally, by outlining the most common 
reasons for patients declining or withdrawing from an exercise programme, 
it provides a basis on which strategies to make exercise acceptable can be 
formed. To develop exercise as a therapy, it appears that traditional 
exercise programmes need to be modified or tailored to each patient to 
increase practicality, e.g. delivered in a local centre or scheduled around 
existing commitments. Another approach would be to explore novel types 
of exercise which are such as neuromuscular electrical stimulation, which 
may be less demanding and required less of a change in lifestyle thus be 
acceptable to a greater proportion of patients. 
 
 In conclusion, although aiming for universal acceptability is 
unrealistic, these findings suggest that there is a need to modify current 
programmes or explore novel alternatives if exercise is to be acceptable 
and practical for the majority of patients with or cured of cancer. Future 
work is needed examine in more detail the factors influencing uptake in 
patients with a wide range of cancers and stage of disease.
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CHAPTER 6: 
EXERCISE AS A SUPPORTIVE THERAPY IN INCURABLE 
CANCER: EXPLORING PATIENT PREFERENCES 
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6.1 Introduction 
Therapeutic exercise programmes improve physical fitness, 
psychological well-being and quality of life in patients receiving curative 
treatment for cancer (Conn et al, 2006). Patients with incurable cancer 
may also benefit from exercise, but the evidence in this group is limited 
and further study is required (Oldervoll et al, 2006; Stevinson and Fox, 
2006). Which types of exercise to explore in this group requires careful 
consideration as the rates of uptake and completion for programmes 
EDVHGRQµWUDGLWLRQDO¶H[HUFLVHVDUHonly about two-thirds and one half 
respectively (Chapter 5; Maddocks et al, 2009). For an exercise to be a 
practical therapy for patients with incurable cancer, the majority should 
be capable of undertaking it and find it acceptable. 
 
 One approach to improve acceptability is to develop exercise 
programmes based on patients¶ exercise preferences in order they are 
congruent with the needs and interest of patients (Booth et al, 1997). 
Although some work on exercise preferences has been carried out, this 
is limited to patients with less common cancers, e.g. brain, non-Hodgkin 
lymphoma, ovarian, and exercise has not been presented to patients 
with details of the intensity, duration and frequency likely to be required 
to provide a therapeutic effect (Vallance et al, 2006; Jones and 
Courneya, 2002; Jones et al, 2007; Stevinson et al, 2009). Further, little 
is known about preferences for more novel and more passive forms of 
exercise, e.g. neuromuscular electrical stimulation and whole-body 
vibration, which may be preferred by some patients.  
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 This study has determined the acceptability of six exercise 
programmes based on different types of exercise to patients with 
incurable common cancers. This included identifying the most 
acceptable delivery method, location and time relative to anticancer 
treatments, and exploring if the choice for a particular exercise 
programme was influenced by various patient characteristics, e.g. 
habitual exercise behaviour, performance status or presence of co-
morbidities. 
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6.2 Methods 
6.2.1 Subjects 
Over a one-year period commencing January 2008, patients with 
histologically confirmed incurable cancer and an Eastern Cooperative 
Oncology Group (ECOG) Performance Status (Oken et al, 1982) of 0 to 
2 attending oncology outpatient clinics or a daycase chemotherapy 
suite at Nottingham University Hospitals NHS Trust were identified by 
their medical records. Whilst attending a scheduled clinic or 
chemotherapy appointment, patients were approached and invited to 
take part unless nursing staff considered it inappropriate to do so, e.g. 
because of high levels of psychological distress or confusion. All gave 
written informed consent and the study was approved by Nottingham 
Research Ethics Committee 1 (ref. 07/H0403/116). 
 
6.2.2 Questionnaire 
A 19-item questionnaire was developed with the help of the Nottingham 
&DQFHU3DWLHQWV¶6XSSRUW*URXS and the University of Nottingham 
Survey Unit used KeyPoint© version 5.5 (Speedwell, Cambridgeshire, 
UK) to provide a self-contained questionnaire with standardised 
instructions which could be presented on a laptop computer 
(Appendices 1.5 and 1.6). The questionnaire covered three broad 
themes: 
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Exercise behaviour: current and pre-diagnosis exercise 
behaviours were estimated using items from the Godin Leisure Time 
Exercise Questionnaire (Godin and Shepard, 1985; Godin et al, 1986). 
An independent evaluation found this to compare favourably to nine 
other physical activity questionnaires with test-retest ICCs over two 
weeks RIíKDYLQJEHHQUHSRUWHG-DFREVHWDO993). Patients 
were asked to report the number of times they did strenuous, moderate 
and mild intensity exercise for at least 15 minutes during a typical week, 
on a five-point scale (íííRU7 times per week). An 
activity score was calculated by multiplying the lower value of the 
SDWLHQW¶VUHVSRQVHE\QLQHILYHDQGWKUHHIRUVWUHQXRXVPRGHUDWHDQG
mild intensity exercise respectively and summing these together. A 
higher score indicates greater levels of physical activity. 
 
Preference for type of therapeutic exercise programme: To 
introduce the purpose of therapeutic exercise, participants were 
LQIRUPHGWKDWµ([HUFLVHKDVEHHQXVHGDVDWKHUDS\WRLPSURYHSHRSOH¶V
physical condition, mood and quality of life. We are going to show you a 
selection of exercise therapies that may provide EHQHILW¶Six different 
therapeutic exercise programmes were then illustrated in turn by a 
looping short video clip with accompanying text describing the content, 
intensity and frequency of sessions and duration of the exercise 
programme (Table 6.1). For example, for the exercise programme 
EDVHGRQZDONLQJSDWLHQWVZHUHLQIRUPHGWKDWµHach session would 
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consist of three 10 minute walks with rest periods in between and this 
would be for three days a week for six weekV¶. 
 
Table 6.1 Description of the exercise programmes. 
Exercise type Intensity 
Single 
session  
content 
Session 
frequency 
(times/week) 
Duration 
(weeks) 
Walking 
 
Moderate, i.e. brisk 
walking on the flat 
Three 10min walks 
with rest periods 
between 
3 6 
Treadmill  
walking 
Moderate, i.e. brisk 
walking on the flat 
Three 10min walks 
with rest periods 
between 
3 6 
Stationary  
cycling 
Moderate but not 
exhausting íPLQ 3 10 
Resistance training Low to moderate 
Four leg exercises 
2 sets of 8 
repetitions 
3 6 
Whole-body 
vibration Low to moderate 
Three 3min stands 
with rest periods 
between 
3 10 
Neuromuscular 
electrical 
stimulation 
Low to moderate 
íPLQ
stimulation to both 
thighs 
5 6 
 
 
Programmes based on walking, treadmill walking, cycling or 
resistance training were selected because of reported benefit in 
patients with or cured of cancer (Conn et al, 2006) and those utilizing 
neuromuscular electrical stimulation or whole-body vibration because of 
reported benefit in other patient groups, e.g. chronic heart failure, 
chronic obstructive pulmonary disease (Vivodtzev et al, 2008; Rehn et 
al, 2007). To minimise bias in the presentation of exercise programmes, 
video clips were filmed independently (Black Hawk Productions Ltd, 
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UK) using a standardised setting, model and clip length. The 
descriptions for each programme were also presented uniformly in 
order that SDUWLFLSDQW¶VFRXOGLQWHUSUHWthe differences between the six 
programmes in terms their content, e.g. session length and frequency 
(Appendix 1.6). 
 
Patients were asked to indicate if, at that moment in time, they 
were physically capable of undertaking such an exercise programme 
and, if so, whether they would be prepared to undertake the 
programme. If they were not prepared, they were asked to give reasons 
for this using free-text. After providing responses for all six exercise 
programmes, patients were asked to indicate which, if any, of the 
programmes they would be most prepared to undertake, providing 
reasons where possible using free-text. 
 
Programme delivery preferences: for the programme they would 
be most prepared to undertake, patients were asked to indicate their 
preferences for the delivery method (alone or in a group, supervised or 
unsupervised), location (home, hospital, community centre, gym) and 
timing relative to any anticancer treatments received (during or 
immediately after chemotherapy or radiation therapy). 
 
6.2.3 Protocol 
A member of the research team obtained demographic data verbally or 
from the medical records and introduced the questionnaire. The patient 
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was asked to complete the questionnaire unaided, in a setting of their 
choice, e.g. consulting room, treatment bay, with the member of the 
research team providing assistance only if requested. Data were 
captured in real-time using an Apache Webserver, version 2.2 (Apache 
Software Foundation) and uploaded to a central database. 
 
7KHVDPSOHVL]HZDVEDVHGRQWKHSUHFLVLRQWRZKLFKSDWLHQWV¶
preferences for each type of exercise programme could be estimated 
and assumes the estimated preference for each type of exercise lies 
within the range 10-60%. With a sample size of 200, two-sided 95% 
confidence intervals for preferences for each type of exercise can be 
estimated to within ±7% when a large sample normal approximation is 
used (nQuery Advisor® version 6.0). 
 
6.2.4 Statistical analysis 
Normally distributed continuous data and skewed data were 
summarised by mean (SD) or median [IQR] respectively. Change from 
pre-diagnosis to current physical activity level was calculated using a 
Wilcoxon signed-rank test. Frequency counts and percentages with 
95% confidence intervals were calculated for responses to 
questionnaire items; perceived physical capability and preparedness to 
undertake each type of exercise programme, most preferred exercise 
therapy programme, delivery method, location and time. Responses to 
open-ended questions were pooled and grouped into themes using 
content analysis. 
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Multiple logistic regression was used to examine the 
associations between gender, age, performance status, current activity 
score and presence of co-morbidities with being capable and prepared 
to undertake each of the exercise programmes. Age, performance 
status and activity score were categorised arbitrarily using cuts off 
points of 65 years, 1 and 15 respectively; the latter equivalent to three 
sessions of moderate exercise a week. For each exercise programme, 
a single logistic regression model containing all independent variables 
was used to estimate odds ratios, 95% confidence intervals and P 
values. 
 
All calculations were performed using Statistical Software for the 
Social Sciences (SPSS) version 15.0 with the exception of confidence 
intervals, which were calculated using WLOVRQ¶VPHWKRG:LOVRQ
and Confidence Interval Analysis (CIA) version 2.1.2 (Trevor Bryant, 
University of Southampton). A p value of <0.05 was regarded as 
statistically significant.
 148 
 
6.3 Results 
6.3.1 Participants 
Of 225 eligible patients approached, 200 (89%) enrolled and completed 
the study. Twenty five patients declined participation citing that they 
lacked interest (n=19), felt active enough (n=3), were too tired (n=2) or 
in discomfort (n=1). Participants had a range of common cancers and 
groups at highest risk of cancer cachexia were well represented, for 
example, 46 (23%) and 39 (20%) had lung and upper-gastrointestinal 
cancer respectively. The majority were currently receiving palliative 
chemotherapy and compared with pre-diagnosis, participants¶current 
physical activity scores were significantly lower (median [IQR] fall 10 
>í@, p<0.01). (Table 6.2). 
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Table 6.2 Patient details. Reported as counts unless stated otherwise. 
Demographic 
 
 
Sex (male / female) 97 / 103 
Age (mean (SD) years) 64 (9) 
Diagnosis 
  Lung (non-small cell, small cell, mesothelioma) 
  Breast 
  Upper-GI (pancreatic, oesophageal, gastric, gallbladder) 
  Colorectal 
  Urological (prostate, renal, bladder) 
  Gynaecological  
  (ovarian, endometrial, cervical, falopian tube) 
  Other  
  (head and neck, non-Hodgkin lymphoma, leiomyosarcoma) 
 
46 (29, 15, 2) 
40 
39 (20, 9, 9, 1) 
34 
21 (14, 5, 2) 
 
16 (12, 2, 1, 1) 
 
4 (2, 1, 1) 
Current treatment 
  Chemotherapy 
  Radiotherapy 
 
185 
0 
Previous treatment 
  Chemotherapy 
  Radiotherapy 
 
63 
86 
Co-morbidities 
  COPD  
  Diabetes 
  Ischaemic heart disease  
  Arthritis 
 
27 
21 
18 
11 
ECOG Performance status 
  0 
  1 
  2 
 
29 
121 
50 
Exercise behaviour (median [IQR] activity score) 
  Pre-diagnosis   
  Current 
 
>í@ 
>í@ 
 
Upper-GI = upper-gastrointestinal; COPD = Chronic obstructive pulmonary disease; 
ECOG = Eastern Cooperative Oncology Group. 
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6.3.2 Physical capability to undertake an exercise programme 
All 200 patients considered themselves physically capable of 
undertaking one or more of the exercise programmes. More than 80% 
felt physically capable of undertaking exercise programmes utilizing 
resistance training, whole body vibration or neuromuscular electrical 
stimulation, whereas only about half felt capable of undertaking 
programmes using walking, treadmill walking or cycling (Table 5.3). 
Specific reasons given for not feeling capable included the presence of 
breathlessness (n=89), tiredness/fatigue (n=62), pain (n=49), leg 
weakness (n=43), poor balance (n=18), joint stiffness (n=13), concern 
regarding the exercise equipment (n=12) and both breathlessness and 
leg weakness (n=9). Non-VSHFLILFFRPPHQWVZHUHDOVRFRPPRQHJ³,
ZRXOGQRWEHDEOHWRGRWKDW´Q  
 
6.3.3 Preparedness to undertake an exercise programme 
Two-thirds (n=133) of patients reported being prepared to undertake 
one or more exercise programmes at that moment in time. Individually, 
this was highest for neuromuscular stimulation (60%) and lowest for 
treadmill walking (33%) (Table 5.3). For all exercise programmes, 
reasons given for being capable but not prepared included a lack of 
interest (n=47), being content with current levels of activity/not 
perceiving a need for exercise (n=33), completing an activity without 
purpose (n=19), time commitment/scheduling difficulties (n=15), the 
programme being insufficiently challenging (n=13), wanting to avoid 
exercise-induced symptoms (n=6), or having other priorities, e.g. family 
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or work (n=4). For patients prepared to undertake exercise, the decision 
did not appear to be influenced by the timing of the programme in 
relation to anticancer treatments (Table 6.3). 
 
 One-third (n=67) were not prepared to undertake any of the 
exercise programmes. Across the six programmes reasons given by 
this group included a lack of interest (n=109), being content with current 
levels of activity/not perceiving a need for exercise (n=63), time 
commitment/scheduling difficulties (n=20), other priorities, e.g. family or 
work (n=16), completing an activity without purpose (n=7), the 
programme being insufficiently challenging (n=6), or wanting to avoid 
exercise-induced symptoms (n=4). Although numbers are smaller, 
again the decision did not appear to be particularly influenced by the 
timing of the exercise programme in relation to anticancer treatments 
(Table 6.3). 
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Table 6.3 Current physical capability and preparedness to undertake an 
exercise programme. 
 Frequency 
yes/no 
 
% yes [95% CI] 
Do you think you are physically capable of undertaking this type of exercise therapy 
programme? 
Walking 
Treadmill walking 
Stationary cycling 
Resistance training 
Whole body vibration 
Neuromuscular electrical stimulation 
107/93 
97/103 
81/119 
183/17 
163/37 
191/9 
54 
49 
41 
92 
82 
96 
[47 to 60] 
[42 to 55] 
[34 to 46] 
[87 to 95] 
[76 to 86] 
[92 to 98] 
Would you be prepared to undertake an exercise therapy programme similar to this? 
Walking 
Treadmill walking 
Stationary cycling 
Resistance training 
Whole body vibration 
Neuromuscular electrical stimulation  
57/50 
32/65 
38/43 
91/92 
95/68 
114/77 
53 
33 
47 
50 
58 
60 
[44 to 62] 
[24 to 43] 
[36 to 58] 
[43 to 57] 
[51 to 66] 
[50 to 64] 
For each of the treatments you have received, would you be prepared to undertake an 
exercise therapy programme at these times? 
Patients prepared to undertake one or more exercise programmes: 
During chemotherapy 
After chemotherapy 
During radiotherapy 
After radiotherapy 
During combined chemotherapy and radiotherapy 
After combined chemotherapy and radiotherapy 
121/7 
120/8 
40/14 
39/15 
7/2 
7/2 
95 
94 
74 
72 
78 
78 
[89 to 97] 
[88 to 97] 
[61 to 84] 
[59 to 82] 
[45 to 94] 
[45 to 94] 
Patients not prepared to undertake any exercise programme: 
During chemotherapy 
After chemotherapy 
During radiotherapy 
After radiotherapy 
During combined chemotherapy and radiotherapy 
After combined chemotherapy and radiotherapy 
0/63 
5/58 
2/18 
1/19 
0/3 
0/3 
0 
8 
10 
5 
0 
0 
[0 to 1] 
[3 to 17] 
[3 to 30] 
[1 to 24] 
[0 to 56] 
[0 to 56] 
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6.3.4 Most preferred type of exercise programme and delivery 
For the 133 patients willing to undertake exercise, the most preferred 
type of exercise to undertake at that moment in time was 
neuromuscular electrical stimulation, followed by walking and 
resistance training (Figure 6.1 and Table 6.4). Reasons given for 
selecting the preferred programme included the practicality or 
convenience of the type of exercise (n=33), previous experience of the 
exercise (n=22), enjoyment (n=20), wanting to improve leg strength 
(n=19), curiosity or interest (n=15), being within their capabilities 
(n=13), having a focus on general fitness (n=12), or the positive 
physical challenge it presented (n=9). 
 
The majority of patients expressed a preference to undertake the 
exercise programme at home, alone and unsupervised. A minority 
(n=15, 12%) preferred group exercise, with a community centre the 
preferred meeting place (Table 6.4). 
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Table 6.4 Patients preferred type of exercise programme and delivery 
preferences (n=133). 
 Frequency % [95% CI] 
Which type of exercise programme would you be most prepared to undertake at this 
moment in time? 
Walking 
Treadmill walking 
Stationary cycling 
Resistance training 
Whole body vibration 
Neuromuscular electrical stimulation 
29 
5 
9 
25 
18 
47 
22 
4 
7 
19 
14 
36 
[16 to 30] 
[2 to 9] 
 [4 to 12] 
[13 to 26] 
 [14 to 20] 
[35 to 44] 
How would you most prefer to undertake the exercise programme? 
Alone, unsupervised 
Alone, supervised 
In a group, unsupervised 
In a group, supervised 
106 
5 
7 
15 
80 
4 
5 
12 
[72 to 86] 
[2 to 9] 
[3 to 11] 
[7 to 18] 
Where would you most prefer to undertake an exercise programme? 
Home 
Hospital 
Community centre 
Gym 
110 
5 
11 
7 
83 
4 
8 
5 
[75 to 88] 
[2 to 9] 
[5 to 14] 
[3 to 11] 
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Figure 6.1 Most preferred type of exercise programme by number of patients 
with 95% confidence intervals. 
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6.3.5 Influence of patient characteristics on exercise programme 
preference 
Older patients and those with a low performance status were less likely 
to be capable of and prepared to undertake the cycling exercise 
programme (odds ratios 0.36 and 0.21 respectively, p<0.05) and 
patients with a low performance status were less likely to be prepared 
to undertake the programme of treadmill walking (odds ratio 0.19, 
p<0.05) (Table 6.5). There were non-significant indications that older 
patients, males and those with low performance status, activity scores 
and comorbidities felt less capable of and prepared to undertake 
exercise programmes utilising walking, treadmill or cycling and 
generally more likely to undertake programmes utilising resistance 
training, whole body vibration or neuromuscular electrical stimulation 
(Table 6.5). These characteristics were also non-significantly 
associated with being less prepared to undertake at least one exercise 
programme. 
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Table 6.5 Influence of patient characteristics on preparedness to undertake each type of exercise programme expressed as odds ratios [95% 
confidence intervals]. 
Characteristic 
(baseline category second) 
Walking Treadmill  
walking 
Stationary 
cycling 
Resistance  
training 
Whole  
body vibration 
Neuromuscular 
electrical stimulation 
 
Gender: male vs. female 
Age: YV 
Performance status: 2 vs. 0±1 
Current activity score: <YV 
Comorbidities: YV 
 
0.74  [0.38, 1.41] 
0.68  [0.36, 1.31] 
0.37  [0.14, 1.01] 
0.62  [0.31, 1.25] 
0.77  [0.37, 1.58] 
 
0.84  [0.37, 1.82] 
0.65  [0.29, 1.43] 
 0.19   [0.04, 0.87]* 
0.97  [0.42, 2.20] 
0.67  [0.27, 1.69] 
 
0.93  [0.44, 1.98] 
 0.36  [0.17, 0.79]* 
 0.21  [0.06, 0.78]* 
0.99  [0.45, 2.19] 
1.75  [0.80, 3.86] 
 
1.17  [0.66, 2.07] 
0.69  [0.39, 1.23] 
0.67  [0.33, 1.38] 
1.63  [0.87, 1.23] 
1.06  [0.57, 1.97] 
 
1.22  [0.69, 2.15] 
1.15  [0.65, 2.04] 
0.64  [0.31, 1.32] 
0.80  [0.43, 1.48] 
1.03  [0.56, 1.91] 
 
1.27  [0.72, 2.25] 
1.00  [0.56, 1.78] 
0.79  [0.38, 1.61] 
1.27  [0.68, 2.38] 
1.23  [0.66, 2.29] 
 
 
* statistically significant (p<0.05) 
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6.4 Discussion 
This is the most in-depth survey of the exercise preferences of patients 
living with a range of common cancers. When provided with the full 
details of exercise programmes utilizing various types of exercise and 
reflecting common regimens, two-thirds of patients appeared capable of 
and prepared to undertake at least one of them. This proportion is in 
keeping with the median [IQR] uptake of >í@reported by a 
recent systematic review of therapeutic exercise in people with or cured 
of cancer across a range of settings (Chapter 5; Maddocks et al, 2009). 
Of those patients prepared to undertake a programme, the most 
preferred type of exercise was neuromuscular electrical stimulation 
(36%) followed by walking (22%), resistance training (19%) and whole 
body vibration (14%) with treadmill walking and stationary cycling 
selected by less than 10% of patients. This suggests that to engage the 
majority of patients with common incurable cancers in their most 
preferred form of exercise, a range of therapeutic exercise programmes 
may need to be offered, taking into account the clear preference for the 
exercise to be undertaken at home and unsupervised. 
 
3DWLHQWV¶SUHIHUHQFHVUHJDUGLQJWKHGHOLYHU\RIH[HUFLVHwere 
generally in keeping with those of other patients with or cured of cancer. 
In a group of non-+RGJNLQ¶VO\PSKRPDVXUYLYRUVRYHUKDOIIHOWDEOH
(53%), and interested (55%), in participating in an exercise programme 
and the majority had preference to complete exercise sessions at home 
(Vallence et al, 2006). Similarly, in a group of mixed cancer survivors, 
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the majority reported a preference towards recreational types of 
exercise, particularly walking, and undertaking exercise at home and 
unsupervised (Jones and Courneya, 2002). One advantage to the 
present study is that patients who were not prepared to undertake any 
of exercise programmes were not asked about the delivery of a fictitious 
exercise programme as in previous studies (Vallance et al, 2006; Jones 
and Courneya, 2002; Jones et al, 2007). 
 
The evidence base regarding the exercise programmes we 
examined is limited in people with incurable cancer, particularly for the 
more novel forms of exercise, e.g. neuromuscular electrical stimulation. 
Our results can be used to help inform the selection of appropriate 
types of exercise in which to examine uptake, adherence and efficacy in 
this group and, on the basis of its popularity, neuromuscular electrical 
stimulation appears worthy of study. Patients cited practicality and 
convenience as the main reason for selecting this as their preferred 
choice and, compared to many exercises, neuromuscular electrical 
stimulation is relatively passive and requires less motivation and 
change in lifestyle, e.g. it can be undertaken whilst sitting watching 
television, reading etc. Nonetheless, this choice is likely to have been 
based mainly on the information given rather than actual experience of 
neuromuscular electrical stimulation and further work is required to 
explore the acceptability of its use. Except for walking, there will also be 
varying degrees of experience with the other types of exercise and this 
knowledge could have further informed our findings. 
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 One third of patients surveyed were not prepared to undertake 
any of the exercise programmes, which is also in keeping with the 
findings of the systematic review (Chapter 5; Maddocks et al, 2009). 
The main reason given for being unprepared to exercise was a lack of 
interest, and there was a tendency for older or male patients and those 
with a low performance status or activity score to be the least prepared 
to undertake exercise. There is always likely to be a proportion of 
patients for whom any form of exercise is unacceptable, even when 
able and aware of the potential benefits. Indeed, Clark et al (2007) 
surveyed 128 patients with advanced cancer receiving palliative 
chemotherapy and found that although most patients could identify an 
immediate benefit from exercise, only a third were interested in 
receiving support to increase their exercise participation. Some authors 
have suggested offering exercise as an integrated component of cancer 
treatment as a means to improve patient interest (Irwin et al, 2008). 
However, whether this could improve uptake to exercise programmes 
remains to be seen. 
 
 This work builds on a review of the acceptability of exercise as a 
therapy in which a need to determine the most acceptable types of 
exercise was identified. Although we asked about the most common 
types of exercise, some patients may have had a preference towards 
an alternative, e.g. yoga or swimming, and further work may include an 
option to report alternative preferences.  Another limitation was the 
potential for researcher bias in the questionnaire. Attempts were made 
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to minimise bias, for example, video clips were filmed independently, 
each type of exercise was presented using a standardised format and 
the six programmes were reasonably comparable in terms of their 
content. Nonetheless, we were limited by the lack of available evidence 
in this group and it may be that one or more of the programmes are 
shown to provide little therapeutic benefit in the future. Finally, although 
all participants had incurable disease and a similar performance status, 
there was heterogeneity in the sample in terms of cancer type. 
Therefore, it remains possible that patients with specific types of cancer 
have preferences that went undetected. We plan to focus future work 
on patients with lung and upper gastro-intestinal cancers to address this 
particular issue. 
 
 Future studies expanding on this work could explore factors 
contributing to preparedness to exercise in more depth, e.g. motivation, 
confidence, educational level and social status, along with any 
willingness or preference to undertake other types of exercise not 
represented in the six programmes.  Although we gave participants the 
opportunity to provide some free-text responses to questionnaire items, 
a more in-depth exploration of wKLFKDFWLYLWLHVSDWLHQWV¶SDUWLFLSDWHLQ
and why, which factors lead to a lack of interest to exercise and 
whether tailoring programmes would alter preparedness to exercise 
would all have added to the richness of the data obtained. Some 
selective follow-up interviews and/or focus groups with participants 
would have made a useful contribution but was overlooked. 
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The longer term aim is to develop therapeutic exercise for people 
with incurable cancer as part of a proactive rehabilitation programme in 
order to optimise physical function, independence and psychological 
well-being for as long as possible. Intuitively, success is more likely the 
sooner it commences after diagnosis rather than waiting until significant 
loss in function has occurred. Thus, we explored the views of patients 
with a reasonable performance status, many of whom were receiving or 
had received chemotherapy or radiotherapy as part of their cancer 
management. Although all patients had a good performance status, 
their exercise levels had already fallen from pre-diagnosis levels, 
supporting our rationale for early intervention. 
 
In conclusion, these findings suggest that it is realistic to 
consider exercise as a supportive therapy for patients with incurable 
cancer, including those receiving anticancer treatments. Further work to 
examine the safety, adherence and efficacy of exercise is required and 
these data can inform future studies so the most popular forms of 
exercise are examined. 
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CHAPTER 7: 
RANDOMISED CONTROLLED PILOT STUDY OF 
NEUROMUSCULAR ELECTRICAL STIMULATION OF THE 
QUADRICEPS IN PATIENTS WITH NON-SMALL CELL  
LUNG CANCER 
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7.1 Introduction 
Cachexia is particularly common in patients with incurable non-small 
cell lung cancer (NSCLC) leading to muscle wasting and weakness, 
which impair physical function and quality of life (Laviano and Meguid, 
1996; Courneya and Freidenreich, 1999; Rejeski and Mihalko, 2001). 
Anti-cancer treatments causing fatigue can also lead to physical 
inactivity and further muscle deconditioning (Muscaritoli et al, 2006). 
Effective treatments are lacking and new approaches are required. 
 
 Therapeutic exercise may be one component of a multimodal 
approach to the management of patients with or at risk of cancer 
cachexia (Fearon et al, 2008). However, there are issues with 
acceptability and only about half of patients with or cured of cancer are 
willing and able to complete an exercise programme (Chapter 5 
Maddocks et al, 2009). Further, patients experiencing breathlessness 
and/or fatigue at low levels of exertion may find more active types of 
exercise, e.g. walking, circuit training, too demanding (Irwin and 
Ainsworth, 2004; Oldervoll et al, 2006). One approach which avoids 
some of these difficulties is neuromuscular electrical stimulation 
(NMES) of the quadriceps muscles. NMES can be self-administered at 
home while seated and, being a passive intervention, it demands less 
motivation and change in lifestyle than traditional forms of exercise. 
Thus, it may help overcome some of the practical barriers identified in 
the systematic review presented in Chapter 5 (Maddocks et al, 2009). 
In support of this, when therapeutic programmes using NMES were 
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directly compared to more traditional types of exercise, e.g. walking, 
stationary cycling, they were preferred by patients with incurable cancer 
because of their perceived practicality and convenience (Chapter 6; 
Maddocks et al, in press). 
 
Stimulation is administered by a small battery operated unit, 
which, via self-adhesive electrodes, produces a controlled contraction 
and relaxation of the underlying muscle equiYDOHQWWRí50% of the 
SDWLHQW¶V maximum voluntary contraction. Treatment regimens generally 
consist of a 30 minute period of stimulation 5±7 times a week. In 
healthy subjects, NMES leads to similar changes in muscle 
biochemistry (Nuhr et al, 2004; Dal Corso et al, 2007; Sillen et al, 2008) 
and improvements in strength as found with volitional resistance 
training (Bax et al, 2005). NMES has increased quadriceps muscle 
strength by 10±40% in patients with chronic obstructive pulmonary 
disease (COPD) or heart failure, with improvements in exercise 
capacity and health-related quality of life seen in some studies (Nuhr et 
al, 2004; Dal Corso et al, 2007; Neder et al, 2002; Bourjelly-Habr et al, 
2002; Quittan et al, 2001; DREãiNHWDOa). NMES has not been 
formally examined in patients with cancer to our knowledge. Thus, the 
primary aim of this pilot study was to explore if it is a feasible and 
tolerable intervention for patients with NSCLC. Secondary aims were to 
examine efficacy around muscle strength, exercise endurance, physical 
activity levels and health-related quality of life for the purpose of 
informing the design of future studies. 
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7.2 Methods 
7.2.1 Subjects 
Patients with NSCLC and an ECOG performance status of 0 or 1 were 
recruited from thoracic oncology clinics. Medication had to have been 
stable for at least one week and patients were excluded if they had 
received radio- or chemotherapy within the last four weeks, lost >10% 
of their pre-morbid body weight, had ischaemic heart disease, a cardiac 
pacemaker, or any problem that might affect their ability to undertake a 
walking exercise test. Patients gave written informed consent and the 
study was approved by Nottingham Research Ethics Committee (ref. 
05/Q2402/62) and registered with Current Controlled Trials (ISRCTN 
86814835). 
 
7.2.2 Measurements 
7.2.2.1 Acceptability 
Acceptability of NMES was DVVHVVHGE\SDWLHQWV¶ adherence to the 
recommended duration and frequency of NMES, recorded in a self-
report daily diary (Appendix 1.7). PDWLHQWV¶H[SHULHQFHs of NMES, 
recorded using a semi-structured evaluation form, were also captured 
on completion of the programme. The form used an open question to 
obtain any good or bad comments about NMES, e.g. any difficulties 
with its use, and specifically asked patients to record if they would be 
prepared to use it again in the future (Appendix 1.8). 
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7.2.2.2 Quadriceps muscle strength 
Assessed with a Cybex NORM dynamometer (Cybex, division of Lumex 
Inc, New York, USA; software version 2.06) using a protocol previously 
used in patients with NSCLC (Wilcock et al, 2008a). Equipment set up 
and test settings were standardized for each patient during all tests. 
The dynamometer was set up to only allow isokinetic exercise, i.e. for 
any force exerted the machine produced an equivalent resistance and 
thus the lower leg could only move at a prefixed speed. Patients were 
seated with the padded lever arm of the dynamometer placed just 
above the ankle of the dominant leg, i.e. the one preferred to kick a ball 
with, and undertake 30 maximal isokinetic contractions through a fixed 
range of movement from knee flexion to extension at a fixed speed of 
180°sec-¹. The speed was pre-determined to replicate joint movements 
during functional movements, e.g. stair climbing or postural adjustments 
during gait. The first five repetitions are for familiarisation purposes and 
maximum strength is indicated by the peak torque (Newton metres, 
Nm) obtained in the remaining 25 repetitions (Wilcock et al, 2008a; 
Kannus, 1994). This protocol has been shown to be acceptable to 
sixteen patients with thoracic cancer, all of whom were prepared to 
repeat the test, and highly reliable with a between day test-retest ICC 
[95% CI] of 0.91 [0.82í0.95] (Wilcock et al, 2008a). 
 
7.2.2.3 Exercise endurance 
Assessed using the ESWT (Department of Respiratory Medicine, 
Glenfield Hospital, Leicester, UK) (Revill et al, 1999). Patients walk 
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around two cones 10m apart at a constant pace dictated by an external 
audio signal from a tape cassette player. The test kit contains eight 
cassettes, covering a range of walking speeds from 1.78 to 6km/h. For 
each patient, the walking speed is selected to be closest to a workload 
HTXLYDOHQWWRRIWKHSDWLHQW¶VSUHGicted peak oxygen uptake. This is 
calculated from the maximum walking speed achieved by the patient in 
a prior ISWT. This is carried out in an identical manner to the ESWT 
except that the frequency of the audio signals and walking speed 
progressively increases (Singh and Morgan, 1992; Singh et al, 1994). 
The ESWT is continued until the patient is unable to maintain the pace 
or if the maximum duration of the test is reached (20 minutes) and the 
distance walked in metres is recorded as the test outcome. Although 
the ESWT has not yet been used in patients with cancer, it has also 
been shown to be reliable with a mean [95% CI] difference in distance 
walked RIP>í@IRXQGLQSDWLHQWVZLWK&23'FRPSOHWLQJ
sequential tests on two separate days (Revill et al, 1999). The ISWT 
was also shown to be acceptable to 41 patients with advanced disease 
(Booth and Adams, 2001). 
 
7.2.2.4 Free-living physical activity 
Assessed as mean daily step count measured over a period of one 
ZHHNXVLQJDQ$FWLY3$/PRQLWRU3$/WHFKQRORJLHV/WG*ODVJRZ
UK). This small, lightweight (20 x 30 x 5mm, 20g) uni-axial 
accelerometer is applied to the mid-thigh using adhesive pads and is 
worn continuously except for when showering / bathing or during 
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NMES. 7KH$FWLY3$/step count has been shown to be accurate 
across a range of walking speeds (0.6-2.4m/s) with measurement error 
of <5% (Grant et al, 2006; Ryan et al, 2006; Maddocks et al, 2008). 
Unlike other accelerometers, it also does not record erroneous steps 
during motor vehicle travel (Gotshall et al 2003; Le Masurier & Tudor-
Locke, 2003; Maddocks et al, 2008). 
 
7.2.2.5 Spirometric values 
Forced expiratory volume in one second (FEV1) and forced vital 
capacity (FVC) were measured with participants seated as the best of 
three recordings using a dry wedge spirometer (Vitalograph Type R 
Spirometer, Buckingham, UK). 
 
7.2.2.6 Health-related quality of life 
Assessed using the EORTC QLQ C-30 core questionnaire and LC-13 
lung cancer module (Aaronson et al, 1993; Bergman et al, 1994; 
Nicklasson and Bergman, 2007). From the core questionnaire, the 
global quality of life and physical functioning sub-scales were used and 
the lung cancer module provided an additional scale concerning 
physical symptoms. The physical functioning and symptom questions 
use a four-point response scale, the global quality of life question uses 
a seven-point scale, and all total raw scores are linearly converted to a 
0±100 score. For global quality of life and physical functioning, a high 
score represents a better quality of life or level of function. For the 
symptom scale, a high score represents a greater level of symptom 
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distress. Both instruments have been widely used in patients with 
cancer and have recently been validated in patients with thoracic 
cancer in a palliative care setting as described previously (chapter 4, 
Nicklasson and Bergman, 2007). 
 
7.2.3 Neuromuscular electrical stimulation 
Delivered by a MicroStim Exercise Stimulator MS2v2 (Odstock Medical 
Ltd, Wiltshire, UK) using two 7cm round PALS® Platinum self-adhesive 
electrodes (Axelgaard Manufacturing Co Ltd, Denmark) placed on the 
anterior thigh over the body of the quadriceps muscle. The programme 
consisted of daily stimulation to one thigh at a time for 15 minutes, 
increasing to 30 minutes after one week. One treatment session for 
both thighs would therefore last 30±60 minutes in total. Pulse waveform 
(symmetrical biphasic squared), frequency (50Hz) and width 
(350microseconds) were constant throughout the four week period. The 
amplitude (device output 0±P$WHVWHGDFURVVȍZDVLQLWLDOO\
set to elicit a visible and comfortable muscle contraction; patients were 
encouraged to subsequently increase the amplitude as tolerated. The 
proportion of the treatment duration which was active stimulation, i.e. 
the duty cycle, increased on a weekly basis from 11% to 18% to 25%, 
remaining constant thereafter.  
 
 The programme was based those found to be most beneficial in 
promoting hypertrophy and improvements in strength in other patient 
groups with deconditioned muscles (Neder et al, 2002; Quittan et al, 
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+DUULVHWDO'REãiNHWDOD Roig and Reid, 2009). 
The stimulation parameters were selected to favour gains in strength 
over endurance (frequency), minimise skin irritation by instigating 
contraction at low amplitudes (pulse width) and allow for sufficient 
recovery of the muscles between contractions to minimise muscular 
fatigue (duty cycle) (Baker et al, 2000; Vivodtzev et al, 2008; Dehail et 
al, 2008). Stimulation frequency and pulse width are important in 
determining the profile of change obtained with a NMES programme. 
7KHXVHRIKLJKHUIUHTXHQFLHVLH40Hz, has been suggested to 
preferentially target type II muscle fibres and lead to improvements in 
muscular strength rather than endurance as was the aim with the 
current programme (Bax et al, 2005; Dal Corso et al, 2007). Wider 
pulses were selected as these lead to greater force production and are 
most appropriate when attempting to achieve a visible tetanic 
contraction HVWLPDWHGíPDximum voluntary contraction) of 
larger muscle groups such as the quadriceps (Vivodtzev et al, 2008). 
The duty cycles were selected as a means to prevent muscular fatigue 
during and post-stimulation. Skeletal muscle fatigues more rapidly 
during NMES than during volitional exercise due to differences in motor 
unit recruitment order and imprecise control of motor unit recruitment 
and the level of muscular contraction (Delitto et al, 1990; Peckham and 
Knutson, 2005; Dehail et al, 2008). Therefore, relatively short active 
periods íDQGORQJLQDFWLYHSHULRGVZHUHVHOHFWHG to allow 
sufficient recovery of the muscle following each contraction (Vivodtzev 
et al, 2008). 
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7.2.4 Protocol 
All assessments, except free-living physical activity, were carried out in 
a human performance laboratory based in the Clinical Sciences 
Building (Nottingham University Hospitals NHS Trust, City Hospital 
Campus) at the same time of day (±1h). Patients were given written 
instructions to avoid caffeine for one hour, large meals for two hours, 
excess alcohol the night before the tests and to keep the times of any 
drug administration constant. Verbal encouragement was minimal and 
standardised. Patients were randomised 1:1 into NMES or control 
groups (no intervention) using randomised permuted blocks generated 
by an independent researcher and concealed using opaque envelopes.  
 
Over a five-week period, all patients attended the hospital three 
times and received two home visits; those in the NMES group received 
two additional home visits. The initial home visit was to begin recording 
free-living physical activity. One week later, at hospital, patients 
undertook spirometry and two ISWT, 30 minutes apart, the first for 
familiarisation purposes. The maximal walking speed achieved in the 
second ISWT was used to determine the ESWT walking speed. The 
next day, an ESWT was undertaken followed, after 30 minutes rest, by 
assessment of quadriceps muscle strength. Those receiving NMES 
were taught how to use the stimulator and received two additional 
weekly home visits to facilitate optimal usage and adherence. After 
three weeks, all patients were visited at home to begin recording free-
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living physical activity. One week later, at the final hospital visit, the 
ESWT, quadriceps muscle strength and spirometry were repeated and 
the evaluation form completed. Patients randomised into the control 
group were given the opportunity to use NMES for four-weeks following 
the formal study period as a method to optimise recruitment and 
retention (Figure 7.1). 
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Time point 
 
NMES group 
 
 
Control group 
 
Initially 
 
Home visit to consent and 
UHFHLYH$FWLY3DO 
 
Home visit to consent and 
UHFHLYH$FWLY3DO 
 
Baseline week :HDU$FWLY3DOIRUZHHN 
Monday to Monday. 
:HDU$FWLY3DOIRUZHHN 
Monday to Monday 
 
 First evaluation visit: 
 Questionnaires about 
health, medication and 
quality of life 
 height, weight, spirometry 
 first ISWT 
 30 minutes rest 
 second ISWT 
 
Second evaluation visit: 
 ESWT  
 30 minutes rest  
 Cybex dynamometry  
 
Receive stimulator and 
training protocol 
 
First evaluation visit: 
 Questionnaires about 
health, medication and 
quality of life 
 height, weight, spirometry 
 first ISWT 
 30 minutes rest 
 second ISWT 
 
Second evaluation visit: 
 ESWT 
 30 minutes rest  
 Cybex dynamometry 
 
Control period 
End of week 1 Home visit  
End of week 2 Home visit  
End of week 3 Home visit to receive 
$FWLY3DO 
 
:HDU$FWLY3DOIRUZHHN 
Monday to Monday. 
Home visit to receive 
$FWLY3DO 
 
:HDU$FWLY3DOIRUZHHN 
Monday to Monday. 
 
End of week 4 Third evaluation visit: 
 Questionnaires about 
health, medication and 
quality of life 
 height, weight, spirometry 
 ESWT 
 30 minutes rest 
 Cybex dynamometry 
 
End of study 
Third evaluation visit: 
 Questionnaires about 
health, medication and 
quality of life 
 height, weight, spirometry 
 ESWT 
 30 minutes rest 
 Cybex dynamometry 
 
Receive stimulator and 
training protocol 
 
 
Figure 7.1 Study overview 
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7.2.5 Statistical analysis 
Normally distributed data were expressed as mean ± standard 
deviation. Age, body mass index, spirometric values and baseline 
values and changes in quadriceps muscle strength, exercise 
endurance, free-living physical activity and health-related quality of life 
ZHUHFRPSDUHGEHWZHHQWKHFRQWURODQG10(6JURXSVXVLQJ6WXGHQW¶V
t-test. Change between groups was compared by mean differences and 
their 95% confidence intervals. The use of change rather than absolute 
values was preferred in light of the exploratory nature of this study, the 
small sample size, which was only sufficient to detect differences of 2 
standard deviations between groups, and the large degree of natural 
variability in many of the chosen outcomes. Calculations were 
performed using Statistical Package for the Social Sciences (SPSS) 
version 15.0. A p value of <0.05 was regarded as statistically 
significant. 
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7.3 Results 
7.3.1 Participants 
Of 53 patients approached over a two-year period commencing in 
January 2006, 16 completed the study (Figure 7.1; Table 7.1). All 
patients were able to complete all assessments. In the NMES group, 
due to equipment failure, quadriceps muscle strength and free-living 
physical activity data was lost in one patient each. Three patients, (two 
in the control group), reached the maximum duration (20 minute) of the 
ESWT at baseline; only one in the control group achieved this 
subsequently. There were no significant differences in age, body mass 
index or spirometry, nor baseline values of quadriceps muscle strength, 
exercise endurance and free-living physical activity between the control 
and NMES groups (Table 7.1). To date, thirteen patients have died with 
a median (range) survival of 40 (10 67) weeks. 
 
 
 
 
 
 
 
 
 
 
 
 177 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2 Study flow diagram. 
 
 
 
 
 
 
 
 
 
Eligible patients: 
53 
Declined 35: 
  refused information sheet,12 
  too much commitment, 7 
  not interested, 4 
  felt active enough, 4 
  not prepared to travel, 3 
  other reason, 5 
 
Completed :8 
Control group: 
8 
Stimulation 
group: 8 
Completed :8 
Withdrawals 2: 
  concurrent illness, 1 
  failed screening, 1 
 
Enrolled: 
18 
Randomised: 
16 
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Table 7.1 Patient details at baseline. Mean (SD) unless otherwise stated. 
 Control (n=8) NMES (n=8)  p value 
Sex (m / f) 5 / 3 4 / 4 - 
Age (years) 64 (5) 56 (9) 0.65 
ECOG performance status (0 / 1) 2 / 6 2 / 6 - 
Body mass index (kg/m2) 26.2 (1.2) 27.2 (2.8) 0.39 
Diagnosis 
adenocarcinoma 
squamous 
large cell 
undifferentiated 
 
3 
2 
1 
2 
 
5 
3 
0 
0 
 
- 
Stage (III / IV) 2 / 6 3 / 5 - 
Treatment history 
surgery 
chemotherapy 
radiation therapy 
 
1 
8 
3 
 
2 
8 
3 
 
- 
Medication 
non-opioid analgesic 
weak opioid analgesic 
inhaled bronchodilator 
inhaled corticosteroid 
oral bronchodilator 
hormone therapy 
ȕ±blocker 
other 
 
4 
4 
8 
1 
1 
1 
0 
8 
 
0 
1 
2 
1 
0 
2 
1 
5 
 
- 
 
Spirometry 
FEV1 (L) 
FVC (L) 
FEV1/FVC (%) 
 
1.64 (0.78) 
2.56 (0.63) 
59 (21) 
 
1.71 (0.69) 
2.63 (1.01) 
66 (11) 
 
0.87 
0.87 
0.72 
Quadriceps muscle strength (Nm) 57 (23) 46 (22) 0.34 
Distance walked on ESWT (m) 845 (517) 660 (550) 0.50 
Mean daily step count 5554 (4581) 5061 (1516) 0.78 
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7.3.2 Use of NMES 
Patients reported undertaking NMES for a median (range) of 80% (69±
100) of the overall recommended treatment time, often whilst carrying 
out activities such as watching television, or completing a crossword. 
The main reason for missing a treatment session was another activity 
taking priority. No serious adverse events were reported. Three patients 
reported minor muscle discomfort following the first day of use, lasting 
about one hour. One patient each commented that the treatment 
sessions sometimes felt long or restricted other activities. At the end of 
the study, all patients provided positive comments about the ease of 
use of the device, and three about its impact; "The stairs are easier 
now", "I am better at standing up after sitting around" and "My legs feel 
more solid when I am walking". All were prepared to use NMES again. 
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7.3.3 Physical performance 
Quadriceps muscle strength and free-living physical activity levels 
improved by a mean of 7.4 Nm (22%) and 136 steps (11%) respectively 
in the NMES group whilst exercise endurance deteriorated by a mean 
of 20m (4%). This compared to essentially no change -2.0 Nm (0%), or 
a mean deterioration of 633 steps (3%) or 159m (12%) in quadriceps 
muscle strength, free-living physical activity levels and exercise 
endurance respectively in the control group (Table 7.2). The mean 
difference in outcomes between the two groups varied from 8 to 21% in 
favour of the NMES group; however the degree of difference was not 
statistically significant (Table 7.2). On an individual patient basis, for 
each of the outcome measures, consistently more patients improved in 
the NMES group than the control group (Figure 7.2). 
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Table 7.2. Mean (SD) absolute and percentage change in outcome measures. 
 Baseline 
Post-
intervention 
Change 
Difference in change 
[95% CI]  p value 
Quadriceps muscle strength 
    absolute (Nm) 
        control group 
        NMES group 
    percentage (%)     
        control group 
        NMES group 
 
 
56.9 (22.9) 
45.8 (22.2) 
 
100 
100 
 
 
54.9 (18.9) 
55.1 (24.9) 
 
101 (26) 
122 (31) 
 
 
-2.0 (9.0) 
7.4 (10.3) 
 
0 (26) 
22 (31 
 
 
 
9.4 [-1.3, 20.7] 
 
 
21 [-10, 53] 
 
 
 
0.08 
 
 
0.17 
Distance walked on ESWT 
    absolute (m) 
        control group 
        NMES group 
    percentage (%) 
        control group 
        NMES group 
 
 
845 (517) 
660 (550) 
 
100 
100 
 
 
687 (499) 
640 (569) 
 
88 (31) 
96 (51) 
 
 
-159 (222) 
-20 (254) 
 
-12 (31)  
-4 (51) 
 
 
 
138 [-118, 394] 
 
 
8 [-37, 54] 
 
 
 
0.27 
 
 
0.70 
Mean step count per day 
    absolute (steps) 
        control group 
        NMES group 
    percentage (%) 
        control group 
        NMES group 
 
 
5554 (4581) 
5016 (1515) 
 
100 
100 
 
 
4922 (3512) 
5301 (2077) 
 
97 (26) 
111 (52) 
 
 
-633 (1335) 
136 (2660) 
 
-3 (26) 
11 (52) 
 
 
 
768 [-1530, 3066] 
 
 
15 [-35, 65] 
 
 
 
0.48 
 
 
0.49 
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Figure 7.3 Number of patients improving or deteriorating in outcome. 
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7.3.4 Health-related quality of life 
Health-related quality of life deteriorated by a small and similar degree 
in both groups. Scores for global quality of life, physical functioning and 
lung cancer symptoms changed by 1, 4 and 3 points respectively in the 
NMES group compared to 0, 3 and 4 points in the control group. The 
mean difference between the two groups did not exceed one point and 
was not statistically significant for any of the outcomes (Table 7.3) 
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Table 7.3 Mean (SD) change in health-related quality of life scores. 
 
Baseline Post-intervention Change 
Difference between 
groups [95% CI] 
p  value 
Symptoms sub-scale 
control group 
NMES group 
 
15 (8)  
16 (5) 
 
18 (8) 
19 (7) 
 
3 (4)  
4 (9) 
 
 
0 [-8,3] 
 
 
0.94 
Physical functioning subscale 
control group 
NMES group 
 
77 (13)  
82 (9)  
 
 
72 (22) 
79 (14) 
 
-4 (12) 
-3 (12) 
 
 
-1 [-14,11] 
 
 
0.85 
Global Quality of Life 
control group 
NMES group 
 
 
56 (13)  
59 (24) 
 
 
55 (17) 
59 (17) 
 
-1 (12) 
0 (13) 
 
 
0 [-13,6] 
 
 
 
0.95 
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7.4 Discussion 
The findings from this pilot study suggest that NMES is acceptable and 
tolerable to patients with NSCLC. Adherence over a longer period will 
need to be formally evaluated, and it may help to halve the overall 
treatment duration by stimulating both thighs simultaneously but on 
average patients reported undertaking NMES on five days of each 
week. Patients receiving NMES fared better than the control group with 
improvements in quadriceps muscle strength and free-living physical 
activity and less of a decline in exercise endurance. However, there 
were no significant differences between the NMES and control groups, 
health±related quality of life appeared relatively unchanged, and 
efficacy requires further exploration in adequately powered studies. 
 
The use of therapeutic exercise to improve physical function and 
quality of life in patients with cancer has mostly involved those receiving 
curative treatment with limited experience in patients with incurable 
cancer (Conn et al, 2006; Maddocks et al, 2009). Nonetheless, 
programmes based on traditional types of exercise often experience 
difficulties with recruitment and retention due, in part, to their impractical 
nature (Maddocks et al, 2009). This was particularly apparent in a 
recent study by Temel et al (2009), in which patients with non-small cell 
lung cancer were offered an eight week mixed aerobic and resistance 
training programme based in a hospital setting. Of 25 patients who 
consented to the study and started the programme, only eleven 
completed it and achieved only a low level of attendance (Temel et al, 
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2009). The authors suggested that programmes should be offered in 
the home as a means to improve practicality providing rationale to 
explore more novel therapies. We first explored NMES by including it as 
one of six different types of exercise when determining the preferences 
of two-hundred patients with incurable cancer, mostly receiving 
chemotherapy (chapter 7; Maddocks et al, in press). When provided 
with videos of each type of exercise and full details of a programme 
likely to provide benefit, NMES was the most preferred type of exercise, 
mainly because of its perceived practicality and convenience (chapter 
7; Maddocks et al, in press). Our completion and adherence rates 
(100% and 80% respectively) support this notion. 
 
 NMES has been used therapeutically for at least 20 years, 
mainly as an adjunct in the rehabilitation of patients with neurological 
conditions involving upper-motor neurone lesions, e.g. post-stroke, 
spinal cord injury (Sheffler and Chae, 2007). More recently, the use of 
NMES has been examined in patients with COPD (e.g. Bourjelly-Habr 
et al, 2002; Neder et al, 2002; Dal Corso et al, 2007) or chronic heart 
failure (e.g. Quittan et al, 2001; Nuhr et al, 2004; 'REãiNHWDOD
Details on these studies have been described previously in chapter 
three. After several weeks of use, evidence suggests that NMES results 
in similar beneficial changes in muscle as with other types of exercise, 
such as improved oxidative capacity resulting from changes in fibre 
type and levels of oxidative enzymes (Nuhr et al, 2004; Dal Corso et al, 
2007; Sillen et al, 2008). Improvements in muscle function and ability to 
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exercise are also comparable to those found from other types of 
exercise. A recent meta-analysis of data in patients with COPD 
demonstrated moderate improvements in muscle function and exercise 
performance from NMES programmes with mean [95%CI] 
improvements in peak torque and 6MWT distance of  9.7 [1.2í18.1]Nm 
DQG>í86]m respectively (Roig and Reid, 2009). Similarly, in 
patients with chronic heart failure, a median [IQR] improvement in 
muscle function following NMES programmes of >í@has been 
found and, where measured, maximal and sub-maximal exercise 
capacity has improved E\>í@. In patients with cancer, the 
literature appears limited to a single case report of the beneficial effect 
of NMES in a patient with lung cancer and brain metastases (Crevanna 
et al, 2006). 
 
The mean improvement in quadriceps muscle strength in the 
NMES group was 22%, in-keeping with WKHígains reported by 
others (chapter 3). This is likely to be within the limits of measurement 
accuracy of the assessment protocol (Wilcock et al, 2008a) and is 
suggestive of a clinically meaningful change, although this would need 
to be validated against external criteria and by patient report. With 
similar magnitudes of change in quadriceps muscle strength, others 
have also reported improvements in exercise capacity/endurance 
assessed by various means, e.g. 6-minute walk test (Dal Corso et al, 
2007; Neder et al, 2002; Bourjelly-Habr et al, 2002). By comparison, 
exercise endurance assessed by the ESWT deteriorated in the NMES 
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group. There are several possible explanations for this discrepancy, 
including differences in the patient groups and stimulation programme. 
All of our patients had advanced incurable disease and some were 
rapidly progressing whilst other studies were in patients with chronic 
disease which was more stable in nature. Outcomes were evaluated 
after 4 weeks of NMES compared to 6±10 weeks in other studies and 
perhaps this was too short for changes in exercise endurance to 
appear. Furthermore, we only stimulated the quadriceps whilst others 
have concurrently stimulated additional muscle groups such as the 
glutei (Zanotti et al, 2003), hamstrings (Quittan et al, 2001; Bourjelly-
Habr et al, 2002) and calves (Harris et al, 2003; Nuhr et al, 2003). The 
quadriceps are usually targeted as they represent a large proportion of 
lower limb muscle mass and are important in many activities of daily 
living, e.g. sit-to-stand, ambulation. Targeting additional muscle groups 
may provide further benefit. However, this needs to be balanced 
against the increased demand on the patient with added stimulator 
channels and more electrodes to position, some of which may require 
external assistance and compromise the overall experience. Finally, we 
used the ESWT which may have created a potential mis-match 
between two of the outcome measures used. The high frequency 
(50Hz) of stimulation we used may favour improvements in muscle 
strength by producing a training effect biased towards type II muscle 
fibres (Baker et al, 2000; Vivodtzev et al, 2008). Although this will 
improve the contractile property of the muscle, as measured with the 
maximal strength test, it will only marginally increase the oxidative 
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capacity of the muscle as these fibre types are low in mitochondrial 
density and easily fatigued (Dal Corso et al, 2007). 
 
Three of the 16 patients reached the maximum duration of the 
ESWT (20min) at baseline, suggesting that it is not an ideal 
assessment for the range of abilities found in this patient group due to a 
ceiling effect. Further, its inclusion limited the rate of recruitment, as 
many potential participants were excluded and not approached 
because of contra-indications to undertaking a maximal exercise test. 
Moreover, formal exercise tests are artificial and an assessment of a 
SDWLHQW¶VFDSDFLW\DVRSSRVHGWRZKDWWKH\DFWXDOO\GRfrom day to day. 
For this reason, physical activity level was included as a potentially 
more meaningful outcome (Dahele et al, 2007). The mean daily step 
count, as measured by the ActivPAL monitor, improved in the NMES 
group and decreased in the control group. The experience of assessing 
physical activity level was promising. Unlike the walking tests, the use 
of physical activity monitors did not exclude any patients from entering. 
Those with significant comorbidities, including ischeamic heart disease, 
could be included the free-living assessment of this aspect of physical 
function does not place any additional stress on the patient. 
Anecdotally, all patients recognised the value of measuring and 
quantifying their physical activity and feedback around their use of 
chosen monitors was generally positive. Few patients experienced 
difficulties using them for one week and data were only lost on one 
occasion. Of the outcome measures used in the study, it is suggested 
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that this is one worth developing further. In the first instance, research 
questions should be based around formally assessing acceptability in a 
larger group of patients and deterring the optimal methodology, e.g. 
duration of monitoring and treatment of missing data. 
 
In this study, NMES has been portrayed as a convenient and 
practical approach to exercise well-suited to those patients who are 
unable or unwilling to undertake more traditional types of exercise. 
However, some differences between NMES and other exercise, e.g. 
walking and stationary cycling, need to be noted. Programmes of 
NMES target a limited number of muscles whilst more traditional types 
of exercise can be used to train numerous muscle groups concurrently. 
NMES is undertaken whilst seated and has no direct training effect on 
the cardiorespiratory system whilst traditional exercises can incorporate 
aerobic and muscular training to provide added benefit. In addition, the 
use of a stimulator means the exercise being undertaken independently 
and family and friends are unable to join in and provide peer support. 
Therefore, whilst NMES may prove to be a useful clinical tool, it may 
best be offered in combination with other types of exercise or as a 
means to improve strength specifically so patients become capable of 
undertaking more active types of exercise. A better understand of how 
NMES compares to or compliments other types of exercise is required. 
 
The data from this pilot study can be used to inform sample size 
calculations in the future, for example, a controlled study would require 
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25 patients per group to reliably detect the observed difference in peak 
WRUTXHRI1PĮ ȕ 0.05). Undertaking controlled studies of 
NMES is challenging because of the difficulties of blinding a treatment 
which produces a visible contraction of the muscle. We considered a no 
treatment control group sufficient for this pilot study, however, it is 
possible that our findings reflect that those in the NMES group derived 
greater psychological benefit from undertaking the intervention and/or 
the two additional visits from the physiotherapist. This could have 
enhanced their motivation to be more active and to perform better in the 
assessments. Future studies could include the use of a placebo or 
dummy stimulator, with no or minimal output, or an active control group 
offered a stimulation programme unlikely to be of physiological benefit, 
e.g. once weekly, but having similar contact time with professionals. 
  
In conclusion, NMES appears an acceptable and tolerable 
exercise intervention and one worth pursuing in patients with lung 
cancer. If successful, it may be best offered as a proactive supportive 
care intervention soon after diagnosis, in order to preserve muscle 
mass and physical function as best as possible, rather than wait until 
the cachectic process is advanced.
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CHAPTER 8:  
PHYSICAL ACTIVITY LEVEL AS AN OUTCOME MEASURE FOR 
USE IN CANCER CACHEXIA TRIALS: A FEASIBILITY STUDY 
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8.1 Introduction 
Cachexia is common in patients with cancer of the lung and upper 
gastro-intestinal tract causing weight loss, muscle wasting, fatigue 
and mood disturbance (Gordon et al, 2005). These consequences 
can limit treatment options, quality of life and survival. There are no 
satisfactory treatments and cachexia is a major unmet need in 
supportive and palliative care (Muscaritoli et al, 2006; Steer, 2003). 
Increasing understanding of the pathophysiology of cancer 
cachexia is allowing new treatments to emerge and the previous 
three chapters have been concerned with the use of therapeutic 
exercise in this group. However, these interventions need to be 
assessed using outcome measures which are meaningful to 
patients. 
 
 The assessment of physical activity may be one such 
measure; levels of physical activity relate to psychological well-
being and quality of life (Rejeski and Mihalko, 2001; Netz and Wu, 
2005) and patients with incurable cancer generally want to maintain 
their independence for as long as is possible. Subjective 
assessments of physical activity, e.g. by questionnaire or activity 
diary, can be inaccurate and unreliable (Dahele and Fearon, 2004; 
Prince et al, 2008). An objective assessment is possible from the 
use of activity monitors such as pedometers and accelerometers. 
Pedometers use spring-lever technology and are not sufficiently 
sensitive to detect stepping at walking speeds typical of older 
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people (~1.0m/s). More sensitive accelerometers such as the 
$FWLY3$/are therefore preferred in these groups (Mathie et al, 
2004; Valanou et al, 2006). This small lightweight monitor is easily 
sited on the anterior thigh and can record several parameters of 
physical activity, e.g. sit to stand transitions, time spent upright, step 
count, over a one week period. The ActivPAL monitor has been 
used in small pilot studies and appears to be acceptable, but this 
has not been formally tested and the optimal duration of monitoring 
is unknown. Further, it is unclear if the more detailed information it 
provides has advantages over a simple step count, which can be 
measured more cheaply, and how the outcomes it produces 
compare to commonly-used functional assessment tools. 
 
The primary aim of this study was to formally assess if the 
XVHRIWKH$FWLY3$/PRQLWRUZDVDFFHSWDEOH to patients with lung 
or upper-gastrointestinal cancer, who are most likely to be offered 
interventions aimed at preventing or managing cancer cachexia. 
Secondary aims were to explore the optimal period of monitoring, 
the added value of the monitor's estimate of energy expenditure 
over a step count, and the extent to which physical activity reflects 
physician-rated performance status. 
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8.2 Methods 
8.2.1 Subjects 
Patients with lung or upper-gastrointestinal cancer and an ECOG 
performance status of 0±2 as judged by the treating physician were 
recruited from oncology clinics (Oken et al, 1982). Patients were 
excluded if they were receiving radio- or chemotherapy, had 
undergone surgery within the last four weeks or had severely 
restricted mobility, e.g. due to uncontrolled pain on movement. 
Patients gave written informed consent and the study was approved 
by Oxfordshire A Research Ethics Committee (ref. 07/Q1604/16) 
and registered with Current Controlled Trials (ISRCTN 32511542). 
 
8.2.2 Instruments 
8.2.2.1 Activity monitor 
The $FWLY3$/PRQLWRU3$/WHFKQRORJLHV/WGGlasgow, UK) was 
selected because its accuracy is well documented, it provides more 
detailed information than some other monitors, is easy to apply and 
our research group had prior experience of its use in people with 
cancer. It is a small, lightweight (20 x 30 x 5mm, 20g) uni-axial 
accelerometer that is applied to the anterior thigh using adhesive 
PALStickies and a layer of Tegaderm dressing. The 
ActivPAL records time spent sitting, standing and walking, sit-to-
stand transitions, step count and rate of stepping (cadence) over a 
one week period. Accompanying software allows each of these 
outcomes to be displayed by hour, day or week (Figure 8.1). 
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Figure 8.1 Display from the $FWLY3$/PRQLWRr software. 
 
Colour coded postural data displays which position the patient was in; 
sitting or lying / standing / walking, at any given time of monitoring 
Weekly view outlines daily:  
 step count 
 number of up /down transitions  
 time spent in each posture 
These outcomes are 
summarised for the 
entire week of monitoring 
Hourly view displays data in 
15 second time periods and 
summarises outcomes for 
each hour of activity 
Raw movement data (10Hz) 
can also be viewed as an 
excel file to detect fidgeting 
movements which may not 
be presented in the hourly 
view 
Daily view can be used 
to identify a pattern of 
activity, for example: 
 active periods  
 sedentary periods 
 waking up 
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Measurement of time spent in a given posture has been 
validated using video analysis (Grant et al, 2006) and the step 
count has been shown to be accurate across a range of walking 
speeds (0.6-2.4m/s) with measurement error of <5% (Grant et al, 
2006; Ryan et al, 2006; Maddocks et al, 2008). Despite its 
sensitivity during slow walking, thH$FWLY3$/GRHVQRWUHFRUG
erroneous steps during motor vehicle travel as can be a problem 
with other accelerometers (Gotshall et al 2003; Le Masurier & 
Tudor-Locke, 2003; Maddocks et al, 2008). The monitor also 
provides an estimate of energy expenditure in metabolic equivalent 
hours (METh), based on the time spent sitting, standing, walking 
and cadence, however, this outcome has not been validated. 
 
8.2.2.2 Patient activity diary 
Patients were asked to complete a paper diary daily for one week 
recording the time they got up, went to bed, slept during daytime 
hours and any period when they did not wear the activity monitor, 
providing a reason where possible. They were asked to note any 
problems experienced with the monitor, e.g. skin irritation, 
discomfort, and, at the end of the week, to indicate if they found 
wearing the monitor acceptable and if they would be prepared to 
repeat the experience (Appendix 1.9). 
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8.2.3 Protocol 
Patients were pURYLGHGZLWKDQ$FWLY3$/PRQLWRU during a 
hospital or home visit on a Monday and taught how to apply, 
remove and reapply it. The monitor was positioned on the mid-third 
of the anterior thigh of their dominant leg. A helpline number was 
provided in case of a technical problem, e.g. low battery warning. 
Patients were instructed to wear the monitor at all times, except 
when submersed in water, e.g. bathing, showering, and swimming, 
and to complete the activity diary as above. The monitor and diary 
were retrieved at a second visit one week later. Data were uploaded 
to a comSXWHUXVLQJ$FWLY3$/3URIHVVLRQDOVRIWZDUHYHUVLRQ
5.8.2.2) and data from each Monday were omitted, leaving six full 
days of data, Tuesday (day 1) to Sunday (day 6), to be analysed. 
To assess compliance, each hour of data was visually inspected 
(up to10Hz) for signs of movement. If no movement was found, the 
hour was registered as non-compliant unless it corresponded to a 
period of sleep in the diary. 
 
 Acceptability, the primary endpointZDVGHILQHGDVRI
SDWLHQWVZHDULQJWKHPRQLWRUIRURIWKe time based on a 
consensus view of the Cachexia subgroup of the National Cancer 
Research Institute Palliative Care Clinical Studies Group. No 
specific sample size is necessary for the proposed method of 
analysis, but the intention was to recruit 60 patients based on the 
likely accrual given the duration of the study. 
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8.2.4 Statistical analysis 
Normally distributed continuous data and other forms of data were 
expressed as mean (SD) or median [IQR] respectively. 
Acceptability: The total period of non-compliance in hours was 
expressed as a percentage of the 6 day period of monitoring. The 
proportion of patients ZHDULQJWKHGHYLFH% of the time was 
calculated with 95% confidence intervals using Wilson's method 
(Wilson, 1927). Content analysis of the diary determined factors 
contributing to non-compliance. 
 
Optimal duration of monitoring: To examine for the effect of 
duration of measurement, the changes in step count and estimated 
energy expenditure between each two consecutive days, e.g. day 
1±2, 2±3, were calculated. Difference in daily step count and daily 
estimated energy expenditure obtained over 2 or 4 and 6 days of 
monitoring were compared using a Wilcoxon signed rank test and 
Students t-test respectively. 
 
Relationship between overall energy expenditure and step 
count: The monitor provides an estimate of energy expenditure 
(METh) based on the time spent sitting, standing, walking and 
cadence. If a close relationship exists between the estimated 
energy expenditure and the step count, i.e. step count is the 
primary determinant of the estimate, the energy expenditure may 
add little additional information over this outcome. Because step 
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count is a component of the estimated energy expenditure, a direct 
comparison was not possible. Thus, daily overall energy 
expenditure was separated into expenditure due to stepping and 
non-stepping activity, i.e. sitting and standing. Non-stepping energy 
expenditure was correlated with daily step count XVLQJD3HDUVRQ¶V
correlation coefficient and the square of the correlation was used to 
estimate the proportion of the variance in the non-stepping energy 
expenditure which could be explained by stepping energy 
expenditure. To allow comparison with stepping energy 
expenditure, daily step count was multiplied by the mean energy 
per step for the entire sample to provide an arbitrary but 
comparable value, and agreement was examined using Bland and 
Altman's approach (Bland and Altman, 1999). 
 
Physical activity according to performance status: Mean daily 
number of sit-to-stand transitions, time spent upright (standing or 
stepping), step count and estimated energy expenditure across the 
6 days of monitoring were compared between groups according to 
ECOG performance status using a one-way ANOVA and post-hoc 
comparisons with a Bonferroni correction. 
 
All calculations were performed using Statistical Package for 
the Social Sciences (SPSS) version 14.0 and a p value of <0.05 
was regarded as statistically significant. 
 
 201 
 
8.3 Results 
8.3.1 Participants 
Of 78 patients approached over a one-year period commencing in 
July 2007, 62 were enrolled into the study. Two patients withdrew, 
one as a result of a fractured femur following a fall and another due 
to monitor failure leading to loss of data (Figure 8.2). Of the 60 
participants, most had lung cancer, around a third had concurrent 
co-morbidities and a wide range of physical activity levels were 
represented within the group (Table 8.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.2 Study flow diagram. 
 
Eligible patients: 
78 
Declined 16: 
  not interested, 8 
  refused information sheet, 3 
  not well enough, 2 
  other reason, 2  
  lost to follow-up, 1  
 
 
Analysed: 
60 
Enrolled: 
62 
Withdrawals 2: 
  fall, fractured femur, 1 
  monitor failure, 1 
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Table 8.1 Patient details. Mean (SD) unless otherwise stated. 
Sex (m / f) 40 / 20 
Age (years) 68 (9) 
Diagnosis and histology 
  lung / upper-gastrointestinal cancer 
squamous 
adenocarcinoma 
small cell 
undifferentiated  
mesothelioma 
 
58 / 2 
25 
16 
9 
5 
5 
Disease extent 
local / advanced 
 
35 / 25 
Metastases 
bone  
lung 
liver 
pancreas 
adrenal 
brain 
breast 
 
11 
10 
4 
2 
2 
2 
1 
Co-morbidities 
Ischemic heart disease  
COPD 
Arthritis 
Diabetes 
Other 
 
15 
9 
7 
4 
3 
Medications 
ȕ-blockers 
ACE inhibitors 
strong opiods 
NSAIDS 
weak opiods  
corticosteroids 
 
13 
11 
9 
9 
6 
3 
ECOG Performance status 
  0  
  1  
  2 
Daily physical activity 
  up/down transitions 
  time spent upright (h.min) 
  step count 
  estimated energy expenditure (METh) 
      stepping activity 
      non-stepping activity 
 
8 
34 
18 
 
45 (16) 
4.20 (2.10) 
4244 (2939) 
32.1 (1.3) 
29.2 (0.7) 
2.9 (1.9) 
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8.3.2 Acceptability 
Fifty-nine of the 60 patients (98ZRUHWKHPRQLWRU0% of the 
time, giving a 95% confidence interval for the proportion of patients 
wearing the device the minimum required time in a large population 
of 91±7KXVWKH$FWLY3$/PRQLWRUIXOILOOHGWKHGHILQLWLRQRI
acceptability. The mean level of non-compliance was 2% of the total 
duration of monitoring, equating to 55 minutes per day. 
 
 All patients indicated that they found the device acceptable, 
with 55 (92%) prepared to repeat the experience. Nine patients 
reported minor skin irritation which settled on removal of the self-
adhesive dressing. Other problems, reported by one patient each, 
were the monitor being an annoyance in bed, or when leaning on 
their thigh to stand from sitting, and the monitor falling off and 
having to be re-applied. 
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8.3.3 Optimal duration of monitoring  
Between-day variation in median [IQR] step count was high 
throughout the six days of monitoring ranging from 24% [15±45] to 
35% [15±63]. Change in mean (SD) estimated energy expenditure 
was proportionally less and more consistent at 2 (2)% (Table 8.2). 
 
Table 8.2. Percentage change in daily step count and energy expenditure. 
 Day Step count 
Energy expenditure 
 (METh) 
 
median IQR. mean SD 
1 to 2 24.2 14.7 ± 45.3 1.8 1.5 
2 to 3 35.2 14.5 ± 63.3 2.2 2.1 
3 to 4 29.5 15.7 ± 47.4 2.0 2.1 
4 to 5 31.5 16.2 ± 48.0 1.8 1.5 
5 to 6 34.2 17.0 ± 63.0 2.0 1.8 
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Median [IQR] daily step counts obtained over 2 (3669 [2226±6131]) 
and 4 (3563 [2216±6165]) days of monitoring were significantly 
different to that obtained over 6 days (3317 [2164±5676]), p=0.01 
and <0.01 respectively (Table 7.3). Mean (SD) daily energy 
expenditure measured over 2 days (32.3 (1.6) METh) and 4 (32.2 
(1.3) days were significantly different to that obtained over 6 days 
(32.1 (1.3) METh), p<0.01 and p=0.01 respectively (Table 8.3). 
 
Table 8.3. Change in average daily values according to duration of 
monitoring. 
Day 
Median [IQR] 
step count 
Mean (SD) 
energy expenditure 
(METh) 
Daily Over 2,4 
and 6 days Daily 
Over 2,4 
and 6 days 
1 / Tue 3536 [2314±6130]  32.3 (1.7)  
2 / Wed 3702 [2062±6336] 3669 [2226±6131] 32.3 (1.5) 32.3 (1.6) 
3 / Thu 3490 [1934±6762]  32.4 (1.6)  
4 / Fri 3252 [1826±6236] 3563 [2216±6165] 32.1 (1.4) 32.2 (1.3) 
5 / Sat 3334 [1630±5594]  32.1 (1.5)  
6 / Sun 2770 [1652±4402] 3317 [2164±5676] 31.8 (1.2) 32.1 (1.3) 
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Mean of stepping energy expenditure and step count (METh)  
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8.3.4 Relationship between energy expenditure and step count 
The mean (SD) overall daily energy expenditure was 32.1 (1.3) 
METh, with non-stepping activity (29.2 (0.7) METh) and stepping 
activity (2.9 (1.9) METh) accounting for 91 (5) and 9 (5)% of overall 
energy expenditure respectively. The correlation between non-
stepping energy expenditure and daily step count was negative and 
strong (r=í0.91, p<0.01), thus 85% of the variance in the non-
stepping energy expenditure could be explained by the stepping 
component. The Bland and Altman plot revealed a mean (2SD) 
difference of 0.02 (0.42) METh between the step count (expressed 
in METh units) and stepping energy expenditure (Figure 8.3). 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 8.3. Bland and Altman plot of the mean and difference between 
daily stepping energy expenditure and step count expressed in METh. 
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8.3.5 Physical activity according to performance status  
With the exception of up-down transitions, each component of 
mean daily physical activity measured by the monitor declined as 
performance status worsened (Table 8.4). The differences for time 
spent upright, step count and estimated energy expenditure were 
statistically significant (p<0.01 to 0.03) and the decline in mean 
daily step count was particularly apparent (Figure 8.4). 
 
 
 
 
 
 
 
 
 
 
 
                                                    ECOG performance status 
 
Figure 8.4 Mean daily step count according to ECOG performance status. 
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Table 8.4 Mean (SD) daily physical activity according to ECOG performance status. 
 
Performance 
status 0 
Mean difference 
[95% CI] 
Performance 
status 1 
Mean difference  
[95% CI] 
Performance 
status 2 
Up-down transitions 46 (7) 1 [11, -13] 47 (16) -7 [-17, 2] 40 (19) 
Time spent upright (h) 7.5 (1.8)* -3.2 [-4.6, 1.8] 4.3 (1.7)* -1.3 [-2.3, 0.3] 3.0 (1.5)* 
Step count 8880 (3104)* -4796 [-6705, 2886] 4084 (2228)* -1703 [-2914, 492] 2382 (1540)* 
Energy expenditure (METh) 34.2 (1.4)* -2.1 [-3.0, 1.2] 32.1 (1.0)* -0.8 [-1.4, 0.3] 31.3 (0.8)* 
 
* significantly different to others (p<0.05) 
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8.4 Discussion 
This is the first study to formally assess the acceptability of the use of 
WKH$FWLY3$/SK\VLFDODFWLYLW\PRQLWRURYHUDRQHZHHNSHULRGLQ
patients with cancer. Compliance in the group was high, exceeding the 
set standard, and the majority of patients were prepared to repeat the 
experience suggesting it is feasible to use the monitors in future 
studies. There is no gold standard for assessing compliance, and it is 
generally based on patient self-report of achieving an arbitrarily set 
standard (Ward et al, 2005; Paul et al, 2008). The inclusion of analysis 
of movement data will have increased the accuracy of the assessment 
and the standard we for a minimum level of compliance was relatively 
high, with others suggesting minimum compliance of 60% (Ward et al, 
2005). 
 
 3DWLHQWV¶SK\VLFDODFWLYLW\OHYHOVZHUHORZHUWKDQWKRVHUHSRUWHG
in healthy volunteers and other patient groups (Tudor-Locke et al, 
2009). Most took <5000 steps a day and spent two-thirds or more of 
their waking time either sitting or lying underscoring physical activity as 
a key therapeutic target for this patient group. There is a lack of directly 
comparable data but this level of activity is similar to that seen in 
patients with upper-gastrointestinal cancer receiving palliative 
chemotherapy (Dahele et al, 2007). Levels of physical activity will 
naturally vary from day to day, and can be influenced by factors such as 
the day (weekends generally lower) and in response to being monitored 
(generally an initial increase). They will also be affected by fluctuations 
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in external factors, such as the weather or social events, and the 
SDWLHQW¶VPRRG7KHUHIRUHWKHORQJHUWKHSHULRGRIPRQLWRULQJWKHPRUH
accurate an assessment is likely to be, but this has to be balanced 
against the practicality of wearing a monitor for an extended period of 
time. We considered one week a pragmatic period to examine and 
standardised the start day so that the six complete days of monitoring 
consisted of four weekdays followed by two weekend days. Both daily 
step count and estimated energy expenditure reduced over the period 
of monitoring, which could relate to a monitoring effect or a habitual 
reduction in activity on a weekend. Based on the variability seen in step 
count, we do not recommend less than six full days of monitoring, which 
is in general agreement with the recommendations for monitoring 
activity in other patient groups (Ward et al, 2005; Paul et al, 2008). This 
limits the strength of findings from previous cancer cachexia studies, 
which have only monitored physical activity for a few days or less 
(Fouladiun et al, 2007). 
 
 Components of physical activity PHDVXUHGE\WKH$FWLY3$/
were compared across patients according to their performance status 
as determined by their oncologist. Although the inter-rater reliability of 
the ECOG performance scale is only modest (Sorensen et al, 1993), it 
is a widely used in clinical tool and this comparison allowed insight into 
how physical activity patterns may change as global physical function 
deteriorates. In our participants as performance status worsened, the 
number of up-down transitions, time spent upright and amount of 
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energy expended declined. Conversely, the number or bouts of physical 
activity, indicated by up-down transitions, remained relatively 
unchanged suggesting that function becomes limited by the capacity to 
work for prolonged periods of time rather than the ability to stand. This 
is in agreement with Dahele et al (2007), who observed a tendency for 
patients with upper-gastrointestinal cancer and a poor performance 
status to spend less time upright as more active patients despite 
standing a similar number of times. There was wide variation in physical 
activity within each performance score and overlap between adjacent 
scores. Therefore, although the discriminate ability of the ECOG 
performance scale is supported, physical activity level measured with 
the ActivPAL should be more sensitive to change. Thus, this may be 
a useful method to help detect small but important effects of 
interventions that may not amount to a change in performance score.  
 
The assessment of physical activity levels as an outcome 
measure for cachexia studies is attractive, offering a patient-centred 
outcome concerned with functional status and independence. The 
responsiveness of this outcome requires further exploration, but 
physical activity declines as cachexia progresses (Fouladiun et al, 
2007) and improvements have been seen following a pilot intervention 
study of neuromuscular electrical stimulation of proximal leg muscles in 
patients with lung cancer (Chapter 7; Maddocks et al, 2009). On the 
other hand, the not insignificant cost of monitors, time to process 
physical activity data and potential for missing data all need to be borne 
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in mind. In this study patients with a reasonable performance status 
were selected as this reflects the population we aim to target with 
proactive supportive therapies designed to maintain function. Future 
studies may examine the relationship between physical activity and 
quality of life in patients with a wider range of performance status and to 
determine what level of physical activity is generally required to allow 
patients to remain independent at home in different social 
circumstances, e.g. living alone or with a carer, in a house or a flat, etc. 
The relationship between physical activity levels and commonly used 
performance scales, e.g. ECOG, Karnofsky, could also be explored.  
 
The estimate of energy expenditure provided by the monitor has 
not been validated and should be treated with appropriate caution. 
Comparison with the current gold standard measure of energy 
expenditure, i.e. doubly labelled water, is required. We found that step 
count was strongly related to both stepping and non-stepping energy 
expenditure suggesting that these estimates added little additional 
LQIRUPDWLRQDERXWDSDWLHQW¶VSK\VLFDODFWLYLW\ level. This raises the 
possibility that a step count could be a reasonable proxy for energy 
expenditure, and as such, could be obtained using a cheaper 
accelerometer or pedometer. Nonetheless, this would have to be 
balanced against the loss of the other supplementary information the 
ActivPALPRQLWRUSURYLGHVHJXSGRZQWUDQVLWLRQVWLPHVSHQW
XSULJKW)XUWKHULQDUHFHQWFRPSDULVRQRIWKH$FWLY3$/PRQLWRU3$/
7HFKQRORJLHV8.DFKHDSHU3$/OLWHDFFHOHURPHWHU3$/
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Technologies, UK, £200) and a high-HQG6:í<DPD['LJL-
:DONHUpedometer (New lifestyles Inc, Missouri, USA, £30), we found 
the pedometer to become progressively less accurate as walking 
speeds slowed to those typical of older patients, and all but the 
$FWLY3$/UHFRUGHGHUURQHRXVVWHSVGXULQJPRWRUYHKLFOHWUDYHO
(Maddocks et al, 2008). 
 
 In conclusLRQWKH$FWLY3$/PRQLWRUworn for one week is an 
acceptable method of providing an assessment of free-living physical 
activity in patients with cancer. A mean daily step count obtained over 6 
days appears to be an appropriate outcome to use in future studies. 
Although it is of particular relevance to assessing the impact of a 
cachexia intervention, this outcome has the potential to be a useful 
outcome across the whole spectrum of health research.
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CHAPTER 9.  
GENERAL CONCLUSIONS AND SUGGESTIONS 
 FOR FUTURE WORK 
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9.1 Introduction 
This chapter revisits the original aims and objectives and reflects on the 
work in this thesis. The background chapters and four original studies 
are retraced and the main strengths and limitations are outlined before 
general conclusions are drawn. Suggestions for further work and 
potential clinical implications of the findings are then outlined before 
closing remarks are made. 
 
9.2 Aims and objectives revisited 
The overall aim of this thesis was to examine the role of therapeutic 
exercise in patients with or at risk of cancer cachexia to help maintain 
physical function and independence for as long as possible.  
 
Objectives set out in the first chapter were to: 
 review the use of exercise in patients with cancer to determine if it 
is an acceptable and practical therapy 
 identify and pilot the most acceptable type(s) of exercise in patients 
with incurable cancer most risk of cachexia 
 identify and examine outcome measures suitable for use in studies 
aimed at maintaining physical function in this group. 
 
 The first objective was achieved by reviewing the use of exercise 
in patients with curable or incurable cancer (chapter 3), rates of uptake, 
adherence and completion to exercise programmes and common 
reasons for patients declining or withdrawing from an exercise study 
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(chapter 5). These components of the thesis considered the prior use of 
therapeutic exercise to help identify how exercise could be optimally 
used in those with or at risk of cancer cachexia. Although the evidence 
base suggested exercise to be of benefit, multiple barriers to exercise 
were identified and issues with acceptability and practicality were 
uncovered. Highlighting challenges of using exercise as a therapy 
prompted the exploration of alternative approaches, e.g. NMES. 
 
 The second objective was achieved through chapters 2, 6 and 7 
in which NMES was identified as a potential therapy, found to be 
popular among patients and piloted in those with incurable lung cancer. 
Asking patients for their preferences was a useful way to identify types 
of exercise that were in-keeping with their interests and needs. Their 
answers supported our assumption that novel therapies such as NMES 
may be preferred over more traditional types of exercise because of 
their practicality and convenience.  In the pilot study we selected 
patients with lung cancer at high risk of cachexia and potentially able to 
gain the most from therapeutic exercise. Although this was a difficult 
group to examine, all patients completed the study and allowed the 
research aims to be met. 
 
 The third aim was achieved by the undertaking of a background 
review into the assessment of physical function (chapter 4) and 
preliminary and more focused examinations of an activity monitor in 
chapters seven and eight respectively. Among other outcomes used to 
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assess aspects of physical function, physical activity level was identified 
as having high face validity and reflecting patients¶GHVLUHWRUHPDLQ
active and independent. The use of lightweight monitors to objectively 
assess physical activity level was considered and one, the ActivPAL
was chosen for use in the NMES study (chapter 7). On the basis of our 
experience with the monitor and patient feedback, we highlighted its 
potential role in future studies and formally examined its acceptability in 
chapter 8. 
 
9.3 Main strengths and limitations 
A number of strengths and some important limitations to this thesis 
should be considered. 
 
9.3.1 Strengths 
Despite exercise having been studied in patients with cancer for over 
twenty years, this has been the first time that more novel approaches, 
e.g. NMES and whole-body vibration, have been considered in this 
group. These may help improve the acceptability and practicality of 
therapeutic exercise by overcoming many of the issues with 
impracticality demonstrated in chapter 5. 
 
 The exercise preferences study presented in chapter 6 used an 
innovative methodology to overcome many of the pitfalls of previous 
studies, which used a reductionist approach and compartmentalised 
exercise programmes befroe asking about each separate element, e.g. 
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session length, frequency, duration etc.. The use of looping video clips 
and clear descriptions of exercise programmes likely to provide benefit 
helped better inform patients about the type of exercise in question and 
contextualised it within a real-world setting. This is likely to have 
improved patients¶comprehension and understanding of what they 
were asked, potentially leading to more valid and relevant findings. 
 
 The sample size for each study was appropriate to the research 
design and aims. For example, the aim of chapter 6 was to determine 
the acceptability of six programmes based on different types of 
exercise. Therefore, the large sample size (n=200) was based on the 
precision to which the preferences of a larger group could be estimated; 
two-sided 95% CIs would not exceed ±7%. In contrast, the pilot study in 
chapter 7 aimed to explore if NMES was a feasible and tolerable 
intervention. Therefore a smaller sample size (n=16) was used, which 
was adequate to pilot the use of NMES, but was only sufficient to detect 
differences of two standard deviations between groups. 
 
 Where possible, study aims were grounded within clinical 
practice and lead to conclusions that could immediately be utilised by 
others. For example, chapter 8 examined the use of the ActivPALWR
DQVZHUTXHVWLRQVVXFKDVµLISDWLHQWVDUHDVNHGWRZHDUWKHmonitor for 
RQHZHHNGRWKH\"¶DQGµKRZPDQ\GD\VPRQLWRULQJDUHUHTXLUHG"¶ By 
designing studies around meaningful research questions such as these, 
findings can immediately be utilised researchers and clinicians alike. 
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 A further strength is the undertaking of one of a limited number 
of intervention studies in chapter 7. Only a handful of research groups 
have successfully completed an exercise study in patients with 
incurable disease. Where they have, this has taken considerable time 
and effort, for example Temel et al took three years to accrue 25 
patients with advanced NSCLC to their hospital-based programme 
(Temel et al, 2009). Exploratory work to determine the most appropriate 
types of exercise to study is important, but interventions must be 
offered and examined if advances are to be made in a timely manner. 
 
9.3.2 Limitations 
The omission of more qualitative data is unfortunate. The use of patient 
interviews and focus groups would have been an equally valid means 
of examining the role of therapeutic exercise in this setting and would 
have complimented the findings of each piece of work. When exploring 
issues around acceptability, preferences and experiences in chapters 5, 
6 and 7 respectively some more open questioning would have 
enhanced the richness of the data obtained from the patient diaries and 
feedback forms. 
 
 In some of the studies, the large sample size targets meant that 
in order to recruit within the restraints of time and resource, reasonably 
broad eligibility criteria were used. On occasions this resulted in a 
degree of heterogeneity in terms of cancer diagnosis, particularly in 
chapter 6. The result was that some patients had cancers in which 
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cachexia is not particularly prevalent, e.g. breast or urological cancers, 
which reduces the external validity of findings. 
 
 More detail on the nutritional status of participants, i.e. previous 
weight loss or body mass index, would have been useful to help 
determine their degree of cachexia, malnutrition and anorexia. As many 
studies lack this information, the reader is left to make assumptions 
about whether the groups have or are at risk of cachexia based on their 
diagnosis, disease stage and treatment status. More transparency with 
regards to these parameters is required in the future. 
 
 A further limitation, which was more of a missed opportunity, 
relates to chapter 8 in which physical activity level was assessed in 
patients with incurable lung or upper-gastrointestinal cancer.  Although 
the specified research aims were achieved, this sample provided an 
excellent opportunity to examine how physical activity level related to 
other factors, e.g. quality of life, fatigue, symptomology. Information on 
these relationships could have easily been achieved with the inclusion 
of relevant self-report questionnaires, completed the patient¶V
convenience, and would have further enhanced the findings. 
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9.4 General conclusions 
Findings of individual studies have been discussed in the relevant 
chapters and should be considered in light of the main strengths and 
limitations, but can be summarised as follows: 
 
 Only half of all patients with or cured of cancer offered an exercise 
programme complete one, mainly due to a lack of interest or the 
impractical and demanding nature of the exercise offered. There is 
a need to modify existing programmes or explore more practical 
alternatives if exercise is to be acceptable and practical for the 
majority of patients. 
 When presented with a range of exercise programmes, two-thirds 
of a group of patients with incurable cancer felt capable and 
prepared to undertake at least one programme. Neuromuscular 
electrical stimulation was the most popular therapy and patients 
cited the practicality and convenience of this therapy as the main 
reason for their choice, in keeping with a clear preference for 
exercise to be undertaken at home and unsupervised. 
 Neuromuscular electrical stimulation appears to be an acceptable 
and tolerable exercise intervention for patients with non-small cell 
lung cancer. In the pilot study patients who received stimulation 
generally fared better than those in the control group, with 
improvements in quadriceps muscle strength and physical activity 
and less of a decline in exercise endurance. Further studies to 
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formally examine the longer term acceptability and efficacy of this 
therapy in patients with lung cancer are warranted. 
 The wearing of DQ$FWLY3$/PRQLWRUIRURQHZHHNLVDQ
acceptable method of assessing free-living physical activity level in 
patients with incurable upper-gastrointestinal or lung cancer.  A 
mean daily step count measured over 6 days appears to be an 
appropriate outcome to use in future studies. 
 
Collectively, this work supports the use of therapeutic exercise in 
patients with or at risk of cancer cachexia. It highlights a particular role 
for novel approaches, e.g. NMES, which may require lower levels of 
motivation and less of a change in lifestyle than traditional types of 
exercise and thus be more acceptable to patients  
 
9.5 Suggestions for further work 
As well making a unique contribution to the evidence base, this thesis 
provides rationale for further study to examine the acceptability of 
exercise, neuromuscular electrical stimulation as a novel exercise 
therapy and physical activity level as an outcome of physical function. 
 
9.5.1 Acceptability of exercise 
The systematic review and exercise preferences study helped identify a 
need to make exercise programmes more practical and convenient. 
Further work into the acceptability of therapeutic exercise could 
examine in more detail factors influencing uptake. Possible approaches 
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include the use of qualitative interviews to explore levels of motivation 
and self-efficacy at different time points, applying behavioural models to 
explore patient readiness to change, or conducting focus groups to 
determine whether modifying or tailoring exercise programmes would 
DOWHUSDWLHQWV¶preparedness to undertake them. A useful development 
of the exercise preferences study would be to provide patients with an 
opportunity to perform a typical session of the various types of exercise, 
especially given that more novel therapies, e.g. neuromuscular 
electrical stimulation, were popular choices. 
 
9.5.2 Neuromuscular electrical stimulation 
In the pilot study, neuromuscular electrical stimulation was acceptable, 
tolerable and appeared to provide benefit to some patients. NMES 
potentially has multiple applications as a supportive therapy across a 
number of patient groups, e.g. incurable upper-gastrointestinal, and 
clinical scenarios, e.g. patients prescribed corticosteroids or on bed rest 
with spinal cord compression. In patients with incurable cancer, 
success is more likely if NMES can be offered proactively soon after 
diagnosis rather than reactively once significant loss in function has 
occurred. In practice this would necessitate offering it alongside first-
line palliative chemotherapy, the standard treatment following a 
diagnosis of incurable NSCLC. This is appropriate given that 
chemotherapy can lead to deterioration in muscle strength and physical 
activity levels (Ancoli-Israel et al, 2001; Kasymjanova et al, 2007).  
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 Our group have recently secured funding for a Phase II study of 
NMES in this setting with the overall aim to formally examine if NMES is 
an acceptable supportive therapy. This will help determine the 
justification for a definitive phase III trial. We are offering a longer 
programme of NMES, timing assessments to the administration of 
chemotherapy, and including measures of muscle strength, mass and 
physical activity level. In two sub-studies, patient experiences of NMES 
will be explored with semi-structured interviews and the molecular 
events underlying the regulation of muscle mass will be examined using 
muscle biopsy techniques. 
 
9.5.3 Physical activity level 
The ILQDOVWXG\GHPRQVWUDWHGWKHIHDVLELOLW\RIXVLQJDQ$FWLY3$/
monitor to assess physical activity level in patients with cancer.  A step 
count remains a suitable outcome for use in future studies but the 
added value of additional outcomes, e.g. time spent upright, is worth 
determining. Another aim would be to determine, and if necessary 
improve, the accuracy of the PRQLWRU¶VHQHUJ\H[SHQGLWXUHHVWLPDWH
Such studies would require doubly-labelled water so would be costly, 
but by computing algorithms to adjust the overall energy estimate 
DFFRUGLQJWRDSDWLHQW¶VUHVWLQJHQHUJ\H[SHQGLWXUHWKHUHLVSRWHQWLDOWR
develop an outcome of use to all researchers interested in cachexia, 
e.g. nutritionists, pharmacologists, physiologists etc. It would also be 
useful to begin to examine the relationships between physical activity 
level, independence and quality of life with a large-scale cross-sectional 
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study. This would seek to determine the strength of any relationships 
and identify µWKUHVKROGV¶RI physical activity relating to various social 
circumstances, e.g. to remain independent at home alone or with 
spouse. This knowledge would help indentify if interventions aimed at 
maintaining physical activity have the potential to reduce or delay the 
need for additional home care or admission to hospital. 
 
9.6 Clinical implications 
The ultimate purpose of research is to improve the quality of routine 
patient care. Although this work is unlikely to bring about change in 
isolation, the findings may lead to developments in local clinical practice 
and inform others who influence teams providing care.  
 
 In the United Kingdom, an increasing number of multidisciplinary 
teams use exercise to help people diagnosed with incurable cancer 
stay as active and independent as possible for as long as possible.  A 
number of these are known to the research team and have been kept 
abreast of our findings through regular meetings, seminars and 
publications. Interest in this work has grown and some teams have 
begun to make changes to their practice in line with our 
recommendations. For example, more clinicians are measuring physical 
activity level objectively and use outcomes with their patients as 
motivational and education tools. Some teams have also introduced 
10(6WRWKHLUFOLQLFDOµWRRONLW¶and offer it to patients they feel would 
benefit from strength training but who are unable or unwilling to 
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undertake more traditional types of exercise. Evidence supporting the 
wider use is of course lacking but this initial interest is encouraging. 
 
9.7 Closing remarks 
Conducting research into exercise in the supportive and palliative care 
setting is challenging but fulfilling. Supportive care is an emerging field 
of research and initial efforts were directed towards developing strong 
links with the oncologists from whom patients would be recruited. Each 
study took considerable time to complete and during the recruitment 
process the role of exercise in light of a diagnosis of incurable cancer 
was questioned by some patients. However, those who enrolled onto a 
study engaged with the research process, developed an insight into the 
potential role of exercise and hopefully found personal reward from 
taking part. In light of the general conclusions, they also contributed to 
the generation new knowledge around therapeutic exercise, which 
should help improve care for others in the future. 
 
This work makes a small but important contribution to the field by 
informing the direction and design of future work examining therapeutic 
exercise in those with or at risk of cachexia. In the longer term, 
therapeutic exercise will likely be supplemented by nutritional support 
and immunomodulatory agents to form part of a multimodal approach to 
cancer cachexia. The continued development and careful matching of 
each component offers the best hope for patients to remain active and 
independent for as long as possible. 
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1.1 ECOG Performance Status scale 
 
Grade ECOG description 
0 Fully active, able to carry on all pre-disease 
performance without restriction 
1 Restricted in physically strenuous activity but 
ambulatory and able to carry out work of a light or 
sedentary nature, e.g., light house work, office work 
2 Ambulatory and capable of all selfcare but unable to 
carry out any work activities. Up and about more than 
50% of waking hours 
3 Capable of only limited selfcare, confined to bed or 
chair more than 50% of waking hours 
4 Completely disabled. Cannot carry on any selfcare. 
Totally confined to bed or chair 
5 Dead 
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1.2 Karnofsky Performance Status scale 
 
Grade KPS description 
100 Normal no complaints; no evidence of disease. 
90 Able to carry on normal activity; minor signs or 
symptoms of disease. 
80 Normal activity with effort; some signs or 
symptoms of disease. 
70 Cares for self; unable to carry on normal activity 
or to do active work. 
60 Requires occasional assistance, but is able to 
care for most of his personal needs. 
50 Requires considerable assistance and frequent 
medical care. 
40 Disabled; requires special care and assistance. 
30 Severely disabled; hospital admission is indicated 
although death not imminent. 
20 Very sick; hospital admission necessary; active 
supportive treatment necessary. 
10 Moribund; fatal processes progressing rapidly. 
0 Dead 
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1.3 EORTC core questionnaire 
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1.4 EORTC lung cancer module 
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1.5 Exercise preferences study patient demographics questionnaire 
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1.6 Exercise preferences study main patient questionnaire 
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1.7 Neuromuscular electrical stimulation study patient diary  
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1.8 Neuromuscular electrical stimulation study patient evaluation 
questionnaire 
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1.9 Physical activity level study patient diary and evaluation 
questionnaire 
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2.1.3 Physical activity level study 
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